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Preface 
This dissertation is the result of my own work and includes nothing which is the outcome of 
collaborative work except that declared here and specified in the text. It is not substantially the 
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Research Council Elsie Widdowson Laboratory (MRC-EWL, formerly MRC-Human Nutrition 
Research, HNR) in Cambridge, UK. I collaborated with several members of the Biomineral 
Research group at MRC-EWL as well as the Department of Pathology at the University of 
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of Manitoba, Canada, by Dr Kirk Marat. Sample preparation for the NMR studies was 
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outcome of my own work. The titration of a nanosilica dispersion and the preparation of the 
iron hydroxide nanoparticles were conducted by Mr Carlos Bastos (MRC-EWL). In Chapter 4, 
IL-1β analyses were conducted by Dr Laetitia Pele (MRC-EWL). The gene microarray 
analyses were performed by Dr Mark Boekschoten at Wageningen University (Netherlands). 
In Chapter 6, intracellular TCR and CD3 analyses were conducted by Miss Camilla Fairbairn 
in Dr Suzanne Turner’s laboratory in the Department of Pathology (University of Cambridge). 
In Chapter 7, an alternative nanosilica synthesis was developed for translation into in vivo 
studies by Dr Nuno Faria and Mr Carlos Bastos (both MRC-EWL). Animal work was 
conducted either by Translational Drug Development (TD2) at Translation Genomic 
Research Institute (TGen) or at the MRC-CU in Cambridge (UK) by Drs Jacqueline Shields 
and Luisa Pedro. Sera samples from the study conducted at TGen were sent to Myriad RBM 
for a serum cytokine analyses. In Appendix 2, the clearance of nanosilica after intravenous 
injection in the mice was conducted by Dr Ravin Jugdaohsingh (ICP-OES analyses) and by 
Drs Jacqueline Shields and Luisa Pedro (animal work). In Appendix 3, flow imaging of 
fluorescent bead uptake was conducted by Dr Rachel Hewitt. All other data (analyses and 
interpretation) is the outcome of my own work. 
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Abstract 
Humans are exposed to high levels of amorphous silica on a daily basis, via the diet and the 
use of cosmetic and pharmaceutical products. Amorphous silica particles (10-200 nm) have 
also been developed for use in biomedical applications, including as binding agents in tissue 
repair, drug and gene therapy delivery agents, coatings for medical contrast agents and as 
vaccine adjuvants. Numerous studies have already been conducted to evaluate the cellular 
toxicity of these silica particles but still little is known about their effects both in vitro and in 
vivo, especially of nanosilica particles under 10 nm in diameter. The aim of this thesis was to 
investigate the cellular and in vivo activity of < 10 nm diameter nanosilica particles with 
different properties (e.g., size and dissolution rate in dilute conditions) as it may infer upon 
safety after exposure via the diet and intravenous administration (biomedical applications). 
First, the cytotoxicity of sub-10 nm nanosilica particles, fully characterized by size, dissolution 
rate, zeta-potential and by NMR spectroscopy, on immune cell function was assessed using 
transformed and cancerous cell lines and primary cells. The particles were toxic to the 
immune cells in a dose dependent manner and impaired certain cellular functions. Primary 
cells were most susceptible to nanosilica induced death and, of the primary cells, phagocytes 
were most susceptible to its cytotoxicity. Further investigations were conducted to assess the 
effect of nanosilica on T cells, as there was evidence suggesting that nanosilica particles 
were directly interacting with these cells.  
Nanosilica particles 3.6 nm in diameter were found to have a significant effect on T cell 
function. The particles induced numerous markers of T cell activation, including CD25 and 
CD69 on CD4 T cells, CD8 T cells, gamma-delta T cells and NK/NKT cells, CD95 on CD4 
and CD8 T cells, CD40L, FoxP3, LAP, GARP on CD4 T cells, and IFN-gamma production, 
but it did not induce T cell proliferation. The particles were found to activate T cells 
regardless of their antigenic specificity. Further investigations showed that nanosilica 
interacts with the T cell receptor complex, the first documented case of a non MHC-coated 
nanoparticle directly interacting with this receptor complex. The nanoparticulate induced 
signalling through Zap70, LAT, and, eventually, through NFAT but not through MAPK. Similar 
signalling in the literature has been shown to induce a hyporesponsive T cell state (anergy) 
or activation induced cell death. The induction of the CD25 and CD69 T cell activation 
markers was limited to nanosilica particles below 10 nm in size, while similarly sized iron 
hydroxide nanoparticles (3-5 nm) only induced low levels of CD69 expression on T helper 
cells.  
Finally, it was shown that nanosilica is capable of inducing T cell activation in whole blood, 
though the T cell responses were greatly attenuated. Although identification of activation 
pathway in vivo remains elusive, the nanosilica particles were shown to have therapeutic 
value, decreasing murine subcutaneous tumour growth rate and significantly reducing the 
xxii 
 
formation of lung metastases. Whether these in vivo responses are related to T cell 
activation identified in vitro remains unclear. 
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Chapter 1 - Introduction 
1.1 Silicate chemistry 
Silicon is the second most abundant element in the Earth’s crust and is present throughout the 
geosphere, found in forms including soluble orthosilicic acid (Si(OH)4) and insoluble silica 
particles (both amorphous and crystalline in structure) (Belton et al., 2012; Clarke and 
Washington, 1924; Sommer et al., 2006; Winter, 2012). A brief list summarizing the silicon 
terminology used throughout this report is shown in Table 1.01. Amorphous silica nanoparticles 
were the primary focus of the investigations conducted in this thesis.  
  
Table 1.01. Silicon terminology in this thesis 
Term Properties 
Silicon - Elemental silicon 
- Form not defined 
Silicic acid - Si(OH)4(aq) 
- Dissolved inorganic silicon 
- Also referred to as orthosilicic acid, monosilicic acid, monomeric 
silica, and soluble silica  
 
Silicate - Refers to an anionic silicon compound 
- Most commonly denotes the oxide form of silicon, specifically 
silica and its soluble form  
 
Amorphous 
silica 
- Insoluble silicon with a long-range formula of SiO2 
- No defined structure, contains silicon centres connected to 2, 3 
or 4 other silicon centres through oxygen linkages (Si-O-Si)   
- Also referred to as polymeric or colloidal silica  
Nanosilica - Silica particles below 100 nm in size  
- In this report, “nanosilica” refers to amorphous particles (unless 
stated otherwise) 
 
Crystalline 
silica 
- Insoluble silicon with a long-range formula of SiO2 
- Structured, contains silicon centres connected to 4 other silicon 
centres through oxygen linkages (Si-O-Si). Form depends on 
crystal symmetry     
- Most common forms (polymorphs) include α-quartz and tridymite 
Organic silicon - Refers to silicon species containing a Si-C bond 
- Not naturally occurring 
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The solubility of amorphous silica is low at physiological pH and it increases with pH, as shown 
in Figure 1.01. Insoluble colloidal silica is formed when the concentration of Si exceeds its 
solubility limit, and the properties of these colloidal particles depend on factors such as 
temperature, pH and ionic strength (Iler, 1979; Stumm and Morgan, 1981). Formed by 
condensation of orthosilicic acid, colloidal silica consists of tetraoxosilicon centres (denoted 
previously as Q for quadrafunctional) bound through siloxane linkages. The degree of 
condensation refers to the number of siloxane linkages a silicate centre contains, commonly 
denoted by superscripts. For example, orthosilicic acid (Si(OH)4) is denoted as Q0  while a 
silicate centre linked to 3 other centres (through siloxane linkages) is denoted as Q3. 
Amorphous particles consist of silicate centres linked to 2-4 adjacent silicate centres (Q2-Q4) 
(Jantschke et al., 2014; Kalia et al., 2016) while crystalline particles are comprised of fully 
condensed centres (Q4) (Downs and Palmer, 1994; Kihara et al., 1986; Wright and Lehmann, 
1981). The structure of amorphous and crystalline particles also differ, where the former has 
no inherent structure (amorphous) and the latter has a specific crystal structure (Downs and 
Palmer, 1994; Glinnemann, 1992; Kihara et al., 1986; Wright and Lehmann, 1981). In dilute 
conditions, crystalline silica particles are more persistent than amorphous silicates (Kalia et al., 
2016; Rimstidt, 1997). 
 
 
Figure 1.01. Solubility of amorphous silica at pH 0-14. Reproduced from Jugdaohsingh et 
al. (Jugdaohsingh et al., 2008). 
 
 
 
3 
 
Colloidal silicate dispersions are metastable and follow similar growth processes as other 
nanoparticles, mainly Ostwald ripening and agglomeration (Figure 1.02). Ostwald ripening 
occurs when silicon from the smaller particles dissolves and re-precipitates on the surface of 
larger particles (Belton et al., 2012; Kobayashi et al., 2005). This process is highly dependent 
on the solubility of the monomeric unit, i.e., silicic acid, as it does not occur with materials that 
are completely insoluble or soluble (Fairhurst and Lee, 2008; Lifshitz and Slyozov, 1961; 
Nancollas, 1979). Agglomeration is the clustering of the smaller base particles resulting in the 
formation of larger particles (Belton et al., 2012). The clusters can be loosely bound or strongly 
assembled, which will be referred to as agglomerates and aggregates, respectively 
(classification set out by Powell et al. will be used) (Nichols et al., 2002; Powell et al., 2010). 
The rate of silicate agglomeration is greatest at pH 5-7 (Bergna and Roberts, 2005).  
An important property of colloidal silica particles, and all nanoparticles, is their charge. Charge 
also plays a role in how the particles interact with other materials such as proteins, cells, 
metals, and even self-particles (i.e., aggregation). Silica particles are known to be negative at 
physiological pH (Bergna and Roberts, 2005). The pKa of amorphous silica has been 
determined to be between 6.8 and 7.1 (Belton et al., 2012; Hair and Hertl, 1970), which would 
suggest that 50% of the surface hydroxyl groups are deprotonated at this pH. Nanosilica 
particles are known to be neutral at low pH, conditions in which they are most stable (Bergna 
and Roberts, 2005).  
 
  
 
Figure 1.02. A. General mechanisms of growth of amorphous nanosilica particles. B. Detailed 
mechanism of growth by Ostwald ripening. Reproduced from Belton, Bolt, Iler and Kobayashi 
(Belton et al., 2012; Bolt et al., 1997; Iler, 1979; Kobayashi et al., 2005)  
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Silicon-29 NMR spectroscopy has also been used to characterize silicate condensation 
(Bergna and Roberts, 2005; Kalia et al., 2016). Chemical shifts of the silicate centres with 
ranging condensation levels (Q0 to Q4) have been assigned. The spectra of amorphous 
silicates have broad signals corresponding to the insoluble Si. The lack of repeating structure 
within the particle results in slightly different chemical environments for silicate centres of 
similar condensation levels, resulting in slightly different chemical shifts and broad signals. 
1.2 Exposure to silicon  
1.2.1 Silicon in the diet 
Humans are exposed to high levels of silicates from their diet. High dietary sources of silicon 
include drinking water, cereal grains and products such as beer, nuts and some fruits and 
vegetables (Jugdaohsingh, 2007). In addition to natural sources, amorphous silica is 
commonly added to foods, pills/drugs, and beverages. It is used as an anti-clumping agent, 
thickening and stabilizing agents, and as fillers and abrasives (Jugdaohsingh, 2007). However, 
silicon is only markedly absorbed in its soluble form, meaning most dietary silicon is excreted 
in the urine (Jugdaohsingh et al., 2002; Sripanyakorn et al., 2009).   
Notwithstanding, some ingested solid phase (particulate) silica probably is absorbed from the 
mammalian gut. Although many of the silicate particles that humans ingest are resistant to 
degradation in the gastrointestinal tract, some can potentially be taken up via the numerous 
gastrointestinal particle uptake mechanisms, as depicted in Figure 1.03 (reviewed by Powell 
et al.) (Powell et al., 2010). Firstly, epithelial cells can take up small particles (< 20 nm) via 
endocytosis. Secondly, large particles, > 20 nm, can undergo transcytosis by microfold cells 
(M cells). Thirdly, small and large particles can passively cross the gastrointestinal tract via 
holes created by the loss of endothelial cells. Lastly, disturbances in the tract, caused by drug 
or diet allow small nanoparticles to translocate. Most of these transport mechanisms are not 
efficient, but given the exposure to large numbers of particles, significant numbers may still be 
absorbed and interact with mucosal immune cells.  
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Figure 1.03. Gastrointestinal tract translocation of nanomaterials by: 1) Endothelial cells 
endocytosis of small particles (< 20 nm). 2) Microfold cells (M cells) translocation of large 
particles, > 20 nm. 3) Passive transfer of small and large particles via holes created by the loss 
on endothelial cells. 4) Translocation of small particles through disturbances in the 
endothelium. Reproduced from Powell et al. (Powell et al., 2010) 
 
1.2.2 Biomedical applications 
More recently, amorphous silica nanoparticles have been developed for use in biomedical 
applications. Silica nanoparticles have been shown to be an effective vaccine adjuvant, with 
comparable responses to the Al-based vaccine adjuvants for which many adverse reactions 
are associated (Scaramuzzi et al., 2016; Skrastina et al., 2014). These particles have also 
been shown to be effective binding agents in sutures, cross-linking soft tissues leading to 
increased closure and healing of wounds (Meddahi‐Pellé et al., 2014). Lastly, silica particles 
have been used as agents to delivery drugs, in gene therapies and as contrast agents (for use 
in medical imaging) (Bitar et al., 2012). Silica is commonly used for these applications due to 
its highly tailorable properties.  
1.2.3 Inhalation 
Inhalation is another common route of exposure to silicates. Chronic exposure to crystalline 
silica, most commonly in the workplace, leads to inflammation of the lung and pulmonary 
fibrosis (Leung et al., 2012; Mazurek and Attfield, 2008). The inhalation of amorphous silica is 
also quite common, though its effects are less well understood as trace crystalline silica 
contaminates have skewed the results from many studies (Merget et al., 2002). More recently, 
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amorphous silica nanoparticles 14 nm in diameter were shown to transiently induce pulmonary 
inflammation (Choi et al., 2008).  
1.2.4 Silicate clearance and excretion 
The natural levels of silicon in the periphery are low, ranging from 100-600 μg Si/L (Dobbie 
and Smith, 1982; Sripanyakorn et al., 2009). Blood silicon levels peak 1 to 4 h after 
consumption of silicon containing materials (where time depends on silicon source) and return 
to baseline within ca. 6 h, being rapidly cleared in urine (Jugdaohsingh et al., 2002; 
Sripanyakorn et al., 2009).  
The clearance of intravenous administered nanosilica particles is less well understood. Silica 
nanoparticles 50-200 nm in size have been shown to be predominately excreted in both urine 
and faeces within 72 h (Cho et al., 2009). No particles were detected in the excretions 1 week 
after dose. Organically modified silica nanoparticles were shown to be completely excreted (or 
broken down) over a 15 day period (Kumar et al., 2010). Silica nanoparticles (20 nm and 80 
nm) have also been shown to remain in the liver, spleen and, to a lesser extent, lungs for 
upwards of 30 days (Xie et al., 2010). Nanosilica accumulation in the these organs has been 
shown to induce, for example, the formation of granulomas, hydrotropic degeneration of 
hepatocytes, and pulmonary interstitial thickening (Ivanov et al., 2012; Yu et al., 2013) 
1.3 Biological role and safety of silicon  
In animals, silicon as orthosilicic acid is required for normal growth and a lack of Si (i.e., Si 
deficiency) results in abnormal (stunted) growth (Carlisle, 1976; Carlisle, 1982; Carlisle, 1986). 
Silicon-deficiency also results in bone and connective tissue defects (Carlisle, 1976; Carlisle, 
1982; Carlisle, 1986; Jugdaohsingh, 2007; Jugdaohsingh et al., 2008; Nielsen, 1998; Reffitt et 
al., 2003). In contrast, higher dietary silicon intake has been linked to higher bone mineral 
density (Calomme et al., 2006; Eisinger and Clairet, 1993; Jugdaohsingh et al., 2004; 
Macdonald et al., 2005; Spector et al., 2008). Silicon has also been shown to increase type I 
collagen formation in human osteoblast cells and dermal skin fibroblasts in vitro, and thus it 
has been suggested to play a role in wound healing (Arumugam et al., 2006; Reffitt et al., 
2003). Indeed, silicon-substituted materials (e.g., BioglassTM and Si-substituted 
hydroxyapatite) are now widely used for bone healing (Hench et al., 2004; Porter et al., 2004). 
A mammalian Si transport protein has recently been identified, thus confirming its requirement 
in animals (Garneau et al., 2015; Ratcliffe et al., 2017). 
Silicon has been shown to have a high affinity for aluminum (Jugdaohsingh et al., 2013; Taylor 
et al., 1997), a property that is utilized in nature to lock-up Al in the form of aluminosilicates 
(Al-Si). The freshwater snail Lymnaea stagnalis has been shown to actively increase its 
intracellular silicon levels to sequester toxic aluminum in the form of hydroxyl Al-Si (Desouky 
et al., 2002; Dobranskyte et al., 2004; White et al., 2008). Oligomeric silicon prevents Al 
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absorption and increases its excretion in humans (Jugdaohsingh et al., 2000), thereby 
protecting from Al associated Alzheimer’s disease (Edwardson et al., 1993; Exley et al., 2002; 
González-Muñoz et al., 2008; Jacqmin-Gadda et al., 1996; Rondeau et al., 2000; Rondeau et 
al., 2001). The oligomeric silica has recently been shown to be an amorphous silica 
nanoparticle of ca. 2.4 nm in diameter (Jugdaohsingh et al., 2013). Nano-sized silica species 
are also formed in the snail lysosomes that sequester toxic Al (White et al., 2008).  
1.3.1 The safety of silicate nanoparticles 
The safety/toxicity of amorphous nanosilica particles > 14 nm in diameter has been extensively 
studied, as they are used in numerous commercial and pharmaceutical products (Fruijtier-
Pölloth, 2012). Most commonly, the nanosilica particles used in these studies were generated 
at high temperatures and dissolve in dilute conditions relatively slowly (suppliers include W.R. 
Grace & Co (Ludox), Nanoamor and PolySciences, and are commonly prepared via the Stöber 
mechanism using alkoxy-substituted silicon (Stöber et al., 1968)).  
In vitro testing has shown that these amorphous nanosilica particles (ranging from 14-500 nm 
in size) are toxic towards a range of cell types, e.g., lung carcinoma A529, liver carcinoma 
HepG2 and embryonic kidney HEK293 cells, in a dose dependent manner (Ahmad et al., 2012; 
Akhtar et al., 2010; Fede et al., 2012; Li et al., 2011; Lin et al., 2006; Lison et al., 2008; Lu et 
al., 2011; Mu et al., 2012; Wang et al., 2009a; Wottrich et al., 2004). More specifically, 
amorphous nanosilica has been shown to damage cell membranes (Akhtar et al., 2010; Chang 
et al., 2007; Li et al., 2011; Lin et al., 2006; McCarthy et al., 2012; Napierska et al., 2009; Wang 
et al., 2009a), damage DNA (Choi et al., 2011; Duan et al., 2013; Mu et al., 2012; Nabeshi et 
al., 2011), increase levels of intercellular reactive oxygen species and other oxidative stress 
markers (Ahmad et al., 2012; Akhtar et al., 2010; Duan et al., 2013; Fede et al., 2012; Klein et 
al., 2013; Li et al., 2011; Lin et al., 2006; Liu and Sun, 2010; Lu et al., 2011; McCarthy et al., 
2012; Nabeshi et al., 2011; Park et al., 2013; Radonski and Medina-Martin, 2011; Ye et al., 
2010), and, in some cases, increase cytokines and analytes such interleukin (IL)-6, IL-8  and  
matrix metallopeptidase 9 (MMP-9)) (Liu and Sun, 2010; McCarthy et al., 2012; Wottrich et al., 
2004).  
The effects of silica nanoparticles on primary peripheral cells have also been investigated. In 
peripheral blood mononuclear cell (PBMC) cultures, nanosilica decreased cell viability and 
induced an inflammatory reaction (Fedeli et al., 2013; Mendoza et al., 2014). Monocytes and 
macrophages were shown to be more susceptible to nanosilica induced cell death than 
lymphocytes and epithelial cells, a trend that was assigned to the phagocytic nature of the cells 
(Fedeli et al., 2013). In the presence of protein, the nanosilica particles were shown to induce 
monocyte pyroptosis while necrosis was induced in the absence of protein (Fedeli et al., 2014). 
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In vivo testing has shown that mice injected with amorphous nanosilica have increased levels 
of oxidative and inflammatory markers. Specifically, Park et al. showed that after 
intraperitoneal injection of 50 mg/kg nanosilica particles 12 nm in diameter, nitric oxide levels 
progressively increased over 72 h and blood levels of IL-1β, TNF-α, and IL-6 increased to a 
maximum at 12-24 h and decreased thereafter (Park and Park, 2009). Cho et al. showed that 
intravenous injection of 50 nm nanosilica particles did not induce an inflammatory response, 
while 100 and 200 nm nanosilica particles increased the incidence of inflammation in the liver 
(Cho et al., 2009). These studies would indicate that amorphous silica nanoparticles induce an 
inflammatory response, which is similar, only a magnitude lower, to that caused by crystalline 
silica particles.  
1.3.2 Insoluble silicates and the immune system 
Silica nanoparticles have also been shown to have adjuvant and immunomodulatory 
properties. Antigen presentation by dendritic cells (DCs) increased after exposure to nanosilica 
(51 nm), leading to increased T cell responses to cognate antigen when compared to 
unstimulated DC-T cells (Chen et al., 2014; Hirai et al., 2012). Similarly, greater antibody 
production was induced in vivo when antigen was co-administered with 5-90 nm silica 
nanoparticles (Brandenberger et al., 2013; Marzaioli et al., 2014). Other silicate containing 
materials have also been shown to be immunomodulatory. Cargo-free mesoporous silica 
nanoparticles (104 nm) have been shown to increase the population of effector memory T cells 
and induce cytokine production (Wang et al., 2016). Alkaline mineral solutions with a high 
silicate content (Barodon®) have been shown to increase peripheral T cell numbers and 
increase the response of the T cells to antigen (Koo et al., 2006; Park et al., 2000; Yoo et al., 
2001). 
The interactions between crystalline silica and immune cells have also been well studied due 
to its involvement in silicosis and other pulmonary diseases. Crystalline silica is known for its 
chronic pro-inflammatory properties, which occurs through a cyclic macrophage recruitment-
destruction pathway (Chu et al., 2012; Greenberg et al., 2007). These particles have been 
shown to be much more toxic towards macrophages than other non-Si particles of similar sizes 
(Allison et al., 1966).  
In addition to the toxic effects on monocytes and other phagocytes, crystalline silica has been 
shown to affect other immune cells. Circulating regulatory T cells, a suppressive helper T cell 
subset, in silicosis patients showed decreased function compared to those found in healthy 
individuals. Specifically, the regulatory T cell populations had decreased levels of FoxP3, a 
regulator of this T cell subset, decreased CTLA-4 function, which is an immune checkpoint 
inhibitor, and increased levels of the CD95 death receptor, whose engagement can suppress 
an immune response or induce apoptosis (Hayashi, 2010; Hayashi et al., 2009; Wu et al., 
2005b). The ratio of effector T cells to regulatory T cells was also greater in silicosis patients 
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(Hayashi, 2010; Hayashi et al., 2009). Additionally, exposure to crystalline silica has been 
shown to chronically activate T cells in vivo (silicosis patients) (Hayashi et al., 2009; Wu et al., 
2005b) and in cell culture (Ueki et al., 1994; Wu et al., 2005a).  
There have also been studies conducted assessing the effect of crystalline silica on B cell 
function. Patients with silicosis have been shown to have higher immunoglobulin levels 
(Balamuralikrishnan et al., 2014; Doll et al., 1981; Kalliny and Bassyouni, 2011). Interestingly, 
short term exposure to crystalline particles does not result in increased immunoglobulin levels, 
but instead a marked decrease (Brown et al., 2003). Silicosis patients have also been shown 
to have increased autoantibody levels (Beshir et al., 2015; Brown et al., 2003; Doll et al., 1981; 
Kalliny and Bassyouni, 2011; Otsuki et al., 2006; Pfau et al., 2004), though few studies suggest 
otherwise (Aminian et al., 2009)  
1.4 Cell biology 
1.4.1 Cell death 
As outlined in Section 1.3.1, the effect of amorphous nanosilica on cells has been extensively 
studied (Fruijtier-Pölloth, 2012). These particles are toxic to cells in a dose dependant manner 
and have been shown to induce necrosis and pyroptosis of monocytes (Ahmad et al., 2012; 
Akhtar et al., 2010; Fede et al., 2012; Fedeli et al., 2014; Fedeli et al., 2013; Li et al., 2011; Lin 
et al., 2006; Lison et al., 2008; Lu et al., 2011; Mu et al., 2012; Wang et al., 2009a; Wottrich et 
al., 2004)..  
Cells can undergo death through various mechanisms, including apoptosis, necrosis and 
pyroptosis. Apoptosis is a regulated mode of cell death and it can occur naturally (due to cell 
development and aging) or in response to external stimulus (noxious agents, corticosteroids, 
radiation, cell damage) (Elmore, 2007). The process is initiated by caspases -2, -8, -9 or -10 
which activate caspases -3, -6 and -7. These caspases execute apoptosis by inducing a 
pathway which involves endonuclease activation, degradation of chromosomal DNA, and the 
degradation of nuclear and cytoskeletal proteins. The changes in cytoskeletal makeup, 
specifically the expression of surface phosphatidylserine (PS), are recognised by phagocytic 
cells and the apoptotic body is then phagocytosed without releasing its cellular components, 
thus preventing inflammation (Elmore, 2007; Jorgensen and Miao, 2015).  
Necrosis was initially considered to be an unregulated mechanism of cell death, though recent 
studies have shown that it can occur in a controlled manner (Berghe et al., 2014). Non-
regulated necrosis can occur though the rupturing of the cellular membrane, which leads to 
the release of its cellular components (Lohmann et al., 2009). In controlled necrosis, pores on 
the mitochondrial membrane are opened and protons, which are required for ATP synthesis, 
are lost into the cytosol. The lack of ATP leads to cellular dysfunction and necrosis (Dorn, 
2013).  
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Another mechanism of cell death is pyroptosis. Pyroptosis is regulated by the activation of 
caspase-1, which can be induced by the presence of intracellular pathogens. Caspase-1 
induces the production of IL-1β and IL-18, both of which are inflammatory cytokines, and the 
formation of pores in the cellular membrane. The formation of pores causes cellular swelling 
(due to influx of water), cells lysis and release of its cellular components (Bergsbaken et al., 
2009; Jorgensen and Miao, 2015).   
1.4.2 Cell lines, cell matrixes 
When using in vitro assays for assessing the effects of materials on cells, cell type and culture 
type will significantly impact the findings. Commonly, cell lines are used to study the effects of 
nanoparticles on cells. The effect of nanosilica particles on various cell lines have been 
extensively studied and reviewed by Fruijtier-Pӧlloth (Fruijtier-Pölloth, 2012). Although cell 
lines are inexpensive to work with and can generate highly reproducible results, they are known 
to not completely mimic primary cell cultures (Kaur and Dufour, 2012). Primary cells, which are 
more expensive and more challenging to work with, have been found to respond to different 
stimuli and have differing sensitivities compared to cell lines, and have also been shown to 
yield more varied results due to inter-donor variance (Gazdar et al., 2010; Krebs et al., 2002; 
Norian et al., 2000; Van Belle et al., 2016).   
In addition to differences in cell type/origin, the matrix in which experiments are conducted 
influence the results. For example, primary monocytes treated with silica nanoparticles either 
undergo necrosis or pyroptosis depending on the protein concentration in culture (Fedeli et al., 
2014). Therefore, even results from studies conducted on primary peripheral cells in culture 
would likely differ from those conducted in whole blood.  
Whole blood is a complex matrix containing a high protein concentration, plasma, platelets, 
red blood cells and neutrophils in addition to the PBMCs. Interestingly, each of these additional 
components has been shown to interact with amorphous silica (Clemments et al., 2015; 
Gryshchuk and Galagan, 2016; Lehman et al., 2016; Zhang et al., 2012; Zimmerman et al., 
1986). These interactions would likely impact the cellular response to the particles.  
1.5 General immunology  
1.5.1 Innate immune responses 
The innate immune system is the body’s first line of defence and consists of the cells which 
provide an immediate response to infection. These cells detect infection using cell surface 
receptors, specifically Toll-Like receptors (TLR) and cytosolic pattern-recognition receptors 
(PRR) (Iwasaki and Medzhitov, 2015). These receptors have evolved to detect sequences 
from essential components of foreign pathogens (pathogen-associated molecular patterns 
(PAMPs)) and stress signals from infected cells (damage-associated molecular patterns 
(DAMPs)) (Rock et al., 2011). There are also innate cells capable of detecting unhealthy cells 
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that do not express the receptors present on healthy cells (i.e., MHC class I receptors) (Vivier 
et al., 2008). Upon recognition of these ligands (or lack of self-ligands), the innate cells release 
pro-inflammatory signals, including cytokines and chemokines. 
Many innate cells have endocytic capabilities, i.e., the ability of taking up foreign materials. 
There are many types of endocytic pathways, which have been extensively reviewed (Doherty 
and McMahon, 2009). The endocytic mechanisms of nanoparticles have also been 
investigated. It has been found that silica nanoparticles are recognised by scavenger receptors 
(macrophage receptor with collagenous structure (MARCO), CD204 or CD36) and 
phagocytosed by cells (Hamilton et al., 2006). Cellular death was found to be associated with 
scavenger receptor mediated silica nanoparticle uptake, where no toxicity was evident with 
cells lacking scavenger receptors (Hamilton et al., 2006). Other cell lines have been shown to 
non-specifically endocytose nanosilica particles (Chu et al., 2011; Mohamed et al., 2011). 
After phagocytosis, the material is contained in an early endosome where the fate of the cargo 
is determined (sorted). The material can be immediately recycled back to the surface, 
transferred to the trans-Golgi network (for transfer back to the plasma membrane or for transfer 
to early- or late-endosomes) or it can stay within the endosome which then undergoes 
maturation (into late-endosomes, for material transfer to the trans-Golgi network or lysosomes) 
(Grant and Donaldson, 2009; Huotari and Helenius, 2011). These processes have plasticity 
(i.e., allow for continuous exchange and communication) until the material is transferred to the 
lysosome, a process that is irreversible (Huotari and Helenius, 2011). During the transfer of 
the cargo from early endosome to lysosome, the pH drops for the degradation of the materials, 
where early endosomes have a pH of 6.1-6.8, late endosomes have a pH of 4.8-6.0, and 
lysosomes have a pH of ca. 4.5 (Huotari and Helenius, 2011).  
Silica nanoparticles have been identified in the endo-lysosomes of primary phagocytic cells 
(Fedeli et al., 2013). The high silica nanoparticle load, especially that present in cell culture 
studies, and the low pH environment of the late endosome and lysosomes leads to the 
accumulation of the silicate particles in phagocytes. As outlined in Section 1.1, the solubility of 
amorphous silica is low at and below physiological pH (Jugdaohsingh et al., 2008). In a low pH 
environment like that found in endosomes (early and late) and lysosomes, the dissolution rate 
of the nanosilica particles would be slow. Additionally, the solubility of silicic acid would likely 
be exceeded in these localized compartments, thus preventing particle dissolution. Amorphous 
nanosilica particles have been found to accumulate in the acidic compartments of cells and 
can lead to their rupture (Fedeli et al., 2013). Other studies have also shown silica nanoparticle 
accumulation in endosomal and lysosomal vesicles (Al-Rawi et al., 2011; Chu et al., 2011; 
Corbalan et al., 2011; Drescher et al., 2011; Mohamed et al., 2011). 
Phagocytic cell subsets of particular interest in this study are neutrophils and monocytes. Both 
are responsible for clearing foreign material in the periphery, though their functions differ.   
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Neutrophils are the most abundant cell subset in the periphery, making up >50% of peripheral 
cells (Kruger et al., 2015; Young, 1972). In addition to phagocytosis and breakdown of foreign 
materials in phagosomes as outlined above, neutrophils can employ extracellular traps to kill 
foreign pathogens. Neutrophil extracellular traps (NETs) are comprised of decondensed 
chromatin, histone and granular proteins which are capable of breaking down pathogens 
(Kruger et al., 2015). Neutrophils also release reactive oxygen species, proteases, 
antimicrobial peptides, cytokines and chemokines (Kruger et al., 2015). Little is known of silica-
neutrophil interactions, though limited studies have shown that silica decreases neutrophil 
phagocytosis of bacteria (Zimmerman et al., 1986) 
Blood monocytes are a less frequent peripheral cell comprising ca. 5-10% of the circulating 
cells and are precursors for macrophages, dendritic cells and osteoclasts (Sprangers et al., 
2016). These cells have well established phagocytic capabilities and are involved in adaptive 
immunity as they present antigen to T lymphocytes via their MHC class II receptors. After 
phagocytosis of foreign pathogen or antigen, the proteins are processed with various 
proteases in endosomal and phagosomal compartments (Roche and Furuta, 2015). The MHC 
class II receptor is present in the endosome either from its expression on the cell membrane 
and internalization during the phagocytosis of the foreign material or from transportation to the 
endosome by the Golgi. The receptor then exchanges its class II-associated Ii peptide (CLIP) 
for antigenic peptide and is transported to the cell membrane for presentation of the antigenic 
epitope (Neefjes et al., 2011). Monocytes and its derived cells also provide secondary and 
tertiary signals to the T lymphocytes. Secondary signals, which are costimulatory or inhibitory 
receptors, and cytokines (referred to as signal 3) further mediate the T cell response (Chen 
and Flies, 2013; Iwasaki and Medzhitov, 2015; Sckisel et al., 2015). 
Silica nanoparticles have been shown to effect monocyte function. Some studies have shown 
increased antigen presentation by dendritic cells after silica nanoparticle treatment, leading to 
increased T cell responses (Brandenberger et al., 2013; Chen et al., 2014; Hirai et al., 2012; 
Marzaioli et al., 2014). Other studies have shown that silica decreases monocyte function and 
induces cell death (Fedeli et al., 2014; Fedeli et al., 2013; Zimmerman et al., 1986). 
Natural killer cells are a lymphocyte subset part of the innate immune system (Turvey and 
Broide, 2010).  Natural killer (NK) cells do not have a T cell receptor (TCR) to recognize 
antigen. Instead, NK cells are activated through a number of different receptors, including 
NKp30, NKp44, and CD160,  which recognize stress signals presented on other cells (Long et 
al., 2013; Vivier et al., 2008), and cytokines, including IL-2, IL-12, and IFN-γ (Zwirner and 
Domaica, 2010). These cells have cytotoxic capabilities and can release factors, mainly 
perforin and granzymes, to induce cell death of stressed and diseased cells (Aktas et al., 2009; 
Alter et al., 2004).  
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1.5.2 Adaptive immune response 
The adaptive immune system is the secondary response to an infection. Adaptive immune 
cells, mainly B and T lymphocytes, are recruited to the site of infection by the cytokines and 
chemokines released by the innate immune cells (Alberts, 2002). The response of the adaptive 
immune cells is specific to the infection, thus preventing damage to the host organism. The 
adaptive immune response can be either cell or antibody (humoral) mediated. T lymphocytes 
facilitate the cell mediated adaptive immune response while B lymphocytes facilitate the 
humoral response, which can be either T cell dependent or independent (Alberts, 2002; Nutt 
et al., 2015). Since the majority of the work in this thesis investigated the effects of amorphous 
silica on T cells, a thorough discussion on these cells was included.  
1.5.2.1 T cell immunology 
T lymphocyte precursor cells are produced in the bone marrow and are developed in the 
thymus (Miller, 2011). In the thymus, the cells develop a T cell receptor (TCR), CD4 and CD8 
receptors before they undergo the selection process. The thymic selection process is 
comprised of both positive and negative selection. Positive selection is the process where T 
cells which have a productive interaction with a self-antigen MHC complex expressed on 
thymic epithelial cells are selected for survival (Carpenter and Bosselut, 2010). T cells which 
lack this interaction die of neglect. These weak interactions with self-peptide are required for 
circulating T cells as they maintain a low level TCR signal and naïve T cell homeostasis, both 
of which impact the eventual response of the T cell to cognate antigen (Hogquist and Jameson, 
2014). The positive selection process also dictates whether the cells become a helper T cell 
(CD4(+), through an interaction with a MHC class II receptor) or a cytotoxic T cell (CD8(+), 
through an interaction with a MHC class I receptor). If a T cell interacts too strongly with self-
antigen, i.e., it is autoreactive, the cells are eliminated through TCR mediated apoptosis 
(Palmer, 2003). This process is referred to as negative selection. Autoreactive T cells found in 
circulation have either escaped the negative selection process or are specific to an antigen not 
presented in the thymus (Bluestone et al., 2015; Ohashi, 2002). These T cells are known to 
contribute to various autoimmune diseases (Bellone, 2001; Janeway et al., 1997).  
An adaptive immune response is specific to the infection. T lymphocytes orchestrate an 
infection specific response through antigen recognition by the T cell receptor (TCR), which are 
developed in the thymus to recognize a specific antigenic epitopes. In the periphery, ca. 106 
clonotypes (different epitopes in which the TCR can recognise) have been identified and 
modelling suggests that 1015 to 1020 different TCR clonotypes can be developed in the thymus 
(Laydon et al., 2015; Warren et al., 2011). B cells are also equipped with receptors, referred 
to as B cell receptors (BCRs), to recognize a wealth of antigens. However, unlike traditional 
TCRs, BCRs can recognise both soluble antigen and presented antigen, though induced 
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activation is more efficient when antigen is presented (Avalos and Ploegh, 2014; Yuseff et al., 
2013). 
1.5.2.2 T cell subsets 
The thymic selection process dictates whether a T cell is CD4(+) or CD8(+) (Carpenter and 
Bosselut, 2010). Upon activation, these T cell subsets, helper and cytotoxic respectively, 
respond differently to infection.  
CD4, or helper, T cells mediate the immune response after activation (Geginat et al., 2015). 
Helper T cells recognise cognate antigenic epitope presented in MHC class II receptors on 
antigen presenting cells (APC) with their TCR. The CD4 co-receptor on T cells binds the 
TCR:peptide-loaded MHC class II interaction and downstream signalling commences, leading 
to activation (Chakraborty and Weiss, 2014). Upon activation, CD4 T cells respond by 
producing cytokines and expressing a range of cell surface markers. The cytokines produced 
and surface markers expressed depend on the helper cell phenotype that is induced. The main 
types of helper T cell phenotypes, specifically T helper 1 (Th1), T helper 2 (Th2) and regulatory 
(Treg) (Geginat et al., 2015), are shown in Figure 1.04.  
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Figure 1.04.  The main helper T cells phenotypes and the factors that induce them. Th1 
cells are induced by TCR signalling in the presence of IL-12 and IFN-γ, inducing signalling 
through the STAT1, T-bet and STAT4 transcriptional factors, leading to IFN-γ production. Th2 
cells are induced by TCR signalling in the presence of IL-4, inducing signalling through the 
STAT6 and GATA3 transcriptional factors, leading to IL-4, IL-5 and IL-13 production and 
expression of iCOS (CD278) and CD40L (CD154). Treg cells are induced by TCR signalling 
in the presence of IL-2 and TGF-β, inducing signalling through the FoxP3 and STAT5 
transcriptional factors, leading to IL-2 and TGF-β production and expression of PD-1 (CD279), 
CTLA-4 (CD154) and LAP/GARP. Figure adapted from DuPage, Elgueta, Gauthy, Geginat, 
Janeway Jr, Sahoo and Stockis (DuPage and Bluestone, 2016; Elgueta et al., 2009; Gauthy 
et al., 2013; Geginat et al., 2015; Janeway Jr et al., 2001; Sahoo et al., 2016; Stockis et al., 
2009) 
 
Th1 cells are responsible for activating monocytes and cytotoxic T cells. A Th1 response is 
induced by strong signalling through the TCR and the cytokines IL-12 and IFN-γ (DuPage and 
Bluestone, 2016). These signals induce the transcriptional factors STAT1 (signal transducer 
and activator of transcription (STAT)), STAT4 and Tbet, leading to the production of IFN-γ 
(DuPage and Bluestone, 2016; Lazarevic et al., 2013). This cytokine further supports the 
induction of Th1 cells, activates macrophages (increases their anti-microbial activity), and 
enhances cytotoxic lymphocyte activity (Schroder et al., 2004; Zhu and Paul, 2008) 
Th2 cells are responsible for mediating a response against parasites and are also involved in 
an allergic response (Sahoo et al., 2016). This cell lineage shares many functions with T 
follicular helpers cells, which mediate B cell responses including their survival, proliferation and 
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antibody production (Crotty, 2015). Th2 cells are induced by a weak TCR signal in the 
presence of the cytokine IL-4, inducing the transcriptional factors STAT6 and GATA3 (DuPage 
and Bluestone, 2016). Activated Th2 cells produce the cytokines IL-4, IL-5 and IL-13, which 
effect antibody production by B cells and further support the induction of Th2 cells (Sahoo et 
al., 2016). Th2 cells also express CD154 (CD40 ligand,CD40L) (Jenkins et al., 2008), a ligand 
that engages the CD40 receptor on B cells and it induces its proliferation and survival (Crotty, 
2015; Elgueta et al., 2009). CD278 (inducible costimulatory, iCOS) is also expressed on Th2 
cells and its engagement further induces a Th2 response (Sahoo et al., 2016; Wikenheiser and 
Stumhofer, 2016; Yong et al., 2009). 
Regulatory T cells (Tregs) inhibit immune responses to prevent damage to the surrounding 
tissues and autoimmunity (Arpaia et al., 2015). A regulatory response is induced by TCR 
signalling in presence of the cytokine TGF-β (Chen et al., 2003; Zou, 2005). Transcriptional 
factors foxhead box P3 (FoxP3) and STAT5 are induced leading to the production of IL-10 and 
TGF-β (DuPage and Bluestone, 2016). Tregs express PD-1 (CD279) and CTLA-4 (CD152), 
both of which further support a suppressive environment (DuPage and Bluestone, 2016; 
Francisco et al., 2010; Walker and Sansom, 2015). Regulatory T cells also express latency-
associated peptide (LAP) and glycoprotein A repetitions predominant (GARP) on their surface. 
Both of these proteins are components of the latent-TGF-β complex, which is responsible for 
the release of immunesuppressive cytokine TGF-β (Gauthy et al., 2013; Stockis et al., 2009). 
Two types of regulatory T cells have been identified, natural (nTreg), and inducible (iTreg) 
(Mellanby et al., 2009). nTreg, also referred to a thymic Tregs (tTreg), are positive for the 
transcriptional protein FoxP3 in the thymus. Although these cells express the regulatory 
transcriptional factor, they are not polarized Tregs, as they are still capable of taking on all 
other T helper cell phenotypes (DuPage and Bluestone, 2016). iTregs, also referred to as 
peripheral Tregs (pTreg), are cells that leave the thymus negative of the transcriptional factor 
FoxP3 but take up a regulatory phenotype upon activation. These cells can be both positive 
and negative for the FoxP3 protein (Mellanby et al., 2009)   
CD8 T cells, also known as cytotoxic T lymphocytes (CTLs) when activated, are responsible 
for executing an immune response (Tscharke et al., 2015). CTLs engage stressed, abnormal, 
infected, and cancerous cells and induce their cell death by releasing factors or engaging 
receptors that will induce apoptosis of the target cell (Aktas et al., 2009; Alter et al., 2004; 
Arakaki et al., 2014). These cells can also release IFN-γ to further mediate a cytotoxic 
response (Schroder et al., 2004). CTLs are activated when they recognize their cognate 
antigen presented on an MHC class I receptor (Chakraborty and Weiss, 2014). Peptides 
presented on MHC class I receptors are a sampling of the intercellular proteins, unlike peptides 
presented on MHC class II receptors which are phagocytosed and processed foreign antigen 
(Neefjes et al., 2011). The peptides presented on MHC class I receptors, which are expressed 
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on all cell types (Tourdot and Gould, 2002), are an indication of the function of the cell (Comber 
and Philip, 2014). The peptide that is presented on a virally infected, cancerous or stressed 
cells is different than that of a heathy cell. After engagement of the peptide loaded MHC class 
I receptor by the TCR on CTLs, the CD8 co-receptor binds the TCR:MHC complex and 
activation is initiated (Chakraborty and Weiss, 2014). CTLs can execute an immune response 
in a number of different ways. After engagement of an unhealthy cell, a CTL can release the 
contents of its granules (perforin, granzymes) which induce apoptosis of the target cell. 
Classically, the perforin is thought to form pores in the target cell membrane that the 
granzymes move through to induce target cell apoptosis through the activation of caspases 
(Voskoboinik et al., 2015). Another mode in which CTLs induce target cell death is through the 
Fas death receptor. Target cells, including activated T cells (below), can express the Fas death 
receptor (CD95) that, when engaged, will induce apoptosis. CTLs can express FasL (CD195) 
on its surface or produce and release soluble FasL (sFASL) (Hassin et al., 2011; Stinchcombe 
and Griffiths, 2007). There are other cytotoxic lymphocytes present in circulation, specifically 
γδ T cells and natural killer T cells (NKT), which are thought to bridge the adaptive and innate 
immune responses (below).  
1.5.2.3 T cell signalling 
The signalling induced upon T cell activation is complex and a simplified signalling network is 
shown in Figure 1.05. In a healthy interaction, T cell activation is initiated when the TCR 
engages the peptide loaded MHC receptor (pMHC). Upon engagement, the immunoreceptor 
tyrosine-based activation motif (ITAM), which is located on the intracellular tail of the CD3 
chains and the CD247 protein (also referred to as CD3ζ and TCRζ), becomes accessible for 
phosphorylation (Chakraborty and Weiss, 2014). The exact mechanism in which the ITAM 
becomes accessible for phosphorylation is not known, though there are numerous proposed 
models (the most common models outlined below). Lymphocyte-specific protein tyrosine 
kinase (LCK), which is located on the intercellular end of the CD4 and CD8 co-receptors, 
phosphorylates the ITAM when the co-receptors binds the TCR:pMHC complex (Brownlie and 
Zamoyska, 2013). Proto-oncogene tyrosine-protein kinase Fyn (“Fyn”) has also been found to 
phosphorylate the ITAM, specifically (Love and Hayes, 2010). The phosphorylated ITAM then 
is bound by zeta-chain associated protein kinase 70 (Zap-70), and this kinase is also 
phosphorylated by LCK or Fyn (Goodfellow et al., 2015). The phosphorylated Zap-70 protein 
(pZap-70) propagates the signal by phosphorylating the linker for activation of T cells (LAT) 
(Malissen et al., 2014). Most responses are associated with the engagement of the TCR signal 
through the phosphorylated LAT (pLAT) protein, as it serves as a nucleation point for 
downstream signalling (Malissen et al., 2014). For complete T cell activation, there must be 
sufficient signalling through mitogenic-activated protein kinases (MAPK) and nuclear factor of 
activated T cells (NFAT) (Macian, 2005; Smith-Garvin et al., 2009). When signalling does not 
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occur through both pathways, only certain T cell activation markers are induced and other 
markers, such as clonal expansion and IL-2 production, are not (Chen and Flies, 2013; 
Pennock et al., 2013; Reddy et al., 2004; Sprent et al., 1997). The lack of complete signalling 
can lead to defective activation states such as activation induced cell death (AICD) and anergy 
(below). With efficient TCR antigenic stimulation, both of these signalling pathways are 
sufficiently induced, by downstream signalling through the DAG protein (Macian, 2005; Smith-
Garvin et al., 2009). When there is inefficient TCR antigenic stimulation, co-stimulatory signals 
provided by the cells presenting antigen are required for a complete T cell response (Csencsits 
and Bishop, 2003; Wang et al., 2000). For example, inefficient TCR ligation requires co-
stimulation through CD28 for induction of signalling through MAPK (Boomer and Green, 2010; 
Fathman and Lineberry, 2007) 
In addition to CD28, there are numerous T cell costimulatory receptors, reviewed by Chen et 
al. (Chen and Flies, 2013). Engagement of these receptors, including CD30, iCOS, OX40 and 
signalling lymphocytic activation molecule (SLAM), by their respective ligands can induce T 
cell proliferation, differentiation, survival, cytokine production, cytotoxic function and formation 
of memory cells. Coinhibitory signals, including Fas (CD95), programmed cell death protein 1 
(PD-1), CTLA4 and CD160, limit T cell responses upon their engagement by inhibiting the cell 
cycle and effector function and also by inducing exhaustion and apoptosis.  
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Figure 1.05. T cell signalling pathway after T cell recognition of cognate antigen 
presented on a MHC receptor by an APC or a target cell. After recognition of cognate 
antigen, the ITAM is phosphylated by LCK (located on the intracellular end of CD4/CD8) or 
Fyn. Zap-70 then binds the ITAM and is phosphorylated. pZap-70 propagates the signal by 
phosphorylating LAT and SLP76. The signalling cascade continues through NFAT and, if TCR 
ligation is efficient, through DAG and MAPK leading to complete T cell responses. Co-
stimulation also induces signalling through MAPK.  Adapted from Acuto, Browlie and 
Zamoyska, Dupage and Bluestone, and Fesnak (Acuto et al., 2008; Brownlie and Zamoyska, 
2013; DuPage and Bluestone, 2016; Fesnak et al., 2016).  
 
A third signal, specifically cytokines, further mediate and enhance the T cell activation 
response. For example, dendritic cells can produce IL-12 to induce a Th1 cell phenotype 
(Geginat et al., 2015; Sckisel et al., 2015). Interestingly, if a CD4 T cell receives the signals 
out-of-sequence, its response could be suppressed or the T cell could become paralysed 
(Sckisel et al., 2015). For example, a CD4 T cell that encounters high concentrations of 
cytokine prior to TCR engagement may have impeded responses.  
There are materials that can induce T cell activation in the absence of antigenic presentation 
and co-stimulatory signalling. Calcium ionophores, such as ionomycin, and phorbate esters, 
such as phorbol 12, 13-dibutyrate (PdBu), are known to induce signalling through NFAT and 
MAPK respectively (Bell, 2002; Chatila et al., 1989). These compounds, can therefore be used 
to induce complete T cell activation when added to culture together. There are other 
compounds that can directly engage the TCR/CD3 complex without needing to be presented 
by an APC or a target cell, specifically superantigens and mitogenic antigens. Superantigens, 
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which are produced by bacteria or pathogenic viruses, induce chronic T cell activation by 
binding the TCR and cross-linking it to an MHC receptor (Li et al., 1998). Superantigens are 
also capable of cross-linking to the CD28 costimulatory receptor (Arad et al., 2011; Fraser, 
2011). In vivo, superantigens can induce toxic shock syndrome, with adverse effects such as 
vomiting, rash, fever, and hypotension, and even lethal shock (Fraser, 2011). Synthetic 
mitogenic antibodies, specific for protein sequences on  the TCR, CD3 and CD28 receptors, 
can also be used to induce chronic T cell activation in vitro and in vivo (Suntharalingam et al., 
2006; Trickett and Kwan, 2003). 
1.5.2.4 TCR signalling models 
The most common models on the initiation of T cell signalling, specifically regarding the 
phosphorylation of ITAM, include kinetic segregation and conformational change (though there 
are others which are also reviewed by Charkraborty and Weiss (Chakraborty and Weiss, 
2014)). Briefly, the kinetic segregation (KS) model suggests that the segregation of negative 
regulators of tyrosine initiates T cell activation. Phosphatases, such as CD45, are known to 
oppose the phosphorylation of tyrosines, such as LCK (i.e., CD45 de-phosphorylates LCK). 
The KS model suggests that the forces caused between the cells during the TCR:pMHC 
interaction sterically segregates CD45 from LCK, thus leaving LCK phosphorylated until it 
passes on the phosphate group to the ITAM. The conformational change model suggests that, 
after the TCR binds the pMHC complex, the torsion caused by the moment of the cells initiates 
T cell activation. The torsion forces the TCR (which does not have any intracellular signalling 
motifs) to contact a CD3 receptor, thus initiating intracellular downstream signalling.  
1.5.2.5 General markers of T cell activation  
T cells express numerous receptors and produce cytokines upon activation. Some markers of 
activation are expressed on all T cell subsets, including helper T cell subsets and cytotoxic 
lymphocyte subsets. Generally, these markers are essential for the survival of the activated 
cells. For example, all activated T cells express the CD25 surface receptor. CD25, with CD122 
and CD132, make up the receptor for the cytokine IL-2, a complex commonly referred to a IL-
2R (Létourneau et al., 2009; Malek and Castro, 2010). Activated T cells require IL-2 for late 
stage proliferation and T cell differentiation, and therefore express IL-2R (D’Souza and 
Lefrançois, 2003; Malek and Castro, 2010). Certain T helper cell subsets, specifically Tregs, 
constitutively express IL-2R as IL-2 is required for their homeostasis, development and 
function (Malek and Castro, 2010). Another common marker of T cell activation is the CD69 
receptor. CD69 is expressed on the surface of activated T cells quickly after recognition of 
cognate antigen and it is involved in immune suppression and T cell migration (Mackay et al., 
2015; Radulovic et al., 2013).  CD69 is a more sensitive measure of T cell activation than CD25 
and other activation markers (Fazekas De St. Groth et al., 2004). Another general marker of T 
cell activation is proliferation, though, unlike the previous two markers of activation, it requires 
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complete signalling to be induced (Chen and Flies, 2013; Pennock et al., 2013; Reddy et al., 
2004; Sprent et al., 1997).  
1.5.2.6 Defective activation mechanisms 
When a T cell is not activated properly, it can take up a hyporesponsive state known a T cell 
anergy (Schwartz, 2003). T cell anergy is induced when there is TCR ligation in the absence 
of costimulation, by chronic TCR stimulation, or by TCR stimulation in conditions of high 
coinhibitory signals (Schwartz, 2003; Wells, 2009; Zheng et al., 2008). Treating cultures with 
calcium ionophores, which induce signalling through NFAT and mimic TCR ligation, in the 
absence of phorbate esters is commonly used to induce T cell anergy in vitro (Bell, 2002; 
Macián et al., 2002). Different anergic T cell states have been identified, and reviewed by 
Schwartz (Schwartz, 2003). The properties of T cells in the different anergic states differ 
slightly, where some will respond to restimulation while others do not. However, general 
properties of anergic T cells include a lack of clonal expansion (or an abortive proliferation 
response) and lack (or diminished rate) of cytokine production (Wells, 2009).    
Incomplete or chronic stimulation of T cells can also induce activation induced cell death 
(AICD). AICD is a process in which activated T cells undergo apoptosis via death receptors 
(Arakaki et al., 2014). AICD is initiated when the death/coinhibitory receptor CD95 (Fas) is 
engaged by its ligand (CD178 or FasL). The CD95 receptor then trimerizes and is bound by 
the Fas-associated death domain protein (FADD) in the intracellular region. After the binding 
of FADD to the Fas trimer, FADD-like IL-Iβ-converting enzyme (FLICE), which is a pro-
caspase-8 protein, binds the complex through the death effector domain (DED) site and 
caspase-8 is released in the cell. Caspase-8 induces cell apoptosis, as reviewed in Section 
1.4.1 (Krammer et al., 2007). Activated CTLs and NK cells are known to express FasL and 
therefore can induce AICD (Arakaki et al., 2014) 
1.5.2.7 T cell activation by silica and nanoparticles 
There is some evidence of uncoated nanoparticles effecting T cell function in the literature. 
Insoluble silicates, both amorphous and crystalline, have been found to alter T cell function 
through a phagocyte mediated mechanism (Chen et al., 2014; Pernis, 2004). Specifically, 
amorphous nanosilica increases T helper cell response through the enhancement of antigen 
presentation by dendritic cells (Brandenberger et al., 2013; Chen et al., 2014; Hirai et al., 2012; 
Marzaioli et al., 2014). Chronic exposure to crystalline silica has been shown to impair 
suppressive and enhance inflammatory function of T cells (Hayashi, 2010; Hayashi et al., 2009; 
Matsuzaki et al., 2016). In vitro exposure of peripheral cells to the crystalline silica particles 
was shown to increase T cell CD69 expression (at day 5) and IL-2 production (Ueki et al., 
1994; Wu et al., 2005a).   
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Other silicate containing materials have also been shown to enhance T cell function, though 
the mechanism behind these responses remains unknown. The addition of an alkaline mineral 
solution containing ca. 4 M Si has been found to increase peripheral T cell numbers and 
enhance T cell responses to antigen in horses and pigs (Koo et al., 2006; Yoo et al., 2001). 
Cargo-free mesoporous silica nanoparticles were shown to increase the population of effector 
memory T cells and induce cytokine production (Wang et al., 2016).  
Non-silicate nanoparticles have been well established to induce T cell activation. These 
materials, which are engineered with a peptide loaded MHC receptor coating, mimic antigen 
presentation by an APC or a target cell (Serra and Santamaria, 2015). They can also induce 
T cell activation through the delivery of antigen or drugs to APCs for enhanced responses 
(Serra and Santamaria, 2015).  The effect of non-coated nanoparticles is less well understood. 
The addition of cobalt nanoparticles and fullerenes to T cell containing cultures increases the 
levels of IFN-γ in the supernatant (Liu et al., 2009; Petrarca et al., 2005). The mechanism of 
activation induced by these materials was remains unclear. 
1.5.3 Cells that bridge innate and adaptive immune cells 
There are immune cells, mainly natural killer T (NKT) cells and γδ T cells, which are considered 
to bridge the adaptive and innate immune systems, as they share characteristics from both 
branches of immunity.  
NKT cells are a lymphocyte subset that shares properties of NK cells and T cells. These cells 
have an invariant TCR that recognises the MHC-like CD1b receptor but also can recognize 
stress signals on cells (Vivier et al., 2012; Wesley et al., 2008). γδ T cells are a less frequent 
T cell subset with a TCR consisting of γ and δ chains rather the classical α and β chains 
(Girardi, 2006). The angle between the constant and variable domain of the γδ TCR is smaller 
than that of the αβ TCR (Allison et al., 2001). γδ T cells do not recognize antigen presented in 
MHC receptors but instead recognize soluble antigens, CD1 receptors (MHC-like) and other 
proteins expressed on cell surfaces (Dar et al., 2015; Vantourout and Hayday, 2013; Wiest, 
2016; Wu et al., 2014). The recognition of antigen by γδ TCRs is similar to that of IgG (Wiest, 
2016). 
1.6 Rationale and Aim of the Thesis 
As indicated previously, humans are exposed to high levels of amorphous nanosilica daily. 
Although many studies have already been conducted, amorphous silica comprises of particles 
with such a vast range of sizes and properties (e.g., the degree of condensation) that their 
cellular activity and toxicity is not well understood. With its increasing use in biomedical 
applications, interactions between peripheral cells and nanosilica deserve further scrutiny, 
especially the small and very poorly studied particle sizes (< 10 nm). The aim of this PhD study 
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is to determine the effect of amorphous nanosilica 1-10 nm in diameter on peripheral cell 
activity and how select properties (e.g., size, resorbability) change this activity.  
First, in Chapter 3, investigations were carried out to characterize small amorphous silica 
particles, both in concentrated stock solutions and after dilution to physiological 
concentrations. In Chapter 4, the toxicity of the particles was assessed on cancerous, 
transformed and primary peripheral cells and genomic analyses were conducted to determine 
if the particles induce specific, or unique, cellular responses. Chapters 5-7 investigated the 
effects of the nanoparticles on T cell activation, the mechanism of activation, and likelihood of 
such activation occurring in vivo. Finally, investigations were conducted to determine whether 
these responses could be exploited for use as a therapeutic. 
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Chapter 2 - Methods 
2.1 Chemistry 
2.1.1 Nanosilica preparation 
Nanoparticle dispersions (< 4 nm) were prepared by diluting sodium silicate (#338443; Sigma-
Aldrich Chemical Co., Gillingham, UK) in distilled deionized water (DDW; 18 MΩ/cm) to 20-40 
mM Si and adjusting pH with hydrochloric acid (HCl, 4-5 M or 37%). The dispersions were left 
to equilibriate for 2-24 h at room temperature. Nanosilica particle size was increased (>4 nm) 
by adding a concentrated saline solution (ca. 1.5 M) immediately after pH adjustment or by 
increasing Si concentration. Micron-sized silica particles (ca. 57 nm) were prepared by freezing 
the nanoparticle solutions at -20 °C for 16-24 h immediately after pH adjustment.  Heat-treated 
nanosilica particles were prepared by incubating the nanosilica dispersion at 70 °C 
immediately after pH adjustment. The particles were doped with aluminum (Al) by adding 
concentrated aquoues AlCl (ca. 0.5 M) to the nanosilica dispersions (> 16 h after preparation) 
and incubating for 1 h. Low pH stabilization of dispersions was conducted by rapidly dropping 
the pH of a nanosilica dispersion to 1 with concentrated HCl (37%).  
Ultra-small amorphous nanosilica dispersions (<2 nm) were prepared according to Bastos et 
al. (Bastos et al., 2015). Briefly, 40-500 mM silicic acid was rapidly adjusted to pH 0.9 with 
concentrated HCl (37%). The dispersions were left to equilibriate for 0-24 h at room 
temperature. Size was increased by raising the pH of the dispersion to 4, incubating until the 
desired particle size was obtained, and dropping the pH back below 3.   
pH measurements were conducted using pH test stripes (Sigma-Aldrich Co., #P3536) or a 
combined pH/reference electrode (VWR, #662-1761), following a 2 point calibration using 
appropriate buffers.  
2.1.2 Control particles 
Ludox SM30 (W.R. Grace & Co., US) was selected as a highly condensed nanosilica control 
based on its size (7 nm) and counterion (Na+). Its hydrodynamic diameter after dilution to ca. 
25 mM was ca. 10 nm as determined by dynamic light scattering.  
Min-u-sil® 5 was acquired from US Silica Company for use as a crystalline silica positive 
control. A dispersion was prepared by baking the powder at 200 °C overnight (to break down 
any endotoxins) (Satpathy et al., 2015) and suspending in H2O (Sigma-Aldrich, #W3500).  
Aluminium clusters were prepared using methods based on those set out by Fu et al. (Fu et 
al., 1991). Briefly, an aluminium chloride solution (100 mM Al) was adjusted to pH 4.2 with 
NaOH. The resulting dispersion, which contained visible precipitation, was incubated for 24 h 
and resulted in a dispersion with a median particle size < 2 nm. Attempts were made to 
increase particle size using pH and heat, but none were successful. 
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Gold nanoparticles, (11-mercaptoundecyl)tetra(ethylene glycol) functionalized, were acquired 
from Sigma-Aldrich (#687863). The hydrodynamic diameter of the dispersion after dilution to 
ca. 40 mM Au was ca. 10 nm as determined by dynamic light scattering.  Attempts were made 
to re-disperse the particles with sonication, pH and dispersing agents (citrate) but none were 
successful. 
Iron hydroxide nanoparticles coated with adipate and tartrate were prepared by C. Bastos 
according to methods set out by Powell et al. (Powell et al., 2008). Particles were dispersed in 
water at a concentration of 40 mM Fe prior to being employed in cell assays.   
2.1.3 Characterization of nanoparticle dispersions 
Hydrodynamic particle sizes of the dispersions were determined by dynamic light scattering 
(DLS) on a Zetasizer NanoZS or NanoZSP (Malvern Instruments). Acquisition parameters for 
silicon dioxide were used for nanosilica (refractive index = 1.45, absorption = 0.01), bernalite 
for nanoiron (refractive index = 1.92, absorption = 0.10), gold for gold nanoparticles (refractive 
index = 0.20, absorption = 0.10), and aluminium hydroxide for the aluminium clusters 
((refractive index = 1.53, absorption = 0.01) all in a water solvent at room temperature (0.8872 
cP, refractive index = 1.33) ), using a 173° backscatter angle. Three replicate measurements 
were recorded and their average volume particle distribution, at which 10%, 50% and 90% of 
the particles were smaller (DV0.1, DV0.5 and DV0.9 respectively), was calculated.  
The particle size of the micron-sized silica was determined on a Malvern Mastersizer 2000 
(Malvern Instruments), using parameters for silicon oxide (refractive index = 1.45, absorption 
= 0.01) and a range of mixing speeds (500-5000 rpm) and sonication levels. Three replicate 
measurements were recorded and their average DV0.5 was calculated. 
Zeta-potential was determined using a Zetasizer NanoZSP (Malvern Instruments) using the 
same properties for silicon dioxide and water as the size measurements. A capillary cell cuvette 
(DTS1070) and the Smoluchowski model with F(κa) = 1.50 were used. The nanosilica 
dispersion was adjusted to pH 1.5 to 9 immediately prior to analysis.  Zeta-potential in PBS 
was determined by adding 10% v/v 10x PBS to the nanosilica dispersion and adjusting to pH 
7.0 to 7.1. Zeta-potential in RPMI was determined by adding 50% v/v RPMI1640 to the 
nanosilica dispersion and adjusting to pH 7.4 to 7.5. Three independent dispersions and 3 
replicate measurements were averaged. 
The dissolution of nanosilica was assessed using a molybdic acid dissolution assay derived 
from Alexander (Alexander, 1953). Briefly, 200 μL of a molybdic acid solution (0.0375 M H2SO4 
+ 34.5 mM Mo (as NH4Mo7 4H20) or 0.15 M H2SO4 + 34.5 mM Mo) was added to 100 μL of the 
test solution (nanosilica at 1 mM Si in HEPES buffer (10 and 50 mM, pH 7.4)) in a 96 well 
plate. After mixing for 10 min, the absorbance at 400, 405 or 450 nm was measured on a 
Labsystems Multiskan RC V1.5-0 plate reader (ThermoScientific, UK) or a FLUOstar Omega 
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microplate reader (BMG Labtech). The concentration of silicic acid in solution was determined 
using standard curves generated with SiF4 (1,000 mg/kg Si, Sigma-Aldrich Co). Due to the 
presence of phosphate, it was not possible to determine silicic acid concentrations in media by 
the molybdic acid assay. For this reason, dissolution and size in complex media was 
determined using ultrafiltration and ICP-OES elemental analysis. The dispersions (in 
concentrated stock and after dilution in various media) were ultrafiltered through 3, 50, 100, 
and 1,000 kDa filters (13,000 rpm, 10 min) or centrifuged (1,500 rpm, 5 min). The Si levels in 
the flow through or supernatants were determined by ICP-OES. MWCO and pore size has 
been correlated and will be used to determine the phase distribution (size) of the materials 
(Guo and Santschi, 2007). For both the molybdic acid assay and ultrafiltration, the proportion 
of Si(OH)4 was presented as a percentage of the total Si concentration (%Si as Si(OH)4 = 
[Si(OH)4]/[Sitotal] x 100%) 
A molybdic acid release assay, derived from Iler (Iler, 1979), was used to assess the formation 
of the nanosilicates and the condensation rates of labile nanosilica particles. Briefly, aliquots 
of concentrated nanosilica stocks were transferred to a 96 well plate (3.0 x 10-7 moles Si per 
well, triplicate wells prepared). Immediately after diluting the samples to 100 uL with DDW, 200 
μL molybdic acid solution (34.5 mM Mo (as NH4Mo7O244H20) in 0.15 M H2SO4)) was added 
and the absorbance at 400 nm was measured every 60 s for 5 h, agitating (400 rpm) briefly 
before each measurement. Silicic acid was used as an assay control. Area under the 
absorbance curves (Abs x h, ∆X * (Y1+Y2)/2) was calculated and used to represent relative 
condensation  
Silicon-29 nuclear magnetic resonance (NMR) spectra were acquired on a Bruker AMX500 (at 
99.35 MHz) using a silicon-free probe, a 53 s inter-pulse delay and >3000 π/2 pulses. 
Nanosilica dispersions were prepared and stabilized at pH 1 prior to being loaded into a Kel-F 
NMR tube.  
2.1.4 Tumour digestions 
In vivo tumour inhibition by nanosilica was tested by HS Pharmaceuticals, LLC, at Translational 
Drug Development (TD2, Scottsdale, Az, US) in 2012. Upon study termination, the tumours 
were excised, frozen down and couriered on dry ice (along with sera for ELISA studies 
(below)). Elemental analysis was conducted by digesting the tumours in nitric acid and 
analyzing by ICP-OES. Briefly, a section of the tumours (ca. 100 mg, freeze dried) and 500 µL 
17% HNO3 (high purity, Fluka Ltd) were added to clean PFTE vessels and the digestion was 
carried out in an Milestone UltraWave acid digestion system (Milestone S.r.l., Italy) at  140 °C 
(10 min ramp to 140 °C and 15 min at 140 °C). Sample blanks were similarly prepared without 
samples to determine Si levels in the nitric acid and contamination from the tubes. The digests 
were transferred to clean polypropylene tubes, diluted appropriately, spiked with strontium as 
an internal standard and ICP analysis was conducted.  
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2.1.5 ICP-OES analyses  
Elemental analysis was conducted by ICP-OES on a JY Ultima-2 (Horiba Scientific) fitted with 
a V-groove nebulizer and a flow rate of 0.83 mL/min was used. Media samples containing silica 
were diluted with a NaOH solution (ca. pH 10) to promote silicate dissolution and then analyzed 
for total Si at 251.611 nm. Silicon standards (0.2 to 70 ppm) were prepared in a similar matrix 
with SiF4 (1,000 or 10,000 mg/kg Si, Sigma-Aldrich Chemical Co). Media samples containing 
aluminium clusters were diluted with an HCl solution (50% w/w, 1 M) to promote particle 
dissolution and then analyzed for total Al at 396.152 nm. Aluminum standards (0.2 to 30 ppm) 
were prepared in a similar matrix with an Al standard (1,000 mg/kg Al, Sigma-Aldrich Chemical 
Co). 
Tumour digests were analysed for Si and Sr at 251.611 nm and 346.446 nm respectively. 
Standards were prepared in 17% HNO3 (high purity, Fluka Ltd) and matrix matched standards 
were prepared using pooled digest to identify wavelength interference by the matrix.  
2.2 Cell assays 
This study was approved by the University of Cambridge Human Biology Research Ethics 
Committee (ref. HBREC.2015.10). 
2.2.1 Transfected cells and cell lines 
Epstein-Barr virus transformed B cells were generously supplied by Dr Mark Wills (University 
of Cambridge, Dept. of Medicine, Addenbrookes site), transformed from two healthy donors. 
Epstein-Barr virus, a gamma-herpesvirus, infects resting B cells and causes them to proliferate 
(Chen, 2011). THP-1 cells were acquired from ATCC. Jurkat and Karpas 299 cells were 
supplied by Dr S. Turner (University of Cambridge). The cells were maintained in RPMI media 
containing 10% FBS, 0.3 g/L L-glutamine, 1% penicillin-streptomycin.  
2.2.2 Primary cells  
Peripheral blood mononuclear cells (PBMC) were isolated from single leukocyte cones 
purchased from the National Blood Service (Cambridge, UK) using density gradient 
centrifugation. Cells were used after resting 2 h or froze down in freezing media (10% DMSO, 
50% FBS, 40% RPMI 1640). Frozen cells were thawed, washed in RPMI, and rested 2 h in 
RPMI containing 10% FBS, 0.3 g/L L-glutamine, 1% penicillin-streptomycin and 0.01 µg/mL 
DNase prior to use. The enrichment of monocytes and T cells was conducted through 
monocyte adherence. For monocyte enrichment, PBMC cultures were added to a 6 well plate. 
After incubating for >1 h, non-adherent cells were discarded and adherent cells were scraped 
and transferred to a fresh 6 well plate. After repeating 3 times, cells were counted and used 
after resting for 2 h. For T cell enrichment, PBMC cultures were added to a 6 well plate. After 
incubating for >1 h, non-adherent cells were transferred to a fresh 6 well plate and adherent 
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cells were discarded. After repeating 3 times, cells were counted and enrichment was 
assessed using flow cytometry. T cell enrichment was also conducted using a Pan T cell 
isolation kit (MACS Miltenyl Biotec, #130-096-535). Briefly, PBMC cultures were resuspended 
in PBS+0.5% BSA, Pan T Cell Biotin Antibody Cocktail was added (to stain all non-T cells), 
and the cells were incubated for 5 min at 4 °C. After addition of more buffer and Pan T Cell 
Microbead Cocktail, cells were incubated at 4 °C for 10 min and passed through a LS Column 
in the magnetic field of a MACS Separator. After enrichment, cells were rested for a minimum 
of 2 h prior to use and cells enrichment was assessed using flow cytometry. 
Whole blood from healthy, consenting individuals was collected in heparin tubes and briefly 
mixed. The blood was transferred to fresh tubes in a sterile environment and more heparin 
was added (to a concentration of 0.5 mg/mL) to prevent coagulation.  
T cells from transgenic mice were isolated by cutting up, crushing and grinding freshly isolated 
spleens with frosted microscope slides. Spleens were provided by C. Fairbairn in Dr S. Turner’s 
laboratory in the Department of Pathology at the University of Cambridge. The cells were 
passed through 100 and 40 μm cell strainers before centrifuging at 350 g for 10 min. After 
discarding the supernatants, cells were resuspended in RPMI and centrifuged at 1500 rpm for 
5 min. The cells were suspended in warm tissue culture media and rested 1 h prior to treatment.  
Staphylococcal enterotoxin B (SEB, Sigma Aldrich #S4881), peptidoglycan (PG), anti-CD3, 
anti-CD28, OVA 323-339 (Scientific Laboratory Supplies, #01641) and PHA (Sigma) were as 
positive controls. 
2.2.3 Gene array 
For investigations using the cell lines (EBV B cells, THP-1), 0.5 mL of a cell suspension (at 1.2 
x 106 cells/mL in RPMI + 20% FCS) was mixed with 0.5 mL RPMI +/- 300 μM nanosilica (giving 
0.6 x 106 cells/mL, 150 uM nanosilica). Cells were incubated for 4 h and RNA was collected 
using an RNeasy Mini kit (Qiagen, #74104, below), according to manufacturer’s suggested 
protocol (below). RNA was also collected from cells at time 0. 
Freshly isolated PBMCs (Section 2.2.2) were rested in RPMI + 10% FCS for 2 h prior to testing. 
Cells were resuspended in RPMI + 20% FCS at 2 x 106 cells/mL and 6 mL was added to 50 
mL falcon tubes followed by 6 mL RPMI +/- 300 μM nanosilica (giving 1.0 x 106 cells/mL, 150 
uM nanosilica). Cells were incubated for 4 h and RNA was collected using an RNeasy Mini kit 
(Qiagen, 74104, below). RNA was also collected on cells prior to treatment (time 0). 
RNA was collected according to the manufacturer’s suggested protocol. Briefly, after 
incubating, centrifuging and decanting the supernatant, the RLT buffer and an equivalent 
volume of ethanol (70%) was added to pellet. After mixing thoroughly (through tituration), the 
lysate was transferred to the RNeasy Mini spin column and centrifuged at 8,000 g for 15 s. The 
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RNA (retained on the column) was washed with RW1 and RPE buffer (spinning at 8,000 g for 
15 s) followed by another wash with RPE buffer (8,000 g for 2 min). RNase-free water was 
used to elute the RNA (spinning at 8,000 g for 1 min). 
RNA quantity and quality (by gel electrophoresis) was determined and RNA was stored at  
-80 °C. Samples were shipped on dry ice to Wageningen University for analysis.  
Differences in expression were calculated using an R package limma based on the log2 
intensities using the following calculations:  
For cell lines 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =  2(𝑙𝑜𝑔2(𝑎𝑣𝑔(𝑛𝑎𝑛𝑜𝑠𝑖𝑙𝑖𝑐𝑎))− 𝑙𝑜𝑔2(𝑎𝑣𝑔(𝑐𝑜𝑛𝑡𝑟𝑜𝑙))) 
For PBMCs 
𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 𝑎𝑣𝑔𝑑𝑜𝑛𝑜𝑟𝑒 𝐴−𝐷(2
(𝑙𝑜𝑔2(𝑛𝑎𝑛𝑜𝑠𝑖𝑙𝑖𝑐𝑎,𝑑𝑜𝑛𝑜𝑟 𝐴−𝐷)− 𝑙𝑜𝑔2(𝑐𝑜𝑛𝑡𝑟𝑜𝑙,𝑑𝑜𝑛𝑜𝑟 𝐴−𝐷))) 
 
2.2.4 Flow cytometry assays 
2.2.4.1 Cell treatment 
Test media was prepared immediately prior to addition to cells (with the exception of silicic 
acid). Silicate stocks were filter sterilized (0.2 µm) prior to or after addition to RPMI medium, 
with the exception of the > 100 nm particles which were filter sterilized (0.2 µm) immediately 
after pH adjustment (i.e., before freezing or sterile saline addition). Treatments from low pH 
nanosilica stocks were prepared by either adding the silicate to RPMI, neutralizing with NaOH, 
and filter sterilizing or by added sterile NaOH to RPMI media and adding the sterilized silicate. 
RPMI supplemented with silicic acid was prepared by diluting sodium silicate (ultrapure, 
supplied by Prof. S.D. Kinrade) or Sigma-Aldrich sodium silicate into RPMI, mixing for 5-30 
minutes (spiral mixer) and neutralizing with HCl. After pH neutralization, the media was sterilize 
filtered. The control solution (vehicle) was prepared with NaOH in place of sodium silicate.  
Cells were also treated in Basic Salt Solution (BSS) media.  BSS was prepared as according 
to Pereira et al. (Pereira et al., 2015). Briefly, 1.52 g piperazine-N,N′-bis(2-ethanesulfonic acid) 
(PIPES) was dissolved in 500 mL DDW at ca. 60 °C. After cooling, pH was adjusted to 6.5 and 
NaCl (3.80 g), KCl (0.37 g), MgSO4 (0.06 g), glucose (0.45 g) and CaCl2 (0.11 g) was dissolved 
in the solution. The pH was adjusted back to 6.5 and the media was filter sterilized prior to use.  
2.2.4.2 Cell staining 
CFDA-SE based proliferation assays 
Proliferation was measured by staining the cells with carboxyfluorescein diacetate, 
succinimidyl ester (CFDA-SE, 90%, Sigma-Aldrich Chemical Co., UK). A 10 mM CFDA-SE (in 
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DMSO, stored at -20 °C) aliquot was thawed and diluted to 10 µM in sterile PBS. The CFDA-
SE was diluted further with PBS to a working concentration of 0.1 µM, in which the cells (at ca. 
106 cells/mL) were suspended. After incubating at 37 °C for 7 min, 1 mL FBS and ca. 6 mL 
RPMI + 10% FBS were added to the suspension followed immediately by centrifugation at 
1500 rpm for 5 min. The supernatant was decanted and the pellet was washed twice with 1 
mL FBS and >10 mL RPMI + 10% FBS.  The intensity of CFDA-SE (excitation filter 488 nm 
and emission filter 588 nm) in the cells after the incubation period was used to determine the 
number of cell divisions. For EBV transformed B cells, the proliferation index was calculated 
using: 
          Proliferation index (PI) =  
∑
Ni
2i
 x i
∑
Ni
2i
 
where “N” is the number of events within the generation “i.” The gating of the generations was 
determined by taking the intensity mean of the CFSE stained cells fixed at experimental time 
0 (generation 0) and gating in between the calculated mean intensities of each generation (the 
daughter generation has half the intensity of the parent generation). Representative plots of 
gating are shown in Appendix 1. Data is represented as a percent of the vehicle control. As 
the sodium levels of the nanosilica treatments varied significantly (and consequently their 
vehicle controls), the effect of sodium on cell proliferation was determined. There was only a 
ca. 5% reduction of cell proliferation at the highest sodium concentration that is used in a 
nanosilica stock (data not shown).  
For T cell assays (conducted in PBMC), proliferation was represented as % divided, which 
corresponds to the % of CD4 or CD8 T cells that had undergone one or more rounds of division. 
Representative plots of gating are shown in Appendix 1. 
Lysing  
Prior to staining with fluorescence antibodies (below), whole blood cultures and spleen isolates 
required additional lysing steps to remove red blood cells. Briefly, 2 mL 1x BD Pharm lyse 
(#555899) solution was added to the sample tubes and the samples were gently vortexed. 
After 15 min at room temperature (not exposed to light), the tubes were centrifuged at 200 g 
for 5 min and the supernatants were carefully aspirated. Cells were washed twice with PBS + 
1% BSA (for 7-AAD viability staining, below) or PBS (for Invitrogen live-dead staining, below) 
and the supernatants were aspirated. The cells were washed once more with the respective 
buffers followed by centrifuging at 1500 rpm for 5 min. 
Samples using the 7-AAD viability stain 
Cells were stained for flow cytometry analysis according the manufacturer’s suggested 
protocol with minor changes. Briefly, the cell suspensions were topped up with cold PBS + 1% 
BSA (BSA source: Labtech, #PM-T1725) and centrifuged at 1500 rpm for 5 min. After 
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decanting the supernatants, the cell surface antibodies (in a mixed cocktail) were added to the 
cells in the remaining supernatant (<100 uL). The samples were incubated on ice for 20 min. 
The 7-AAD viability stain was then added and the cultures were incubated for 10 min at room 
temperature. The cells were washed with cold PBS + BSA and fixed in PBS + 2% 
paraformaldehyde. Flow cytometry analyses were conducted within hours.  
Samples using the Invitrogen live-dead stain 
Cells were stained for flow cytometry analysis according the manufacturer’s suggested 
protocol with minor changes. Briefly, the cell suspensions were topped up with cold PBS and 
centrifuged at 1500 rpm for 5 min. After decanting and blotting the supernatants, the Invitrogen 
live dead stain was added to the cells in the remaining supernatant (<100 μL). The samples 
were incubated on ice for 20 min and washed with cold PBS + BSA. The cell surface antibodies 
(in a mixed cocktail) were added to the cultures and the samples were incubated on ice for a 
minimum of 20 min. The cells were washed with cold PBS + BSA and fixed in PBS + 2% 
paraformaldehyde. Flow cytometry analyses were conducted within hours 
Bacterial and bead uptake studies 
Enriched monocytes cultures were treated with nanosilica followed immediately by addition of 
fluorescent beads (final concentration 25 μg/mL) or bacteria (final concentration 3 μg/mL) 
(details of beads and bacterial can be found in Table 2.01). Cultures were incubated for 1 or 3 
h, stained (using the Invitrogen live-dead stain) and flow cytometry was conducted within hours 
Apoptosis-necrosis staining 
Apoptosis and necrosis was measured using the manufacturer’s suggested protocol. Briefly, 
the cell suspensions were topped up with cold PBS + 1% BSA and centrifuged at 1500 rpm for 
5 min. After decanting the supernatants, the cell surface antibodies (in a mixed cocktail) were 
added to the cells in the remaining supernatant (<100 μL). The samples were incubated on ice 
for 20 min. Cultures were then washed twice, once with PBS + 1% BSA and once with PBS. 
After decanting the supernatant, 100 μL annexin buffer (10 mM HEPES, 140 mM NaCl, 2.5 
mM CaCl2, pH 7.4), annexin V and 7-AAD were added to the cells. Cultures were incubated 
for 15 min at room temperature. Annexin buffer (400 uL) was then added and the cells were 
stored on ice followed immediately by flow cytometry analyses. 
Intracellular FoxP3 staining 
Cells were stained for the intracellular FoxP3 protein through permeabilization of the cell 
membrane. Briefly, after staining for surface receptors (Samples using the 7-AAD viability 
stain, without the addition of PBS+2% paraformaldehyde), cells were washed with cold PBS + 
1% BSA. After discarding the supernatant, 250 μL permeabilization solution (100 mL FACS 
lysing solution (BD Biosciences, #349202), 400 mL H2O and 250 μL TWEEN 20 (Sigma), at 
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room temperature) was added to each tube and mixed. After incubating for 10 min (not 
exposed to light), the cells were washed twice with cold PBS + 1% BSA (centrifuged at 1800 
rpm for 8 min, at 4 °C). The intracellular fluorescent antibody was added to the remaining 
supernatant after decanting and cultures were incubated for 20 min on ice. The cells were then 
washed with cold PBS + 1% BSA (centrifuged at 1800 rpm for 8 min, at 4 °C), resuspended in 
cold PBS + 1% BSA, and flow cytometry was conducted immediately. 
2.2.4.3 Flow cytometry analyses 
Flow cytometry was conducted using a Beckman Coulter CYAN ADP flow cytometer (“Cindy”), 
equipped with 405, 488 and 642 nm solid-state lasers and 11 detectors in standard 
configuration. Beckman Coulter Summit software was used for analyses and acquisition. The 
flow cytometer was calibrated with alignment beads (Spherotech, USA), and the coefficients 
of variation for each channel was within the range set by manufacturer. For EBV transformed 
B cells, a minimum of 30,000 gated events were acquired for each suspension. For THP-1, 
Karpas 299, Jurkat, PBMC, enriched T cell cultures, 400,000 events or the complete 
suspensions were acquired. For whole blood and cells extracted from mouse spleens, total 
suspensions were acquired. All cultures were filtered through 35 uM nylon mesh prior 
immediately prior to analysis.   
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Table 2.01. Human antibodies and markers used throughout the investigations  
Marker Stain Supplier 
annexin Pacific Blue ThermoFisher Scientific (#A35122) 
TCR FITC BD Pharmingen (#555547) 
TCRγδ 
PE BD Pharmingen (#333141) 
FITC BD Pharmingen (#347903) 
CD3ε 
PE-Cy5 BD Pharmingen (#555334) 
PE BD Pharmingen (#555340) 
VioGreen Miltenyi Biotec (#130-096-910) 
PE-Cy7 BD Pharmingen (#557851) 
FITC BD Pharmingen (#555332) 
APC-Cy7 BD Pharmingen (#557832) 
CD3-LEAF unconjugated Biolegend (#300414) 
CD4 
PE BD Pharmingen (#555347) 
PE-Cy5 BD Pharmingen (#555348) 
FITC BD Pharmingen (#555346) 
PE-Cy7 BD Pharmingen (#557852) 
CD8 
APC Miltenyi Biotec (#130-091-076) 
APC-Cy7 BD Pharmingen (#557834) 
PE BD Pharmingen (#555635) 
CD11b PE-Cy7 Biolegend (#101216) 
CD11c 
APC BD Pharmingen (#559877) 
PE-Cy5 BD Pharmingen (#551077) 
PE-Cy5.5 Invitrogen (#MHCD11C18) 
CD14 Alexa Fluor 488 BD Pharmingen (#557700) 
CD16b PE BD Pharmingen (#550868) 
CD19 
APC-Cy7 BD Pharmingen (#557791) 
PE-Cy5 BD Pharmingen (#555414) 
CD25 
FITC BD Pharmingen (#555431) 
APC-H7 BD Pharmingen (#560225) 
CD28-LEAF unconjugated Biolegend (#302914) 
CD56 
APC BD Pharmingen (#555518) 
PE-Cy7 BD Pharmingen (#557747) 
CD57 VioBlue Miltenyi Biotec (#130-096-530) 
CD69 
APC BD Pharmingen (#555533) 
FITC BD Pharmingen (#555530) 
CD95 (Fas) APC BD Pharmingen (#558814) 
CD107a FITC BD Pharmingen (#555800) 
CD142 PE BD Pharmingen (#550312) 
CD154 (CD40L) APC BD Pharmingen (#555702) 
CD172a,b (SIRP- α) PE BD Pharmingen (#563441) 
CD178 (FasL) PE BD Pharmingen (#564261) 
CD274 
PE BD Pharmingen (#557924) 
APC BD Pharmingen (#563741) 
FITC BD Pharmingen (#558065) 
CD278 (iCOS) PE BD Pharmingen (#557802) 
CD279 (PD-1) FITC BD Pharmingen (#557860) 
Forkhead box P3 (FoxP3) Alexa Flour 647 BioLegend (#320214) 
Glycoprotein A reptitions 
predominant (garpin, GARP) 
APC BioLegend (#352506) 
IgG FITC BD Pharmingen (#555786) 
Latency associated peptide (LAP) PE eBioscience (#12-9829) 
Polystyrene fluorescent beads FITC Bangs Laboratories (#FS03F/5069) 
Proliferation CFDA-SE (FITC) Sigma-Aldrich (90%, #150347-59-4) 
S. aureus (wood strain without 
protein A) 
FITC Life Technologies (#S2851) 
Target cell Violet ThermoFisher Scientific (#C34557) 
Viability 
Violet fluorescent 
reactive dye 
Invitrogen (#L34955) 
7-AAD 
Life technologies (#A1310), Biolegend 
(#420404) 
 
 
35 
 
Table 2.02. Mouse antibodies and markers used throughout the investigations  
Marker Stain Supplier 
TCR Vα2 PE BioLegend (#127808) 
CD3 V500 BD Pharmingen (#560773) 
CD4 
PE-Cy5 BD Pharmingen (#561836) 
PE-Cy7 BD Pharmingen (#552775) 
CD8b PE BD Pharmingen (#550798) 
CD25 FITC BD Pharmingen (#558689) 
CD69 APC BD Pharmingen (#560689) 
 
2.2.5 Western blot analyses 
Western blot analyses was conducted on lysates of T cells enriched from PBMC cultures (using 
the Pan T cell isolation kit, above). After treatment with nanosilica, the cultures were incubated 
for 0.2-6 h, centrifuged (1,500 rpm, 5 min) and the supernatants were discarded. The cells 
were lysed with 100 μL lysis solution (1 x NuPAGE LDS Sample buffer (Invitrogen, #NP0007), 
1 x Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, #78440) in H2O), 
titurated, and diluted with 300 μL H2O. Lysates were stored at -80 °C until protein analyses 
were conducted. 
For the western blot analyses, cells lysates were diluted in a reducing agent cocktail (6.5 μL 
lysate, 5 μL NuPAGE LDS Sample buffer, 2.5 μL NuPAGE Reducing agent (Invitrogen, cat# 
NP0004), 11 μL H2O) and were heated at 70 °C for 10 min. The gels (4-12% Bis-Tris, 
Invitrogen, #NP0321/0322) were loaded with 15 μL diluted lysates (with the appropriate 
ladders/blanks) and run at 100-150 V in a SDS MOPS running buffer (Invitrogen, #NP0001), 
where the SDS MOPS running buffer in the inner chamber contained NuPAGE Antioxidant 
(Invitrogen, #NP0005). After electrophoresis, the protein was transferred to the membrane 
(PVDF, Invitrogen, cat# LC2005, pre-soaked in methanol) in transfer buffer (10% methanol, 1 
x NuPage Transfer buffer (Invitrogen, #NP00061), 0.1% NuPAGE antioxidant) between filter 
paper and blotting pads, run at 30 V for 60 min. The membrane was then removed from the 
blot module and immersed in block buffer (Thermo Scientific, #37571) for 1 h. The membrane 
was then transferred to a 50 mL centrifuge tube (protein facing in) with 3 mL block buffer 
containing primary antibody (1:1000 dilution, antibody specification below) and was incubated 
overnight at 4 °C (while mixing). The membrane was then rinsed with tris buffered saline with 
TWEEN20 (TBST, Cell signalling, #9997) followed by 5 wash steps (5 min on a shaker in 
TBST). The secondary antibody (HRP-conjugated) was then added and incubated for 30 min 
(while mixing) at room temperature. The membrane was washed with TBST (rinse + 5 x 
washes, as before) and Pierce ECL Plus Western Blotting Substrate (Thermo Scientific, 
#32132) was added. After incubated (while mixing) for 5 min at room temperature, the excess 
substrate was blotted off with filter paper and the membrane was analysed on a GeneGnome 
XRQ digital imager using the ECL Plus reagent settings. Acquisition time was incrementally 
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increased until a signal band (of interest) was saturated. Band volume was determined through 
integration using GeneTools (Syngene) software. An example of the integrations is shown in 
Appendix 1. Antibodies used in the western blot analyses were vinculin (Thermo Scientific, 
#7000626, 1:1000 dilution), pZap70 (Cell Signalling Technology, #2701, 1:1000 dilution) pLAT 
(Cell Signalling Technology, #3584, 1:1000 dilution), Goat anti-rabbit IgG Secondary Antibody, 
HRP-Conjugated (#A16096, 1:1000 dilution) and Precision Protein StrepTactin-HRP 
Conjugate (Bio-Rad, #1610380, 1:10,000 dilution). Precision Plus Protein Western C 
Standards (Bio-Rad, #1610376) was used as the ladder. 
2.2.6 Enzyme-linked immunosorbent assay 
Cytokine analysis was conducted using duoset ELISA kits according manufacturer’s 
specifications. Briefly, 100 μL capture antibody (in PBS) was added to each well of a 96 well 
plate (R&D Systems, #DY990). After incubating overnight, the wells were washed 3 times with 
PBS + 0.05% TWEEN 20, inverting the plate and blotting on paper towel (for the last wash). 
Block buffer (PBS + 1% BSA, 300 μL) was added to each well and incubated for >1 h. After 
washing (3 times, as before), 100 μL sample (or standard made up in CGM or tris buffer saline 
(TBS) + 0.1% BSA + 0.05 TWEEN 20) was added to each well and incubated for 2 h. Plate 
was washed (as before) and 100 μL detection antibody (in TBS + 0.1% BSA + 0.05 TWEEN 
20) was added to each well followed by incubation for 2 h. After washing (as before), 100 μL 
Streptavidin horseradish-peroxidase (HRP) was added to each well and incubated for 20 min 
followed immediately by addition of 1 M H2SO4 (Stop solution). Absorbance at 450 nm and 540 
nm (wavelength correction) were made using a FLUOstar Omega microplate reader (BMG 
Labtech). A 4-parameter logistic regression was used to interpolate for the unknown values. 
For analyses of IFN-γ levels, normal goat serum was used in place of BSA in the diluent 
containing the detection antibody (according manufacturer’s specifications). IL-2 (#DY202), IL-
4 (#DY 204), IL-10 (#DY217B), IFN-γ (#DY285) and lymphotactin (#DXCL10) ELISA kits were 
acquired from R&D Systems. Mouse IgG (#ab151276) and IgM (#ab133047) ELISA kits were 
acquired from Abcam plc, for the analysis of the sera from mice in the in vivo tumour growth 
inhibition studies conducted at Translational Drug Development (TD2, Scottsdale, Az, US) in 
2012 (methods available upon request). Upon study termination, sera was collected and stored 
at -80 °C and shipped on dry ice prior to analyses. Sera was also sent to Myriad RBM for a 
thorough assessment of serum analyte levels. 
2.2.7 Statistical analysis 
Statistical analyses employed are indicated in Figure caption. Most commonly, data is 
expressed as means ± standard deviation (unless otherwise stated). Statistical analyses 
commonly employed include two-tailed Student T-test and a Two-way Anova, where a P value 
of > 0.05 was not considered significant. 
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2.3 In vivo studies 
In vivo studies were conducted under project licence 80/2574 by Drs J. Shields and L. Pedro 
(MRC-CU). For the subcutaneous melanoma tumour model, female C57BL/6 mice were 
injected with 2.5 x 105 B16-F10 cells (ATCC) on both shoulders. Tumour growth was monitored 
for 14 days or until tumour sizes reached the maximum legal limit (12 mm diameter). Mice were 
treated with nanosilica or saline (200 μL) intravenously on days 4, 6, 8, and 11. Tumour 
volumes were calculated by: Volume=π/6×small2×longest. In the metastatic melanoma model, 
mice were intravenously injected with 1.5 x105 B16-F10 cells. Mice were intravenously treated 
with 200 μL nanosilica or saline on days 1, 4, 7, 11, 14, and 18.  Animals were sacrificed on 
day 21 and nodule counts were performed. 
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Chapter 3. Synthesis and characterization of amorphous silica nanoparticles 
3.1 Introduction  
Silica particles can be prepared using various synthetic routes, including the Stӧber reaction, 
Sol-gel synthesis, fuming, and precipitation, the lattermost being the focus of the investigations 
conducting here.  
Amorphous silica nanoparticles are inherently metastable and can undergo processes such as 
Ostwald ripening and agglomeration. Ostwald ripening, as described in the Introduction, occurs 
when the monomeric unit of the system, monosilicic acid for nanosilica, dissolves from the 
smaller particles and resorbs onto the surfaces of larger particles (Belton et al., 2012; Iler, 
1979; Kobayashi et al., 2005). Agglomeration is the formation of larger particles through the 
clustering of the smaller base particles (Belton et al., 2012). The clusters can be loosely bound 
or strongly assembled and are referred to as agglomerates and aggregates, respectively 
(Nichols et al., 2002; Powell et al., 2010). The rate of colloidal silica agglomeration has been 
shown to be greatest at pH 5-7 (Bergna and Roberts, 2005). 
Silica nanoparticle dispersions prepared using the precipitation synthetic route, which can 
produce nanoparticles under 10 nm in size, were the primary focus of these investigations. 
The properties of colloidal silica produced via this method are highly dependent on the 
conditions during preparation. Total Si concentration, pH, temperature, time, and the presence 
of salts (alkali metal salts and ammonium salts) can alter the particle properties significantly 
(Gorrepati et al., 2010; Musić et al., 2011). Using such influences, colloidal silicate suspensions 
of different sizes and properties (mainly dissolution rate in dilute condition) were generated, as 
outlined in the Methods, and were characterized in this chapter for use in subsequent cellular 
investigations (Chapters 4-7).  
3.2 Results and discussion 
3.2.1 Synthesis and Characterization 
3.2.1.1 Nanosilica stability and size 
Silica nanoparticles were prepared here by adjusting the pH of an alkaline sodium silicate 
solution at a concentration that exceeded the solubility of silicic acid at the desired final pH 
(see Chapter 1).  Figure 3.01A and B show the resulting dispersion from adjusting a 23 mM 
Si(OH)4  solution (pH~11) to pH 7 and incubating for >12 h. The first size measurement was 
conducted >12 h after preparation to allow time for the pH and particle distribution to 
equilibriate. At 24 h, the median particle size was ca. 3.6 nm (Figure 3.01B), with a narrow size 
distribution (2-8 nm). The stability of the nanosilica dispersion was investigated beyond 24 h, 
as these dispersions are known to be inherently unstable at physiological pH (Belton et al., 
2012; Bolt et al., 1997; Iler, 1979; Kobayashi et al., 2005). Figure 3.01A shows the particle size 
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distribution of a nanosilica dispersion at pH 7 over 28 days. Over time, the size distribution 
broadened, yielding particles ca. 80% larger on day 28 (Figure 3.01A). 
Ionic strength was used to generate larger particles at a more rapid rate. Concentrated saline 
was added to the silica dispersion immediately after pH neutralization and prior to incubating 
for 16-24 h. Figure 3.01B shows the particle size distribution of nanosilica dispersions 
containing different concentrations of Na+. Particle size increased with the concentration of 
Na+. As increased ionic strength is known to promote agglomeration rather than Ostwald 
ripening (Belton et al., 2012; Iler, 1979), it is likely that these large particles are agglomerates, 
comprised of small particles subunits. Unfortunately, this method of increasing particle size 
also increases the particle size range within the dispersion (i.e., it increases polydispersion). 
The particle size distributions are reported as volume median diameter (DV0.5). 
 
 
Figure 3.01. A. Measured particle size distribution over time after neutralization (to pH 7) of a 
23 mM Si silica dispersion. Size is represented as DV0.1, DV0.5 and DV0.9, i.e., the size 
where 10%, 50% and 90% of the particles have a smaller diameter. Data are means and SD 
of 3 replicate measurements per dispersion B. Particle size distribution of silica dispersions 
(ca. 23 mM Si, pH 7) containing different concentrations of saline, 24 h after neutralisation and 
incubation at room temperature. Data are means of 3 independent dispersions with 3 replicate 
measurements per dispersion 
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3.2.1.2 Nanosilica dissolution and size in dilute conditions (physiological 
concentrations) 
An important property of nanosilica particles is their dissolution rate in dilute conditions, i.e., at 
a concentration below the solubility limit of amorphous silica (ca. 1.7 mM Si at pH 7), as it more 
closely mimics in vivo concentrations. The importance of this property is exemplified by 
crystalline silica, which has chronic inflammatory properties due in part to its 
longevity/persistence, a product of its very slow dissolution rate (Greenberg et al., 2007; 
Rimstidt, 1997). Amorphous silica particles have been shown to dissolve readily after dilution 
while crystalline silica particles do not (Kalia et al., 2016; Rimstidt, 1997). Figure 3.02A shows 
the effect of particle size on dissolution rate. Particle size, which was increased using the 
previous techniques, had very little effect on nanosilica dissolution, all particles <19 nm in 
diameter being > 85% dissolved after 24 h. These date would indicate further that the increase 
in particle size is through weak agglomeration (not aggregation or Ostwald ripening) and, when 
diluted to ca. 1 mM Si, the agglomerates slowly break apart and release their small particles 
subunits which dissolve at the same rate. The larger, micron sized silica particles had a slower 
dissolution rate, suggesting that the particles are more strongly assembled (i.e., are 
aggregates) and remain intact when diluted to ca. 1 mM Si.   
Further investigations were carried out in cell culture media, which contains a higher ionic 
strength, amino acids and other components that may affect the particle size and dissolution 
rate. However, due to the dilute concentrations and low light scattering properties of nanosilica, 
along with the presence of proteins from the serum added, dynamic light scattering size 
measurements were not possible. Additionally, the presence of phosphates, which react with 
molybdic acid in a similar fashion to silicates, in the media prevented the use of molybdic acid 
assays for determining dissolution rates. Therefore, 1,000 kDa ultrafilters (11 nm average pore 
size (Guo and Santschi, 2007)) were used to determine whether particle size was maintained 
while the dissolution rate was determined with 3 kDa ultrafilters (1-2 nm average pore size 
(Guo and Santschi, 2007)). Figure 3.02B shows the percentage of silicon that passed through 
3 and 1,000 kDa ultrafilters after a 3.6 nm nanosilica dispersion was diluted in RPMI + 10% 
FBS media and incubated at 37 °C for 0.5 and 1 h. The majority of the silicon passed through 
the 1,000 kDa ultrafilter, suggesting that significant agglomeration does not occur after dilution 
in cell culture media. At 1 h, 30-50% of the silicon passed through the 3 kDa ultrafilter, 
suggesting that the nanosilica readily dissolves or breaks up into particles under 1 nm in size 
after dilution. Indeed, >90% of the silicon passed through a 3 kDa ultrafilter 8 h after dilution 
(Figure 3.02C). Given that the nanosilica particles completely dissolved within 24 h at room 
temperature (Figure 3.01A) and that dissolution rates increase with temperature (Amram and 
Ganor, 2005; Cama et al., 2002), it is likely that the silicon that passed through the 3 kDa 
ultrafilter is predominantly silicic acid, and not particles <1 nm in size.  
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3.2.1.3 Effect of aluminium, heat and pH on nanosilica size and dissolution 
As persistence in dilute conditions is viewed as a very important property of nanoparticles, 
methods were developed to generate particles with longer lifetimes after dilution. Figure 3.03A 
shows the dissolution rate of a nanosilica dispersion doped with Al prior to dilution in HEPES 
buffer. Nanosilica dispersions (ca. 25 mM Si) prepared using Sigma-Aldrich sodium silicate 
naturally contain ca. 0.04 mM Al, giving a Si to Al ratio of 599:1. The ratio was increased to 74 
Si:1 Al by adding further Al to the dispersion and incubating for 1 h. Increasing the Al levels 
beyond this ratio resulted in complete agglomeration of the dispersion. The additional Al 
prevented a fraction of silicon from solubilizing. This corroborates with studies that showed that 
Al added to dilute silicate solutions (ca. 0.15 mM Si) leads to the formation of aluminosilicate 
nanoparticles, which have a lifetime of greater than 50 d (Jugdaohsingh et al., 2013; Taylor et 
al., 1997). 
 
Figure 3.02.A. Effect of particle size on dissolution rate after dilution of silica dispersions (23 
mM Si, pH 7.0) to ca. 1 mM Si in HEPES buffer (pH 7.0-7.3). Data are means and SD of 3 
replicate measurements per dispersion. B. Percentage of silicon that passed through a 3 and 
1000 kDa ultrafilter following dilution of a nanosilica dispersion (23 mM Si, pH 7.0) to ca. 0.8 
mM Si in RPMI media containing 10% FBS media and incubation at 37 °C for 0.5-1 h. Data 
are means and SD of >6 independent dispersions (for 3 kDa) and 3 independent dispersions. 
C. Percentage of Si that passed through a 3 kDa ultrafilter following dissolution of a nanosilica 
dispersion (23 mM Si, pH 7.0) to ca. 0.8 mM Si in RPMI containing 10% FBS at 37 °C. Data 
are means and SD of >6 independent dispersions. 
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Another way to increase particle lifetime is heat. Figure 3.03B shows the dissolution rate of a 
nanosilica dispersion heated to 70 °C. The particle size increased with heating time, yielding 
particles 6.9 nm in size after 24 h at 70 °C (data not shown). There was an observed decrease 
in dissolution rate with heating time (Fig. 3.03B), where, for example, the non-heat treated 
particles were completely dissolved within 24 h and only ca. 50 % of the 24 h heat-treated 
particles were dissolved at 96 h. It is likely that heat induces particle ripening, either through 
Ostwald ripening or the formation of aggregates, and consequently increases silicate 
condensation (as determined using 29Si NMR spectroscopy (below)).  A highly condensed 
commercial silica nanoparticle (Ludox SM30, DV0.5 = 11 nm) was shown for comparison. 
These particles, which are produced at high temperatures (Bechtold and Snyder, 1951), 
dissolve very slowly in dilute conditions.  
Lastly, pH can be used to increase particle condensation. Figure 3.04 shows the dissolution 
rate of nanosilica particles prepared at 100 mM Si and pH 10. The proportion of soluble silicon 
is greater at pH 10 than at pH 7, as evident from the initial measurements (time 0) which 
indicated that ca. 30% of the silicon is readily soluble at pH 10 compared to less than 20% at 
pH 7 (Figure 3.02 & 3.03). A higher concentration of silicic acid is known to promote exchange 
between soluble and particulate silica, i.e., particle ripening (Lifshitz and Slyozov, 1961). 
Indeed, particle lifetime in dilute conditions increased with an increasing period of incubation 
(of the stock dispersion) at pH 10. The stability of nanosilica dispersions is also greater at high 
pH (Bergna and Roberts, 2005), and therefore longer incubation times can be used without 
there being significant particle agglomeration. All dispersions tested here ranged from 3.6 nm 
to 5.3 nm in diameter and there was no correlation between size and incubation time.   
 
Figure 3.03. The effect of A) Al doping and B) heating (70 °C) on the dissolution rate of 
nanosilica dispersions (23 mM Si, pH 7) after dilution to ca. 1 mM Si in HEPES buffer (pH 7.0-
7.3). Both Al-doping and heating at 70 °C increased the size of the particles (in their stocks) 
but all remained between 3.6 and 6.9 nm. (Note - data similar to B (at 60 °C) was previously 
patented (Bastos et al., 2015)). Data are means and SD of 3 replicate measurements per 
dispersion. 
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Figure 3.04. The effect of incubation time at pH 10 on the dissolution rate of nanosilica 
dispersions (100 mM Si) after dilution to ca. 1 mM Si in HEPES buffer (pH 7.0-7.3). After 
incubating at pH 10, the dispersions were stabilized by rapidly adjusting pH to 1 (see Section 
3.2.7). All particles were between 3.6 and 5.3 nm in size (DV0.5) and there was no correlation 
between size and incubation time. The error associated with the values is 5% but error bars 
were left out for clarity (Note - this data was previously patented (Bastos et al., 2015)). Data 
are means of 3 replicate measurements per dispersion. 
 
3.2.1.4 Low pH synthesis of particles  
The previous synthetic strategy, i.e., precipitation at near-physiological pH, successfully 
generates the particles > 3 nm in size. As it does not consistently generate particles < 2 nm in 
diameter, an alternative synthetic strategy was employed. By rapidly adding a concentrated 
acid to an alkaline silicic acid solution, nanosilica particles ca. 1 nm in diameter can be 
generated at high concentrations (Bastos et al., 2015; Bronder, 1999; Kerek, 2010). Figures 
3.05A and B show the size and dissolution rate of a nanosilica dispersion prepared at 500 mM 
and pH 0.8 (after 24 h incubation). The particles were smaller than those produced at pH 7, 
despite being prepared at a much higher Si concentration (>10 times more concentrated). 
These results might suggest that rapid adjustment to low pH increases the number of 
nucleation points, thereby generating a greater number of smaller particles. The particles 
prepared at low pH dissolve very rapidly upon dilution to 1 mM Si (Figure 3.05B). 
Approximately 50% of the particles were dissolved 0.2 h after dilution and 100% dissolution 
was reached before 2 h. The increased dissolution rate is likely in part due to the increased 
surface area of the particles. Whether an increased degree of amorphousness, i.e., a decrease 
in the amount of silicate connectivity/condensation within the particle, also contributes to the 
increased dissolution rate is unknown. The rapid formation of the particles could be inducing 
precipitation of silicic acid in a less organized fashion.  
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Figure 3.05. Particle size distribution of a nanosilica dispersion (500 mM Si incubated at pH 
0.8 and at room temperature for 24 h, A) and its dissolution rate (B) after dilution to ca. 1 mM 
Si in HEPES buffer (pH 7.0-7.3). Data are means and SD of 3 replicate measurements per 
dispersion. 
 
3.2.1.5. Silicon-29 NMR analysis of nanosilica particles 
Silicon-29 NMR spectroscopy has been used to characterize the degree of condensation of 
insoluble silicate dispersions (Fedeyko et al., 2004; Kalia et al., 2016). The chemical shifts of 
silicate centres with varying degrees of condensation (i.e., Q0-Q4) have been assigned and 
provide a method to quantify the proportion of the silicate centres within a dispersion.  
Here, 29Si NMR spectroscopy was used to characterise two dispersions of approximately the 
same size with varying dissolution rates (the representative size and dissolution plots are 
shown in Figure 3.06A & 3.06B). To maximize signal intensity, dispersions were prepared 
using isotopically enriched silicic acid (99.35% 29Si) which contain a higher sodium 
concentration than the non-enriched stock. Therefore, the particle size distribution of the 
dispersions could potentially be larger than what is shown in the representative plots (which 
show dispersions prepared from normal sodium silicate). Figure 3.06C shows the 29Si NMR 
spectra of the nanosilica dispersions stabilized at pH 1.5. The signals at 0 and -9 ppm 
correspond to orthosilicic acid (Q0) and the silicic acid dimer (Q12) respectively, while the broad 
signals below -15 ppm correspond to the insoluble portion of the dispersion. The lack of 
definition (sharpness) in the signals corresponding to the insoluble portion of the silicate 
dispersion is due to the environmental heterogeneity of the silicate centres. For example, the 
particles contain many Q4 silicate centres and, as there is a complete lack of structure (i.e., it 
is amorphous rather than crystalline), each of these silicate centres is subjected to a slightly 
different chemical environment. Each silicate centre consequently has a slightly different 
chemical shift and, as a result, broad signals (lumps) are present rather than sharp signals. 
The signals from -15 ppm to -32 ppm were assigned to partially condensed silicate centres (Q2 
and Q3) and those further down in frequency (-32 ppm to -52 ppm) were assigned to fully 
condensed silicate centres (Q4), as previously assigned by Kalia et al. (Kalia et al., 2016).  
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Table 3.01 shows, for the two dispersions, the percentage of soluble and insoluble silicon and 
the distribution of silicate centres (or the condensation of silica) within the insoluble portion, as 
determined by spectral integration. Despite storage at the same final pH, the soluble silicon 
content of the materials differed and both were higher than the solubility limit of amorphous 
silica (ca. 1.7 mM Si (Jugdaohsingh et al., 2008)). The distribution of silicate centres within the 
insoluble portion of the dispersion differed significantly between the two materials. The fully 
condensed portion (i.e., a Q4 centre) was greater in the more persistent material (material B). 
Consequently, the partially condensed portion (i.e., Q2+Q3 centres) was lower in material B 
than in material A. Whether this change in is truly due to particle condensation or is due to the 
slight differences in size is unclear. A small increase in size would significantly increase the 
proportion of core (internalized) silicate centres (likely Q4), as there is a cubic relationship 
between radius and the internal volume of a sphere (as the volume of a sphere (V) = 4πr3/3).  
The percentages of partially condensed silicate centres in the two dispersions tested here were 
lower than those previously tested. Kalia et al. showed that a 1.5 nm nanosilica dispersion (by 
TEM) was comprised of 83 ± 2% fully condensed (Q4) silicate centres (Kalia et al., 2016). 
Although particle size was smaller than those tested in the present study, as determined by 
ultrafiltration (96% Si <10 kDa (Kalia et al., 2016) vs ca. 70% Si <50 kDa for material B in the 
present study, data not shown), the percentage of fully condensed silicate centres (Q4) was 
higher. As fully condensed silicate centres can only exist in the core of the particle (not on the 
surface), this may suggest that there is a percentage of partially condensed centres in the core 
of the materials tested here.  
Silicon-29 NMR spectroscopy has been shown to effectively measure nanosilica condensation. 
However, the extensive experimental requirements (long acquisition times (>40 h), isotopic 
enrichment and glass free NMR equipment) and the meta-stability of the silicate dispersions 
make these experiments costly and difficult to build up a large sample dataset. For this reason, 
further studies using 29Si NMR spectroscopy were not conducted.  
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Figure 3.06. Representative size (A.) and dissolution rate (B.) of the two nanosilica dispersions 
(40 mM Si, see below for formulations, denoted as A and B) employed in the 29Si-NMR 
analyses. C. 29Si NMR spectra (99.35 MHz) of the aqueous nanosilica dispersions containing 
40 mM Si (29Si enriched) at 25 °C. The signal corresponding to silicic acid was referenced to 0 
ppm. For material A the silicic acid signal was clipped in the display to maximize the signals 
corresponding to the insoluble silicate. Material A was prepared by adjusting a 40 mM silicic 
acid stock to pH 7, incubating for 2 h and adjusting to pH 1.5. Material B was prepared by 
adjusting a 40 mM silicic acid stock to pH 9, incubating for 18 h at 40 °C, and adjusting to pH 
1.5 after cooling to room temperature.   
 
Table 3.01. Distribution of silicon in the two nanosilica dispersions (40 mM) determined through 
the spectral integration of the 29Si NMR spectra 
Material % Si (+/- 3) % NP (+/- 2) 
 Soluble Insoluble Q2 + Q3 Q4 
A 6 94 44 56 
B 12 88 32 68 
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3.2.1.6 Charge of nanosilica particles  
Next, the charge of various nanosilica dispersions was determined. The interactions between 
the nanosilica particles and cells, proteins and other components in the culture media is largely 
dependent on the charge of the particles. In solution, the charge of a particle is measured at 
the edge of the diffuse layer (i.e., the slipping plane, the point in at which the surrounding 
solution is no longer associated with the particle) (Clogston and Patri, 2011). The charge at 
this point is referred to as the zeta-potential.  
Figure 3.07 shows the zeta-potential of three nanosilica dispersions between pH 1.5 and 9. 
Although the dissolution characteristics of the three nanosilica dispersions (particle size 
ranging between 1 and 5 nm) varied significantly (Figure 3.07A), there was no significant 
difference in zeta-potential (Figure 3.07B). This may suggest that the degree of condensation, 
at least within the narrow range tested here, has little effect on zeta-potential. The zeta-
potentials of the nanosilicates increased with pH. The nanosilica particles carried no charge at 
low pH (< pH 4), which is consistent with nanosilica particles of larger diameters (Bergna and 
Roberts, 2005). As the pH increased above 5.5, there was a significant increase in zeta-
potential. The zeta-potential of the dispersions was not assessed above pH 9 as solubility of 
silicic acid increases significantly above this pH (Jugdaohsingh et al., 2008). The relationship 
between pH and zeta-potential shows a point of inflection at pH 7-7.5, which would suggest 
that at this pH ca. 50% of the surface hydroxyl groups are deprotonated (i.e., pKa = 7-7.5). To 
investigate this further, a nanosilica dispersion was titrated with dilute NaOH (Figure 3.08). The 
dispersion was buffered between pH 6-8 by the nanosilica particles, which would corroborate 
the results indicating that the pKa of the particles is ca. 7. Additionally, the ionization constants 
reported in the literature corroborate these results, where larger silica particles were 
determined to have a pKa of 7.1 (Hair and Hertl, 1970) and 1 nm nanosilica “oligomers” were 
found to have a pKa of 6.8 (Belton et al., 2012). 
Studies have previously shown that nanosilica particles are quite stable under conditions 
where they carry no charge (reviewed by Bergna and Roberts (Bergna and Roberts, 2005)), 
contrary to other nanoparticles which are most stable in conditions where they carry significant 
charge (Gören et al., 2012). Both kinetic and thermodynamic models have been proposed to 
explain this phenomenon, but the problem remains unresolved (Bergna and Roberts, 2005).  
One possible solution is that deprotonation is required for condensation and agglomeration of 
the particles. It has been hypothesised that the polymerization of silicates occurs through the 
electrophilic attack of neutral silicic acid by a negatively charged silicate species (Kinrade and 
Swaddle, 1988). It is plausible that a similar mechanism is occurring with the nanosilica 
particles, i.e., a negative region of a nanosilica particle attacking a neutral area of another 
nanosilica particle. Indeed, it has previously been suggested that negative silicate regions are 
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required for oligomer growth (Iler, 1979).  This would address the observations of increased 
stability and decreased condensation rates (below) at low pH. 
 
 
Figure 3.07. A. Representative dissolution rates of three 40 mM nanosilica dispersions, 
following dilution to 1 mM Si in HEPES buffer (pH 7.0-7.3). B. Zeta-potentials of the three 
nanosilica dispersions between pH 1.5 and 9 in water. Material A was prepared by rapidly 
adjusting a 500 mM silicic acid stock to pH 0.8, incubating overnight and diluting to 40 mM. 
Material B was prepared by adjusting a 40 mM silicic acid stock to pH 9, incubating for 18 h at 
room temperature.  Material C was prepared by adjusting a 40 mM silicic acid stock to pH 9, 
incubating for 18 h at 40 °C, and cooling to room temperature.       
 
Figure 3.08. Titration of 5 mL of a nanosilica dispersion (similar dissolution profile to material 
A in Figure 3.10) with 69 mM NaOH (conducted by C. Bastos).  
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The zeta-potential measurements were previously conducted in the dispersion stock, with the 
required HCl/NaOH to adjust pH. As cells would only encounter the nanoparticulate in more 
complex media, the charge of nanosilica was assessed in two biologically relevant fluids, 
phosphate buffered saline (PBS) and RPMI. Protein was not included in the media as proteins 
would interfere with the DLS measurement and produce artefactual signals. Table 3.02 shows 
the zeta-potentials of the three nanosilica particles (as previously defined in Figure 3.10) in 
PBS and RPMI. Both media stocks alone (i.e., without nanosilica particles) had negative zeta-
potentials, ca. -22.4 mV and -11.2 mV for PBS and RPMI, respectively. The zeta-potential of 
the nanosilica particles in these media was very similar to that of the media alone. This might 
suggest that the particles cannot be detected in the complex matrix. One method of 
determining whether particles are detected by DLS techniques is the derived count rate. 
Derived count rate is the calculated concentration/density of the dispersion, determined by the 
average scattering intensity and the attenuation (a filter is used at the detector) required to 
obtain that intensity. By comparing the derived count rates, it may be possible to determine 
whether nanosilica particles are detected in the media. The nanosilica containing media had a 
higher derived count rate than the media alone, indicating that the nanosilica particles were 
detected in these complex matrixes. These results would suggest that the zeta-potential 
measurements correspond to the nanosilica particles, not the negatively charged species from 
the media formulations. The zeta-potential of the nanosilica particles was similar, but slightly 
less negative, in the complex media compared to stock dispersions. These results corroborate 
with trends reported in the literature, which show that zeta-potential decreases in higher ionic 
strength media (Kobayashi et al., 2005). Further investigations are required to confirm the 
charge of the nanosilicates in more complex media (i.e., media containing proteins from FBS). 
 
Table 3.02. Zeta-potential and derived count rate of nanosilica dispersions (as defined in 
Figure 3.10) in PBS and RPMI. Data are means and SD of 3 independent dispersions with 3 
replicate measurements per dispersion. ND – not determined  
Material 
In PBS In RPMI 
mV kcps mV kcps 
A -14.0+/-1.5 1717+/-2348 -14.6+/-1.8 419+/-488 
B -20.8+/-0.9 1755+/-1841 ND ND 
C -22.1+/-0.4 837+/-416 -17.3+/-3.0 293+/-236 
PBS -22.4+/-0.9 222 +/- 22 - - 
RPMI - - -11.2+/-1.6 29.0+/-7.8 
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3.2.2 Stabilization of nanosilica dispersions 
The metastability of silica nanoparticle dispersions, especially at physiological pH, prevents 
preparation of the suspensions in advance. This instability inserts a degree of complexity into 
more experimentally demanding studies, such as in vivo toxicological studies, as staff need to 
be fluent in the preparation of the materials and would also require the analytical tools for 
characterization. For these reasons, investigations were conducted to identify the conditions 
of greatest nanosilica stability, in an attempt to prolong shelf life of the dispersions.  
An alternative molybdic acid assay was employed to assess the formation and ripening 
processes of labile insoluble silicates. Instead of diluting in a buffer at pH 7 and adding aliquots 
to the molybdic acid solution (pH ~ 0.8, as conducted previously), the silicate dispersion was 
directly diluted with the molybdic acid solution and the optical density at 400 nm (which 
corresponds to the formation of the β-silicomolybdate complex and the amount of silicic acid 
released from the particles) was measured over time (Iler, 1979). Figure 3.09 shows the 
absorbance at 400 nm after silicic acid (40 mM Si, pH ~ 11) and a nanosilica dispersion (500 
mM Si incubated at pH 0.8 for 24 h, as shown in Figure 3.05) were diluted to 1 mM in an acidic 
molybdic acid solution. The optical density reached a maximum ca. 0.5 h after molybdic acid 
was added to the silicic acid solution, which would suggest that silicic acid is completely 
complexed by molybdic acid during this time. There was a slight decrease in absorbance after 
1 h, which is likely due to the instability of the β-silicomolybdate complex (Kley et al., 2014). 
The formation rate of the β-silicomolybdate complex was slower for nanosilica particles 
compared to soluble silica, as silicic acid had to be released from the particles before it could 
be complexed by molybdic acid. The release of silicic acid from the particles was slower under 
the conditions of this assay compared to the previous dissolution assay (Figure 3.05), most 
likely due to difference in pH of the diluent (pH ~ 0.8 here compared to pH 7). Using this assay, 
which has a decreased rate of reaction and therefore greater sensitivity, the ripening and 
formation processes of nanosilicates could be assessed.  
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Figure 3.09. Formation of the β-silicomolybdate complex over time, as measured by the 
absorbance at 400 nm, following dilution of silicate stocks (silicic acid or nanosilica dispersion 
(1-2 nm, 500 mM Si incubated at pH 0.8 for 24 h and at room temperature)) to 1 mM Si in a 
molybdic acid solution (pH ~ 0.8). Data are means and SD (dotted lines) of 3 replicate 
measurements per dispersion. 
 
The effect of concentration on particle formation, ripening and, therefore, stability was first 
investigated. Nanosilica dispersions were prepared at 40 and 500 mM (both at pH 0.8-1) and 
incubated for 0-24 h at room temperature. Figure 3.10A shows the silicic acid release, as 
determined by the formation of the β-silicomolybdate complex, from the 500 mM nanosilica 
dispersions. The formation rate of the β-silicomolybdate complex decreased with longer 
incubation at room temperature (i.e., with increased ageing of the dispersion). There was also 
a similar decrease in β-silicomolybdate formation rate with increased ageing of the dispersions 
prepared at 40 mM Si (Figure 3.10B). However, the formation rate decreased faster with 
ageing for the more concentrated (500 mM Si) nanosilica dispersion. These results are 
consistent with previous studies that have shown that the rate of silicate polymerization 
increases with total Si concentration (Kinrade and Swaddle, 1988). Figure 3.10C shows the 
area under the absorbance curves (from 0-5 h, Abs (400 nm) x h) for each of the dispersions 
tested. The area under the curve is proportional to the relative amount of silicic acid that was 
released in 5 h, and it can be correlated to relative condensation of a dispersion. The plot 
shows that the area under the curves decreases with time and with Si concentration. Whether 
the decrease in the area under the curves (i.e., an increase in condensation) is due to Ostwald 
ripening or agglomeration of the insoluble materials is unknown. 
 
 
53 
 
Figure 3.10. Formation of the β-silicomolybdate complex over time, as measured by the 
absorbance at 400 nm, following dilution of aged 500 mM (A.) and 40 mM (B.) nanosilica 
dispersions (prepared at pH 1) to 1 mM Si in a molybdic acid solution (pH ~ 0.8). The area 
under the absorbance curves (in A. and B.) was determined and plotted against age of the 
dispersion (C.), showing an increase in condensation with ageing. Data are means of 3 
replicate measurements per dispersion. 
 
The effect of pH on silicate condensation and stability was investigated next. Figure 3.11A 
shows silicic acid release, as determined by the formation of the β-silicomolybdate complex 
and represented as areas under the curves, from 40 mM silicate dispersions prepared at pH 
1, 7.4 and 9. Area under the curve decreased rapidly after pH adjustment to 7.4 and 9, 
indicating that silicate condensation occurs rapidly at these pHs. It reached its minimum at 2.5 
h, after which only the soluble silicic acid fraction present in the dispersions was complexed by 
molybdic acid. The difference in solubility of silicic acid at pH 7.4 and 9, ca. 1.7 and 4 mM, 
respectively (Jugdaohsingh et al., 2008), most likely explains the slight difference in the area 
under the curves after 2.5 h. However, although a minimum was reached at 2.5 h, 
condensation of the particles continues after this time (Figure 3.11B and Figure 3.04); the low 
pH conditions of the assay prevent highly condensed particles from releasing silicic acid. The 
large difference in silicic acid release (i.e., condensation rates) between dispersions at low 
(i.e., pH 1) and physiological pH corroborate studies that show nanosilica particles are more 
stable (i.e., have slower polymerization and agglomeration rates) below pH 5 compared to pH 
6-9 (Bergna and Roberts, 2005). 
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Figure 3.11. A. The area under the absorbance curve (measured at 400 nm between 0 and 5 
h), corresponding to the formation of the β-silicomolybdate complex, after dilution of aged 40 
mM nanosilica dispersions (prepared at pH 1, 7.4 and 9) to 1 mM Si in a molybdic acid solution. 
B. The effect of incubation time at pH 7 on dissolution rate of nanosilica dispersions after 
dilution to ca. 1 mM in HEPES buffer (pH 7.0-7.3). Data are means and SD of 3 replicate 
measurements per dispersion. 
 
As nanosilicates were shown to condense at a slower rate at low pH, the suspensions were 
adjusted to low pH as to prolong shelf life. However, dispersions stored at low pH require a 
neutralization step prior to use. The effect of neutralization on particle size was investigated 
here.  
Figure 3.12 shows the effect of neutralization on the phase distribution and particle size of a 
nanosilica dispersion (3-4 nm in diameter, stored at pH 1.5) after adjustment to pH 7.4. The 
proportion of silicon <50 kDa in size (4 nm average pore size (Guo and Santschi, 2007)) 
decreased significantly after pH adjustment (Figure 3.12A). DLS measurements also showed 
a slight increase in particle size immediately after neutralization (Figure 3.12B). The particles 
continued to agglomerate after 10 min, reaching a median particle size of 9 nm at 2 h. These 
results corroborate those that show that condensation and agglomeration rates increase at 
physiological pH. 
Next, the effect of dilution on a neutralized nanosilica dispersion was investigated. Figure 
3.12C shows the phase distribution of the dispersions after dilution in PBS and incubation for 
10 min. Despite having significantly different phase distributions upon neutralisation (Figure 
3.12A), there was no difference in phase distribution upon immediate dilution below 1 mM Si. 
These results would suggest that the growth immediately after pH adjustment is due to weak 
agglomeration. These agglomerates break apart if diluted immediately thereafter.   
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Figure 3.12. A. Percentage of silicon in a nanosilica dispersion (40 mM, pH 1.5) that passed 
through 3 and 50 kDa ultrafilters (ca. 1.5 and 4 nm respectively (Guo and Santschi, 2007)) 
before and after adjustment to pH 7. Data are means and SD of 2 independent replicates. B. 
Particle size distribution (by DLS) of the nanosilica dispersion after pH adjustment to 7. Data 
are means and SD of 3 replicate measurements. C. Percentage of silicon in the nanosilica 
dispersion (40 mM, pH 1.5, as shown in A.) that passed through 3 and 50 kDa ultrafilters (ca. 
1.5 and 4 nm respectively (Guo and Santschi, 2007)) after dilution to 0.4 mM Si and incubation 
for 10 min. Data are means and SD of 2 independent replicates. 
 
3.2.3 Preparation and characterization of control particles 
In this section, investigations were conducted to find non-silica nanoparticles of similar size to 
those used here (in this thesis), as a control for in cellular investigations. Commercially, a 
number of different particles are available, though most are not appropriate. Many dispersions 
1-5 nm in size are supplied at low concentrations (1-2 mM), making it not possible to match 
the concentrations of silica used in the biological assays. Other materials, characterized by 
electron microscopy, have core particle sizes between 1 and 5 nm but when the stabilizer and 
hydrodynamic shell are accounted for, the particles are too large for comparison. For example, 
Figure 3.13 shows the aqueated size of (11-mercaptoundecyl)tetra(ethylene glycol) 
functionalized gold nanoparticles. The core particle size is 3-4 nm by TEM (Sigma-Aldrich, 
#687863) but in suspension (in water) the median particle size is ca. 10 nm, more than double 
that of the nanosilica particles used in the majority of the biological investigations herein.   
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Figure 3.13. Particle size distribution of (11-mercaptoundecyl)tetra(ethylene glycol) 
functionalized gold nanoparticles (Sigma-Aldrich, 687863) 
 
Whether aluminium clusters could be used as control particles was investigated next. 
Aluminium clusters can be formed by increasing the pH of an acidic aluminium chloride solution 
with NaOH (Fu et al., 1991). Figure 3.14A shows the size of an aluminium hydroxide dispersion 
prepared by adjusting a 100 mM Al chloride solution to pH 4.2 with NaOH and incubating for 
24 h. The size of the Al hydroxide clusters was similar to that of the 1-2 nm nanosilica particles 
but the proportion of Al contained within the dispersion, versus soluble Al, is not known. 
Attempts were made to increase particle size above 2 nm, a size where 3 kDa ultrafilters (1-2 
nm average pore size (Guo and Santschi, 2007)) could be used to separate and determine the 
portion of soluble Al. However, every attempt to increase particle size resulted in either no 
particle growth or full agglomeration. Despite not knowing the distribution of Al in the 
dispersion, investigations were carried out to determine whether the clusters agglomerate after 
dilution in cell growth media. Figures 3.14B and C show the phase distribution of the Al 
dispersion after addition to either complete growth media or BSS media (balanced salt solution, 
a minimal salt solution used to decrease the rate of nanoparticle agglomeration (Pereira et al., 
2015)). The aluminium clusters agglomerated rapidly after addition to cell culture media and 
the majority (>90%) of Al did not pass through the 1,000 kDa ultrafilter (11 nm average pore 
size (Guo and Santschi, 2007) at 0.5 h. Due to their rapid rate of agglomeration, Al dispersions 
are not suitable for comparison to the nanosilica dispersions. 
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Figure 3.14. A. Particle size distribution of an aluminium hydroxide dispersion (100 mM Al at 
pH 4.2. Data are means and SD of 3 measurement replicates. Percentage of aluminium that 
passed through 3 and 1,000 kDa ultrafilters (1-2 and 10-11 nm respectively (Guo and Santschi, 
2007)) after addition to BSS (B.) and complete growth media (RPMI+10% FBS, C.) at 1 mM 
Al. Data are means and SD of 2 independent replicates. 
 
An iron hydroxide nanoparticle coated with adipate and tartrate was selected as a control 
particle due to its similar size distribution to that of nanosilica. This material, which was fully 
characterized by Pereira et al.(Pereira et al., 2015), maintains its size in BSS media and 
therefore is suitable for comparison to nanosilica in cell assays.  
3.3 Conclusions 
In this chapter, a range of nanosilica particles were generated and characterized for use in cell 
based assays (as described in the subsequent chapters of this thesis). The nanosilica particles 
generated here were predominantly less than 10 nm in size and dissolved completely within 
48 h after dilution below 1 mM Si. The effect of these labile nanosilica dispersions on cells was 
investigated in the following chapters.  
The relationship between particle dissolution and physiochemical properties was also 
investigated. Particles with a greater persistence in the dilute conditions were found to consist 
of a greater percentage of fully condensed silicate centres (Q4). The materials investigated 
here were less condensed than those investigated in the literature (Kalia et al., 2016). 
Condensation, within the limited range investigated here, was found to have no effect on the 
zeta-potential of the particles.  
In the following chapters, the effect of nanosilica particles on cells was investigated. 
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Chapter 4 – The effects of nanosilica on cell viability and function 
4.1 Introduction 
As noted above, due to its recent use in biomedical applications and the resulting intravenous 
administration route, the effect of nanosilica on peripheral immune cells has been investigated. 
Cells of the innate immune system were the focus for most of these studies as many innate 
immune cell types, including monocytes, phagocytose and clear foreign materials from 
circulation (Murray and Wynn, 2011). Amorphous nanosilica has been shown to be cytotoxic 
to monocytic cell lines, both of human and murine origin (Malugin et al., 2011; Mohamed et al., 
2011; Nabeshi et al., 2011; Park and Park, 2009; Park et al., 2011; Sandberg et al., 2012; 
Waters et al., 2009). Nanosilica particles were also shown to decrease viability in peripheral 
blood mononuclear cell (PBMC) cultures (Fedeli et al., 2013; Mendoza et al., 2014). 
Lymphocytes were more resistant to the particles compared to monocytes and macrophages, 
where the overall resistance to the particles was correlated to phagocytic capabilities of the 
cell (Fedeli et al., 2013).  
Although many have studied the effects of particulate silica on cells, little is known as 
amorphous nanosilica consists of a large range of particles with an even larger range in 
properties. In these investigations, the effect of nanosilica particles under 10 nm in size on 
peripheral immune cells (primary, transformed, and cancerous) was investigated. This may 
infer upon their safety for their therapeutic use. 
4.2 Results and discussion  
4.2.1 EBV transformed B cells. 
B cells virally infected with Epstein-Barr virus, a virus in the herpesvirus family, were used in 
the initial in vitro investigations. These cells are in a constant state of stimulation and have a 
high risk of developing cancer (Chen, 2011; Saha and Robertson, 2011). Due to their chronic 
stimulated state, they proliferate quickly which makes them inexpensive and ideal for easy 
primary cell screening of nanosilica toxicity. CFDA-SE based flow cytometric assays were 
utilized to test the effect of silicic acid and a 3.6 nm nanosilica dispersion on cell proliferation. 
Figures 4.01A and B show their effect on the proliferation of the transformed B cells after 24 
and 48 h, respectively. Silicic acid had no effect on cell proliferation below 1 mM Si while the 
cells treated with 3.6 nm nanosilica above 200 μM Si showed a significant reduction in 
proliferation from that of the control, an effect that was greatest at 48 h. The nanosilica 
dispersion also decreased cell viability. Figure 4.01C shows the effect of nanosilica on cell 
viability and on the proliferation of the viable cells after 48 h incubation. The decrease in 
proliferation was lower when only the viable cells were considered, which may suggest that 
growth inhibition was occurring through a cellular damage/toxicity based mechanism. To 
ensure that the reduction in proliferation was not specific to a certain donor, EBV transformed 
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B cells from another donor were tested. Figure 4.01D shows the effect of 3.6 nm nanosilica on 
the proliferation of 2 transformed B cell lines. At the highest concentration of nanosilica, there 
was significant variability between the two cell lines but growth inhibition by nanosilica was 
observed in both. Further investigations using this assay (EBV B cell line 1, at 48 h incubation) 
were conducted to better understand how the nanosilica was interacting with these cells.  
Figure 4.02 shows the effect of nanosilica size on the inhibition of transformed B cell 
proliferation. An increase in median particle size (by volume, DV0.5) from 3.6 nm to 4.7 nm 
resulted in a 30% decrease in proliferation inhibition. As particle size was increased further the 
effect on proliferation decreased and, at a median particle size of 25 nm, its effect was no 
longer statistically different to silicic acid or to micron-sized silica particles which were used as 
a control. The dissolution rates of the nanosilica particles in simple media were very similar 
(Figure 3.02A), which may suggest that the larger particles were aggregates of the 3.6 nm 
particle. However, the significant decrease in proliferation inhibition with size would suggest 
that aggregates remain intact and do not break up into the smaller particles that they are 
composed of. Whether the presence of cells or the complexity of media is preventing the large 
particles from breaking up is unknown.   
 
Figure 4.01. The effect of silicic acid and 3.6 nm nanosilica on transformed B cell proliferation 
after 24 h (A.) and 48 h (B.) incubation at 37 °C. C. The effect of 3.6 nm nanosilica on cell 
viability and proliferation of viable cells. D. The effect of 3.6 nm nanosilica on transformed B 
cells from separate donors. (*denotes p < 0.001, two-tailed T test, unpaired. Individual percent 
controls averaged between A. 2 experiments with 3 replicates, B-D. 3 experiments with 3 
replicates). (A, B, D) EBV B cells were selected based on FSC versus SSC profiles through a 
B cell gate also which excluded debris. (C) EBV B cells were first selected based on FSC 
versus SSC profiles through a B cell gate also which excluded debris, followed by a viability 
gate (Violet LIVE/DEADLOW). 
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Figure 4.02. The effect of nanosilica size on transformed B cell proliferation. (*denotes p < 
0.001, two-tailed T test, unpaired. Individual percent controls averaged between 3 experiments 
with 3 replicates. Size and concentration averaged from the 3 experiments. EBV B cells were 
selected based on FSC versus SSC profiles through a B cell gate also which excluded debris. 
 
Figure 4.03A shows the effect of nanosilica particles below 2 nm in size on transformed B cell 
proliferation. Only at concentrations of silicon approaching its solubility limit (polymerization 
boundary) did the small nanosilica particles have any effect on proliferation. Figure 4.03B 
shows that the particles below 2 nm in size dissolve much more rapidly than that of the 3.6 nm 
particles, where complete dissolution was reached before 2 h and 24 h, respectively. It is not 
known whether the decreased effect of the small nanosilica dispersion on transformed B cells 
is due to reduced size or increased dissolution rate. Attempts were made to decrease the 
dissolution rate of the small nanosilica dispersion while maintaining particle size, including 
doping with metals (Al, Ca, Fe, Zn) and the use of heat, but none were successful (data not 
shown).  
To test the effect of nanosilica dissolution on transformed B cell activity, two nanosilica stocks 
with median diameters (by volume) of ca. 4.6 nm and varying dissolution profiles were tested. 
Despite having vastly different dissolution rates (Figure 4.04A), there was little difference in 
the inhibition of cell proliferation between the two nanosilica dispersions (Figure 4.04B). This 
would suggest that the decreased activity of the nanosilica dispersion below 2 nm in size is 
due to size and not due to the dissolution rate. It also would suggest that the effect of nanosilica 
at 48 h is a result of its interactions with the cells immediately after addition to media, as the 
lifetime of material A below its solubility is less than 4 h at room temperature.  
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Figure 4.03. A. The effect of 1.9 nm and 3.6 nm nanosilica on the proliferation of transformed 
B cells. B. Dissolution of the nanosilica particles after dilution to ca. 1 mM Si in HEPES buffer 
(pH 7.0-7.3). (‡ denotes p < 0.005, two-tailed T test, unpaired. A. Average of 3 experiments 
with 3 replicates each). EBV B cells were selected based on FSC versus SSC profiles through 
a B cell gate also which excluded debris. 
 
 
Figure 4.04. A. The dissolution of nanosilica particles ca. 4.6 nm in size prepared at different 
pHs after dilution to ca. 1 mM Si in HEPES buffer (pH 7.0-7.3). B. The effect of these particles 
on transformed B cell proliferation. (B The % control, size and concentration averaged between 
3 independent experiments, each with 3 replicates. EBV B cells were selected based on FSC 
versus SSC profiles through a B cell gate also which excluded debris. 
 
In summary, the effect of nanosilica on EBV transformed B cells was investigated. Nanosilica 
was found to decrease the proliferation and induce significant cell death of the virally 
transformed cells. It is suspected that the decrease in cell proliferation is through a cellular-
damage/toxicity based mechanism, as there was a decrease in proliferation inhibition when 
only viable cells were considered versus all cells. A nanosilica dispersion with a median particle 
size of 3.6 nm induced greatest inhibition of proliferation, and increasing or decreasing size 
reduced particle activity. Lastly, the dissolution rate was shown to have little effect on particle 
activity.   
 4.2.2 Leukemic monocytic cell line – THP-1 
Phagocytic cell lines have been used to assess the safety of nanoparticles. Amorphous silica 
nanoparticles 20-400 nm in size have been shown to induce cell stress pathways, increase 
levels of reactive oxygen species and induce cell death of leukemic macrophages and 
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monocytes (Malugin et al., 2011; Mohamed et al., 2011; Nabeshi et al., 2011; Park and Park, 
2009; Park et al., 2011; Sandberg et al., 2012; Waters et al., 2009). Here, the effect of labile 
nanosilica particles below 10 nm in size on the viability of the leukemic human monocytic cell 
line THP-1 was investigated.  
Figure 4.05 shows the effect of silicic acid and 3.6 nm nanosilica particles on THP-1 viability. 
Cell viability decreased slightly over time in the control cultures, which may be due to the 
decrease in available nutrients. Silicic acid had no effect on viability compared to that of the 
untreated cell culture. Nanosilica, at 800 μM Si, significantly decreased cell viability at 48 and 
72 h, though more than 90% of the cells remained viable. Lower concentrations of nanosilica 
had no effect on viability. Indeed, the toxicity of 3.6 nm nanosilica was similar to nanosilica 
particles of 20-400 nm in size, where doses below 0.5 mg/mL (ca. 830 μM Si) did not induce 
significant cell death (Mohamed et al., 2011). These results would suggest that this 
immortalized cell line is quite resistant to nanosilica, even compared to the transformed B cells. 
As cell lines are known not to mimic primary cell cultures (Kaur and Dufour, 2012), further 
investigations using primary peripheral immune cell cultures were employed to assess the 
safety of the nanosilica particles below 10 nm in size.  
 
 
 Figure 4.05. The effect of 3.6 nm nanosilica and silicic acid on THP-1 viability (* denotes p < 
0.05, two-tailed T test, unpaired, averaged between 3 independent experiments, each with 3 
replicates). THP-1 cells were first selected based on FSC versus SSC profiles through a THP-
1 cell gate also which excluded debris. 
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4.2.3 Primary peripheral immune cells  
Next, the effect of nanosilica particles on primary cells was investigated. Peripheral blood 
mononuclear cells (PBMCs), which consist of a mixed population of B cells, T cells, NK cells 
and monocytes, were isolated from blood, treated with nanosilica and analysed using flow 
cytometry. Monocytes, B cells and T cells were the primary focus of these investigations. 
Monocytes were identified by the CD11c receptor, which is expressed on monocytes, 
granulocytes and dendritic cells as it binds various ligands including bacterial components 
(lipopolysaccharide) (Wu et al., 2009). B cells were identified by the CD19 receptor, which is 
involved in numerous B cell functions including B cell differentiation (Del Nagro et al., 2005). T 
cells were identified by the CD3 receptor, which is a component of the T cell receptor complex 
and is essential in signal transduction during T cell activation (Wang et al., 2009b).  
Figure 4.06 shows the effect of nanosilica on monocyte (CD11c+), B cell (CD19+) and T cell 
(CD3+) viability, as determined using an Invitrogen live-dead stain. The representative 
histograms show two distinct populations for each cell type, corresponding to viable cells, i.e., 
those with intact cell membranes which have a lesser fluorescent intensity, and non-viable 
cells, i.e., those with compromised cell membranes which have a greater fluorescent intensity. 
The viability decreased after nanosilica treatment. There was also a decrease in the number 
of cells present in each histogram after nanosilica treatment, which is a result of a significant 
forward scatter-side scatter (FS-SS) profile shift. Cells that have been treated with nanosilica 
shift into the region corresponding to cellular debris and, as debris can give false positive 
signals for viability, it is not possible to incorporate these events in the analysis. Figures 4.07A-
F show the combined toxicity of nanosilica towards monocytes, B cell and T cells, represented 
as both percentage viable and viable cell counts. There was a significant decrease in both 
monocyte viability and viable monocyte counts after nanosilica treatment, where the counts 
decreased to <10% of the control after treatment with nanosilica at concentrations >400 μM 
Si. Similarly, B cells and T cells also showed significant reductions in both the percentage 
viable and viable counts after nanosilica treatment, though the decrease in viable counts for 
these cell types was less than that of monocytes. T cells were most resistant to nanosilica, 
where its viability remained above 40% after nanosilica treatment at 800 μM Si.  The non-
phagocytic nature of T cells is likely related to their increased resistance to the nanoparticulate. 
Specifically, T cell death would likely rely on membrane nanosilica accumulation rather than 
intracellular nanosilica overload due to phagocytosis. These results corroborate previous 
studies, which showed that nanosilica particles were >10 times more toxic towards monocytes 
and macrophages than towards endothelial cells and lymphocytes (Fedeli et al., 2013), a 
response assigned to the phagocytic nature of the cells. 
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Figure 4.06. Representative FACS plots showing the effect of 3.6 nm nanosilica on 
monocyte, B cell and T cell viability in PBMC culture at 24 h. Cells were gated through a 
generous FS-SS gate to exclude debris followed by respective CD11c, CD19 and CD3 gates. 
Monocytes were first selected based on FSC versus SSC profiles through a monocyte gate 
which also excluded debris, followed by a CD11c(+) gate. T cells and B cells were first selected 
based on FSC versus SSC profiles through a lymphocyte gate which also excluded debris, 
followed by CD3(+) and CD19(+) gate, respectively. 
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Figure 4.07. The effect of 3.6 nm nanosilica on percent viability and the viable cell counts 
of CD11c, CD19, and CD3 cells in PBMC culture at 24 h. The data is represented as the 
averages of 4-18 donors (* denotes a significance compared to the control, two-tailed paired 
T test, p < 0.05). Monocytes were first selected based on FSC versus SSC profiles through a 
monocyte gate which also excluded debris, followed by a CD11c(+) gate. T cells and B cells 
were first selected based on FSC versus SSC profiles through a lymphocyte gate which also 
excluded debris, followed by CD3(+) and CD19(+) gate, respectively. 
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Next, the mechanism of nanosilica induced cell death was investigated using the Annexin V 
flow cytometric assay (Biosciences, 2011). In these assays, apoptotic cells were identified 
through the surface expression of phosphatidylserine (PS, by the Annexin V stain), a protein 
that translocates from inner to outer cell membrane during apoptosis, and a fully intact 
membrane, as determined by a lack of intracellular DNA staining. Necrotic cells are also 
positive for PS but their cellular membranes are permeable to intracellular DNA stains. Cells 
that have undergone pyroptosis, another inflammatory mode of cell death, are also positive for 
both intracellular DNA stains and surface PS (Miao et al., 2011). Therefore, it is not possible 
to distinguish between necrosis and pyroptosis using this assay. Crystalline silica was used as 
a positive control as it has been previously shown to induce monocyte apoptosis (Joshi and 
Knecht, 2013). 
Figure 4.08 shows the effect of crystalline silica and nanosilica on monocyte (CD11c) apoptosis 
and necrosis/pyroptosis. The representative histograms (Figure 4.08A) show the intracellular 
DNA stain (7-AAD) against the Annexin V stain after treatment for 8 h. The majority of 
monocytes in the untreated cultures were negative for both 7-AAD and Annexin V, indicating 
that they were viable. After treatment with crystalline silica, the majority of monocytes became 
Annexin V positive and 7-AAD negative, which would indicate apoptosis was induced. 
Nanosilica increased the number of cells positive for both Annexin V and 7-AAD, indicating 
that necrosis/pyroptosis was induced. Figures 4.08B and C show the percentage of monocytes 
that were apoptotic and necrotic/pyroptotic, respectively, from 0.5 to 24 h.  Crystalline silica 
induced significant apoptosis of monocytes from 2 to 24 h, peaking at 8 h. These results 
corroborate those that show the majority of macrophages undergo apoptosis after exposure to 
crystalline particles (Joshi and Knecht, 2013). At 24 h, there was an increase in the percentage 
of necrotic/pyroptotic monocytes, which likely correspond to cells in late stage apoptosis or 
those that have completed apoptosis (Poon et al., 2010). There was a significant increase in 
the percentage of necrotic/pyroptotic monocytes after exposure to nanosilica for 4 to 24 h. 
Nanosilica only induced significant monocyte apoptosis 8 h after treatment. These results 
would suggest the majority of monocytes are dying through either necrosis or pyroptosis. 
Fedeli et al. showed that amorphous nanosilica particles can induce both necrosis and 
pyroptosis of monocytes, where the mechanism of cell death is dependent on the protein 
concentration (Fedeli et al., 2014). Specifically, pyroptosis is induced by nanosilica in media 
containing 10% FBS and necrosis is induced by the particulate in protein free conditions. These 
results would suggest that pyroptosis was induced in the investigations conducted here, as 
media containing 10% FBS was used. Pyroptosis is regulated though the same caspases that 
also regulate the production of IL-1β and IL-18 (Jorgensen and Miao, 2015). To determine 
whether monocyte cell death occurs through necrosis or pyroptosis, the levels of IL-1β in cell 
supernatants was assessed. Figure 4.09 shows the levels of IL-1β in cell supernatants after 
24 h. Low nanosilica concentrations were used to avoid complete cell death. Nanosilica 
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induced low levels of IL-1β production, which may suggest that some cells are dying through 
pyroptosis. However, the induction of monocyte necrosis cannot be ruled out.  
 
Figure 4.08. The effect of 3.6 nm nanosilica on monocyte apoptosis and necrosis. A. 
Representative histogram plots showing the effect of nanosilica treatment CD11c+ monocyte 
Annexin V and 7-AAD positivity at 8 h. The percentage of CD11c cells that are apoptotic (B.) 
or necrotic/pyroptotic (C.). Tabulated data represents the means ± standard deviation for 4 
donors (* denotes a significance compared to the control, two-tailed paired T test, p < 0.05). 
Monocytes were first selected based on FSC versus SSC profiles through a monocyte gate 
which also excluded debris, followed by a CD11c(+) gate. 
 
 
Figure 4.09. The effect of silicic acid and 3.6 nm nanosilica on IL-1β levels in PBMC 
culture supernatants. Cultures were treated with nanosilica for 3 h, resuspended in 
nanosilica-free media and incubated for another 21 h. Tabulated data represents the means ± 
standard deviation for 4 donors. (* denotes a significance compared to the control, two-tailed 
paired T test, p < 0.05). Conducted by Dr L. Pele. 
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Next, the mode of T cell death induced by nanosilica was investigated. Attempts were made 
to first identify the T cells by the T cell receptor (TCR), which recognises cognate antigen in an 
MHC receptor on an antigen presenting cells or infected/stressed cells. However, nanosilica 
inhibited staining of the TCRαβ antibody from 0-2 h (example shown in Figure 4.10A). Further 
studies showed that nanosilica also inhibited staining of the CD3ε antibody during that same 
time window (this was explored in more detail in Chapter 6). As the unbound nanosilica was 
washed from the system prior to staining the cells and that other T cell stains were not inhibited, 
it is possible that nanosilica directly interacts with the receptor. Indeed, studies conducted in 
Chapters 5 and 6 would confirm this interaction and show the consequences of it. For the 
studies of cell death conducted here, a specialized gating strategy was employed to analyse 
the data, where the TCRαβ stain was ignored. Instead, cells were identified by the CD4 and 
CD8 co-receptors, which are expressed on helper and cytotoxic T cells, respectively, and bind 
the TCR:MHC complex during antigen presentation. The two T cell subsets have varying 
functions, where helper T cells mediate an immune response (by releasing cytokines and 
through expression of surface receptors) and cytotoxic T cells execute the immune response 
(by directly engaging unhealthy cells and releasing factors to induce their death). Figure 4.10B 
shows the gating strategy to select the CD4 and CD8 cells. As monocytes are known to 
express CD4 and CD8 (Gibbings et al., 2007; Kazazi et al., 1989; Zhen et al., 2014), they were 
excluded from the analyses using a CD11c stain. 
The effect of crystalline silica and nanosilica on CD4(+) and CD8(+) cell apoptosis and 
necrosis/pyroptosis is shown in Figure 4.10C (representative histograms) and Figure 4.11 
(percentage positive). Crystalline silica had little effect on CD4(+) cells as neither apoptosis 
(Figure 4.11A) nor necrosis/pyroptosis (Figure 4.11B) was significantly induced after exposure 
to the particles. On CD8(+) cells, there was a significant induction of necrosis/pyroptosis 
(Figure 4.11D) 1-2 h after treatment with crystalline silica.  In the literature, the short term 
effects of these particles on T cell apoptosis and necrosis are not known. However, chronic 
exposure to crystalline silica has been shown to increase T cell expression of the Fas death 
receptor that, when engaged, induces cell apoptosis (Hayashi, 2010).  
Nanosilica induced significant apoptosis of CD4(+) cells from 0.5 to 24 h. The induction of 
apoptosis was greatest at 24 h, which might suggest that nanosilica is inducing apoptosis 
indirectly. For example, nanosilica may be inducing T cell death via the activation induced cell 
death (AICD) pathway. This process can be  initiated by numerous signals and is mediated by 
the expression of death receptors, such as the Fas (CD95) death receptor (Arakaki et al., 2014; 
Tummers and Green, 2017). Further studies (Chapter 5) showed that the percentage of CD4 
T cells positive for CD95 increased after nanosilica treatment. Nanosilica also significantly 
increased the percentage of necrotic/pyroptotic CD4(+) cells at 24 h, likely corresponding to 
cells in late stage apoptosis or those that have completed apoptosis (Poon et al., 2010).   
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Nanosilica induced significant apoptosis and necrosis/pyroptosis of CD8(+) cells. As with the 
CD4(+) cells, the induction of apoptosis may occur through AICD as the levels of CD95 on 
CD8 T cells increased (non-significantly) after nanosilica treatment. It is unknown whether the 
7-AAD, Annexin V double positive cells correspond to those that have undergone necrosis or 
pyroptosis. Whether the IL-1β present in supernatant was produced by T cells is unknown. 
Therefore, it is not possible to determine which inflammatory mode of cell death the cells are 
following. 
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Figure 4.10. A. Representative histograms showing the effect of 3.6 nm nanosilica  on TCRαβ 
cell staining within a T cell FS-SC selection gate at 0.5 h. B. Gating strategy for selection of 
CD4 and CD8 cells. C. Representative histogram plots showing the effect of nanosilica 
treatment on CD4 and CD8 cell Annexin V and 7-AAD positivity at 8 h. T cells were first 
selected based on FSC versus SSC profiles through a lymphocyte gate, followed by negatively 
gating out debris and monocytes (CD11c(+)). Helper and cytotoxic T cells were then selected 
with respective CD4(+) and CD8(+) gates 
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Figure 4.11. The effect of 3.6 nm nanosilica on CD4 (A, B) and CD8 (C, D) cells apoptosis 
and necrosis/pyroptosis. Tabulated data represents the means ± standard deviation for 4 
donors (* denotes a significance compared to the control, two-tailed paired T test, p < 0.05). T 
cells were first selected based on FSC versus SSC profiles through a lymphocyte gate, 
followed by negatively gating out debris and monocytes (CD11c(+)). Helper and cytotoxic T 
cells were then selected with respective CD4(+) and CD8(+) gates 
 
The effect of nanosilica on monocyte function  
Though there are studies that show the negative effects of nanosilica on phagocyte function 
(Fedeli et al., 2014; Fedeli et al., 2013; Mendoza et al., 2014), there are contradicting reports 
which show that nanosilica enhances antigen presenting cell (APC) activity. Nanosilica 
particles have been found to increase cross presentation of antigens by APCs (Hirai et al., 
2012) and, consequently, have also been shown to increase T cell response to antigen 
(Brandenberger et al., 2013; Chen et al., 2014; Marzaioli et al., 2014). The nanosilica particles 
used in the literature were larger and more persistent than those tested here. Thus, whether 
nanosilica particles under 5 nm in size also alter monocyte function was investigated here. 
Again, low doses were used to avoid significant cell death.  
First, the effect of nanosilica on the phagocytosis of other foreign materials by monocytes was 
investigated. Figures 4.12A-C show the effect of nanosilica on fluorescent bead uptake by 
monocytes. The representative histograms shows 2 populations with high CD11c positivity, 
corresponding to bead negative and positive cells. At the highest concentration of nanosilica 
used, there was a decrease in number of monocytes present in the histograms and, therefore, 
these concentrations should be considered toxic. After 1 h, more than half of the monocytes in 
the control groups were positive for the fluorescent beads. Increasing the incubation time 
further had little effect on cell positivity, as shown in the Figures 4.12B-C. Treating the cells 
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with low dose nanosilica decreased bead phagocytosis, both in the percentage of cells positive 
for beads and the fluorescent intensity of cells bead positive, i.e., the number of beads the cell 
phagocytosed. These results would suggest that nanosilica has negative effects on monocyte 
phagocytosis of foreign materials, even at concentrations under 150 μM Si. The effect of 
orthosilicic acid on bead phagocytosis was investigated to ensure that these responses were 
due to nanosilica, and not its degradation product. Figure 4.12C-D shows the effect of silicic 
acid on bead uptake. Unlike the particles, orthosilicic acid did not affect bead phagocytosis.  
 
 
Figure 4.12. The effect of 3.6 nm nanosilica and silicic acid on the phagocytosis of 
polystyrene fluorescent beads by monocytes. A. Representative FACS plots showing the 
CD11c cells positive for fluorescent beads after 1 h incubation. The percentage of CD11c cells 
positive for fluorescent beads (B.) and the mean fluorescent intensity of the bead positive cells 
(C.)  after nanosilica treatment for 1 and 3 h The percentage of CD11c cells positive for 
fluorescent beads (D.) and the mean fluorescent intensity of the bead positive cells (E.) after 
silicic acid treatment for 1 h. Tabulated data represents the means ± standard deviation for 3 
donors (* denotes a significance compared to the control, two-tailed paired T test, p < 0.05). 
Monocytes were first selected based on FSC versus SSC profiles through a monocyte gate, 
followed by a monocyte gate (CD11c(+)) and a viability gate (Violet LIVE/DEADLOW). 
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As confirmation, the effect of nanosilica on bacterial uptake by monocytes was investigated, 
using fluorescent (non-viable) Staphylococci aureus. Figures 4.13A-B show the effect of 
nanosilica on monocyte bacterial uptake. Similar to the investigations with the fluorescent 
beads, nanosilica decreased the percentage of cells positive for bacteria, though mean 
fluorescent intensity only decreased at 3 h. These results would suggest that nanosilica, at 
subtoxic doses, has negative effects on monocyte function. Indeed, when the previous data 
was combined, nanosilica (at 150 μM Si) significantly decreased the percentage of cells 
positive for beads or bacteria (1 h, p = 0.0190 and 3h, p = 0.0090, two-tailed paired T test). To 
ensure that decreased bead and bacterial positivity was not due to enhanced degradation of 
the fluorescent material, flow imaging analyses were conducted in parallel (Appendix 3). There 
was no evidence that nanosilica enhanced degradation of the fluorescent materials, which 
would suggest that nanosilica decreases monocyte phagocytosis of foreign materials.   
In addition to the processing and presentation of antigen to T cells via the MHC receptors, 
blood derived monocytic cells also provide secondary signals. These signals can be 
stimulatory, e.g., CD80/86-CD28 signalling, or inhibitory, e.g., PD-L1-PD-1 signalling (Chen 
and Flies, 2013). Inhibitory signals, such as PD-L1, serve as checkpoint inhibitors and limit the 
immune response (Keir et al., 2008). If PD-L1 expression was altered so would the immune 
response. The effect of nanosilica pre-treatment on monocyte PD-L1 expression in response 
to peptidoglycan (PG), which has been shown to induce its expression on healthy monocytes 
(Hewitt et al., 2012), was investigated. Figure 4.14 shows the effect of nanosilica pre-treatment 
on monocyte PD-L1 expression. As with the previous analysis, the number of monocytes 
present in the histograms decreased after nanosilica treatment. Nanosilica pre-treatment at 
near-toxic doses decreased PD-L1 expression in a dose dependant manner, both in the 
percentage of cells positive for PD-L1 and the intensity of its expression (data not shown). It is 
likely that the decrease in PD-L1 expression is associated with cell death, as only at 
concentrations in which there was a significant decrease in monocyte cell counts was there a 
significant decrease in PD-L1 expression. Sub-toxic dose of nanosilica (150 μM) had no effect 
on monocyte PD-L1 expression. 
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Figure 4.13. The effect of 3.6 nm nanosilica on the phagocytosis of fluorescent S. aureus 
by monocytes. The percentage of CD11c cells positive for fluorescent bacteria and the mean 
fluorescent intensity of the bacteria positive cells after nanosilica treatment for 1 and 3 h. 
Tabulated data represents the means ± standard deviation for 3 donors (* denotes a 
significance compared to the control, two-tailed paired T test, p < 0.05). Monocytes were first 
selected based on FSC versus SSC profiles through a monocyte gate, followed by a monocyte 
gate (CD11c(+)) and a viability gate (Violet LIVE/DEADLOW). 
 
Figure 4.14. The effect of 3.6 nm nanosilica on PD-L1 expression by monocytes. A. 
Representative FACS plots showing the CD11c cells positive for PD-L1. B.  The percentage 
of CD11c cells positive for PD-L1 and the viable CD11c counts. Tabulated data represents the 
means ± standard deviation for 3 donors (* denotes a significance compared to the control, 
two-tailed paired T test, p < 0.05). Monocytes were first selected based on FSC versus SSC 
profiles through a monocyte gate, followed by a monocyte gate (CD11c(+)) and a viability gate 
(Violet LIVE/DEADLOW). 
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4.2.4 Gene array analysis  
A microarray was conducted to better understand the effects of nanosilica on cell function. 
Three cell cultures types, EBV transformed B cells, THP-1 cells, and PBMCs, were treated 
with a nanosilica dispersion 3.6 nm in size (at 150 uM Si, to avoid significant cell death) and 
incubated for 4 h prior to RNA collection for gene assays performed by Dr Mark Boekschoten 
(Wageningen University, Netherlands). The expression of genes most significantly affected by 
nanosilica, and other genes of interest, were presented here.  
First, the effect of nanosilica on EBV transformed B cell gene expression was investigated. 
Earlier in this chapter, nanosilica was shown to inhibit proliferation and induce death of the 
transformed cells, though these effects were only evident at concentrations higher than those 
used here. Table 4.01 shows the genes for which their expression was significantly altered by 
nanosilica treatment compared to that of the control. Nanosilica significantly increased 
expression of the gene corresponding to CCL3 (Macrophage inflammatory protein 1α, MIP-
1α). MIP-1α is a chemotactic cytokine (chemokines) that is released during cellular injury or 
infection for the recruitment of proinflammatory immune cells (Maurer and Von Stebut, 2004; 
Menten et al., 2002). Similarly, the gene corresponding to CCL4 (MIP-1β), a chemokine in the 
same family of inflammatory proteins as CCL3, was more highly expressed after nanosilica 
treatment, though to a lesser extent. These result may suggest that nanosilica is inducing an 
inflammatory response in the EBV transformed B cells, potentially through nanosilica induced 
cell damage (injury). Nanosilica has previously been shown to induce expression of these 
genes in the leukemic murine macrophage RAW 264.7 cell line with nanosilica particles 10 
and 500 nm in size (Waters et al., 2009). 
The expression of many genes associated with cholesterol biosynthesis were also significantly 
increased after nanosilica treatment. The most highly up-regulated gene pathways involved 
cholesterol biosynthesis (Table 4.02). These results corroborate studies that have shown 
nanosilica particles 100-400 nm in size increase cholesterol biosynthesis (Chatterjee et al., 
2016). As particles with a greater surface area are known to alter cholesterol biosynthesis to a 
greater extent (Chatterjee et al., 2016), it is not surprising that the 3.6 nm nanosilica particles 
used here induced the expression of these genes at concentrations 10 times lower than those 
previously employed.  
Pathways associated with NF-κβ and inflammation were also significantly up-regulated after 
nanosilica treatment (Table 4.03). NF-κβ signalling is a key regulator of the immune system, 
initiated in response to infection or injury, and is also associated with inflammation (Hoesel and 
Schmid, 2013; Napetschnig and Wu, 2013; Oeckinghaus et al., 2011). As with the induction of 
the CCL3 and CCL4 genes, nanosilica may be inducing cellular damage thus initiating NF-κβ 
signalling. Other gene groups shown in Table 4.03 are associated with poor tumour prognosis 
and autoimmunity. TWEAK and TNFR2 signalling pathways, both of which are linked to NF-κβ 
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signalling, can lead to cell survival and proliferation instead of apoptosis (Faustman and Davis, 
2010; Winkles, 2008). 
Table 4.01. Individual genes in EBV transformed B cells whose expression was 
significantly altered by 3.6 nm nanosilica compared to that of the control  
gene name description 
Limma Fold 
Change q  
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 1.396 0.000 
LDLR low density lipoprotein receptor 1.286 0.000 
HILPDA hypoxia inducible lipid droplet-associated -1.583 0.000 
CCL3 chemokine (C-C motif) ligand 3 1.813 0.001 
SQLE squalene epoxidase 1.354 0.001 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 -1.476 0.001 
EGLN3 egl-9 family hypoxia-inducible factor 3 -1.421 0.001 
MYLIP myosin regulatory light chain interacting protein -1.299 0.003 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 1.277 0.003 
INSIG1 insulin induced gene 1 1.282 0.003 
MSMO1 methylsterol monooxygenase 1 1.395 0.003 
DUSP10 dual specificity phosphatase 10 1.328 0.005 
DHCR24 24-dehydrocholesterol reductase 1.219 0.005 
ANKRD37 ankyrin repeat domain 37 -1.740 0.005 
ZC3H6 zinc finger CCCH-type containing 6 -1.428 0.005 
RGS1 regulator of G-protein signaling 1 1.317 0.005 
CD86 CD86 molecule 1.199 0.016 
SSTR2 somatostatin receptor 2 1.308 0.016 
DHCR7 7-dehydrocholesterol reductase 1.212 0.021 
NRROS negative regulator of reactive oxygen species 1.248 0.029 
SNORD14E small nucleolar RNA, C/D box 14E 1.492 0.033 
DNTTIP2 deoxynucleotidyltransferase, terminal, interacting protein 2 1.132 0.048 
 
Table 4.02. Gene pathways in EBV transformed B cells whose expression was 
significantly altered by 3.6 nm nanosilica compared to that of the control, showing the 
number of genes in the pathway (size), normalized enrichment scores (NES) and q-
values 
name size NES q 
CHOLESTEROL.BIOSYNTHESIS 22 2.760 0.00000 
WP1795.CHOLESTEROL.BIOSYNTHESIS 19 2.657 0.00000 
WP197.CHOLESTEROL.BIOSYNTHESIS 17 2.630 0.00000 
ACTIVATION.OF.GENE.EXPRESSION.BY.SREBF.SREBP. 40 2.600 0.00000 
KEGG_STEROID.BIOSYNTHESIS 20 2.484 0.00000 
WP2706.ACTIVATION.OF.GENE.EXPRESSION.BY.SREBP. 
SREBF. 38 2.459 0.00000 
REGULATION.OF.CHOLESTEROL.BIOSYNTHESIS.BY.SREBP. 
SREBF. 53 2.451 0.00000 
KEGG_RIBOSOME.BIOGENESIS.IN.EUKARYOTES 73 2.226 0.00044 
WP1982.SREBP.SIGNALLING 63 2.176 0.00167 
WP2710.NONSENSE.MEDIATED.DECAY 118 2.171 0.00174 
WP2011.SREBF.AND.MIR33.IN.CHOLESTEROL.AND.LIPID. 
HOMEOSTASIS 17 2.162 0.00190 
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Table 4.03. Gene pathways associated with apoptosis in EBV transformed B cells whose 
expression was significantly altered by 3.6 nm nanosilica compared to that of the 
control 
name size NES q 
BIOC_TNFR2PATHWAY 18 2.134 0.003 
BIOC_STRESSPATHWAY 25 2.116 0.003 
BIOC_NFKBPATHWAY 22 2.003 0.009 
KEGG_NF.KAPPA.B.SIGNALING.PATHWAY 86 1.906 0.023 
WP2036.TWEAK.SIGNALING.PATHWAY 41 1.817 0.036 
P75NTR.SIGNALS.VIA.NF.KB 15 1.837 0.037 
WP254.APOPTOSIS 84 1.804 0.040 
 
The response of THP-1 cell, a leukemic monocyte cell line, to nanosilica was investigated next. 
Table 4.04 shows the genes whose expression was up- or down-regulated 4 h after treatment 
with nanosilica compared to that of the control. There were very few genes whose expression 
was affected by nanosilica treatment. Nanosilica induced expression of genes corresponding 
to proteins with varying functions, such as negative regulation of cytoskeletal organization 
(RND3), cancerous cell growth delay (GPNMB), and breakdown of serine. Most of the genes 
whose expression was altered by nanosilica were unrelated as only one gene pathway showed 
a difference in overall expression after treatment with nanosilica. Gene group WP2739 
amyloids was significantly increased after nanosilica treatment (NES 2.1266, FDR q value 
0.015685). Amyloids, which are protein aggregates, are associated with many diseases such 
as Alzheimer’s and diabetes (Knowles et al., 2014). These results might suggest nanosilica 
increases amyloid production. The decreased genomic response of the monocytic cell line 
investigated here compared to the macrophagic cell line investigated in the literature (Waters 
et al., 2009), could be due to reasons such as concentration (150 μM vs 800 μM), the 
cancerous cell state and/or origin of the cells (human vs mouse).  
 
Table 4.04. Individual genes in THP-1 cells whose expression was significantly altered 
by 3.6 nm nanosilica compared to that of the control  
gene 
name description 
Limma Fold 
Change q  
SDS serine dehydratase 2.157 0.0066 
SGK1 serum/glucocorticoid regulated kinase 1 1.474 0.0066 
TBC1D30 TBC1 domain family, member 30 -1.482 0.0066 
MYLIP myosin regulatory light chain interacting protein -1.345 0.0066 
HMOX1 heme oxygenase (decycling) 1 1.641 0.0433 
RND3 Rho family GTPase 3 1.570 0.0433 
NUPR1 nuclear protein, transcriptional regulator, 1 1.377 0.0433 
GPNMB glycoprotein (transmembrane) nmb 1.252 0.0480 
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The response of primary cells to nanosilica was investigated next. PBMC cultures, a mixed cell 
culture consisting of monocytes, B cells, T cells and other lymphocytes, were used. Table 4.05 
shows the genes of interest whose expression was significantly altered after nanosilica 
treatment. A number of genes associated with T cell function were more highly expressed after 
nanosilica treatment. Specifically, the expression of the genes corresponding to the Ly9 
protein, a member of the signalling lymphocytic activation marker (SLAM) family, and CRTAM, 
a CD8 T cell and natural killer T cell (NKT) activation marker, increased in cultures exposed to 
nanosilica (Patiño-Lopez et al., 2006; Schwartzberg et al., 2009) . The expression of other 
genes associated with T cell activation also increased, including iCOS, CD69, IFN-γ, and IL-
10 (Geginat et al., 2015; Radulovic et al., 2013; Wikenheiser and Stumhofer, 2016). Whether 
these responses are related to the inhibition of T cell receptor staining shown in Figure 4.10 
was investigated in Chapters 5 and 6. Table 4.06 shows the gene groups whose expression 
was significantly up or down regulated after nanosilica treatment. As with the transformed B 
cells, nanosilica induced expression of genes associated with cholesterol biosynthesis, 
inflammation (WP530 cytokine and inflammatory response) and NF-κβ signalling (P75NTR. 
Signals via NF-κβ) in primary cell culture. There were also some lysosomal and endosomal 
genes induced after exposure to nanosilica, potentially suggesting that nanosilica is being 
phagocytosed by monocytes. 
Table 4.05. Individual genes in PBMC culture whose expression was significantly 
altered by 3.6 nm nanosilica compared to that of the control 
gene name description 
Limma 
Fold 
Change q  
SPINK1 serine peptidase inhibitor, Kazal type 1 11.329 0.016 
NRIP3 nuclear receptor interacting protein 3 4.049 0.022 
FNIP2 folliculin interacting protein 2 6.181 0.022 
CSTB cystatin B (stefin B) 2.126 0.031 
TMEM38B transmembrane protein 38B 2.140 0.031 
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 2.375 0.031 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 -2.428 0.031 
LRRK2 leucine-rich repeat kinase 2 -2.822 0.031 
CD79B CD79b molecule, immunoglobulin-associated beta -2.412 0.031 
LY9 lymphocyte antigen 9 2.409 0.034 
NR4A3 nuclear receptor subfamily 4, group A, member 3 2.221 0.034 
CCRL2 chemokine (C-C motif) receptor-like 2 2.797 0.034 
DUSP3 dual specificity phosphatase 3 2.063 0.034 
PTGFRN prostaglandin F2 receptor inhibitor -3.506 0.038 
GAS2L3 growth arrest-specific 2 like 3 2.985 0.038 
BRI3 brain protein I3 1.792 0.048 
NRP2 neuropilin 2 2.240 0.048 
CRTAM cytotoxic and regulatory T cell molecule 2.666 0.048 
BMF Bcl2 modifying factor -2.185 0.048 
CD72 CD72 molecule 2.129 0.048 
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Table 4.06. Gene pathways in PBMC culture whose expression was significantly altered 
by 3.6 nm nanosilica compared to that of the control 
name size NES q 
KEGG Lysosome 122 2.41 0 
Transferrin endocytosis and recycling 29 2.34 0 
KEGG Collection duct acid secretion 27 2.33 0 
Iron uptake and transport 43 2.30 0 
WP2670 Iron uptake and transport 11 2.27 0 
WP2700 Latent infection of homo sapiens with Mycobacterium 
tuberculosis 
30 2.27 0 
Latent infection of homo sapiens with Mycobacterium tuberculosis 33 2.21 2.09 x 10-4 
Phagosomal maturation early endosomal stage 33 2.23 2.35 x 10-4 
Insulin receptor recycling 26 2.23 2.69 x 10-4 
Sphingolipid metabolism 69 2.15 3.84 x 10-4 
KEGG Sphingolipid metabolism 47 2.03 6.82 x 10-3 
Glycosphingolipid metabolism 38 2.01 7.86 x 10-3 
KEGG Vibro cholerae infection 54 2.00 8.83 x 10-3 
WP516 Hepertrophy model 20 1.98 0.0107 
KEGG Synaptic vesicle cycle 63 1.98 0.0108 
P75NTR Signals via NK-KB 15 1.93 0.0175 
WP197 Cholesterol biosynthesis 17 1.94 0.0180 
WP1912 Signalling by insulin receptor 73 1.92 0.0189 
WP2788 Sphingolipid metabolism 45 1.90 0.0235 
KEGG Rheumatoid arthritis 86 1.86 0.0348 
WP530 Cytokines and inflammatory response 23 1.85 0.0434 
Peroxisomal lipid metabolism 21 -2.05 0.0421 
KEGG Peroxisome 79 -2.03 0.0385 
HDACS Deacetylate histones 56 -2.01 0.0324 
 
4.3 Conclusions 
In this chapter, the effect of nanosilica on toxicity and cell function was investigated. First, its 
effect on cell lines was assessed. The nanoparticulate decreased the proliferation of an EBV 
transformed B cell line in a dose and size dependant manner. Nanosilica was also shown to 
induce significant death of these cells. Immortalized phagocytic cells, specifically the cancer 
derived monocytic cell line THP-1, were more resistant to the silica nanoparticles, where the 
viability only decreased by 5% after treatment with high doses and long incubation periods (48 
and 72 h). 
The effect of nanosilica on primary peripheral immune cells was investigated next. The 
nanoparticulate induced significant cell death in all cell types analysed in PBMC cultures. 
Compared to the cancerous and, to a lesser extent, transformed cell lines, the primary cells 
were more susceptible to nanosilica induced cell death. Additionally, it was shown that 
phagocytic cells in primary culture were more susceptible to the cytotoxicity induced by the 
nanoparticulate than non-phagocytes, corroborating studies in the literature which used larger 
nanosilica particles (Fedeli et al., 2013). Investigations on the mode of nanosilica induced cell 
death would suggest that pyroptosis or necrosis is induced in primary monocytes, once again 
corroborating studies with larger nanosilica particles (Fedeli et al., 2014). CD4 and CD8 T cells 
were shown to undergo both apoptosis and necrosis after nanosilica treatment.  
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Microarray analyses showed that gene expression of proteins associated with inflammation, 
cell injury/infection and cholesterol biosynthesis were induced after nanosilica treatment in 
primary and transformed cells, corroborating studies in the literature which employed larger 
particles (Chatterjee et al., 2016; Waters et al., 2009). As with toxicity, the genomic response 
of the cancerous cell line to the nanoparticulate was small. 
The results in this chapter may suggest that nanosilica effects primary T cell function. In the 
apoptosis/necrosis studies, nanosilica inhibited TCR, not CD4 or CD8, staining 0.5-2 h after 
treatment. This may suggest nanosilica is interacting with the T cell receptor. Additionally, the 
induction of T cell apoptosis was greatest 8-24 h after treatment, which may suggest that the 
mechanism of induced apoptosis is indirect and potentially through a process such as 
activation induced cell death. Lastly, nanosilica was found to increase the expression of genes 
associated with T cell activation. Given these results, along with the lack of studies which have 
investigated the effects of nanosilica on T cell function, further investigations on the effect of 
amorphous silica nanoparticles on T cells were warranted. 
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Chapter 5. Effect of nanosilica on T cell activation  
5.1 Introduction 
In the previous chapter, there was evidence that would suggest nanosilica might be inducing 
T cell activation. The nanosilica dispersions were found to induce T cell apoptosis, a process 
that can be initiated by activation induced cell death (AICD) (Arakaki et al., 2014). Additionally, 
when PBMC cultures were treated with nanosilica, there was an increase in the expression of 
multiple genes associated with T cell activation, including iCOS, IFN-γ, Ly9 and CRTAM 
(Geginat et al., 2015; Patiño-Lopez et al., 2006; Schwartzberg et al., 2009; Wikenheiser and 
Stumhofer, 2016).  
In this chapter, the effect of nanosilica on T cell function was investigated by assessing 
expression of activation markers, measuring cell proliferation and analysing cell supernatants 
for cytokines. A nanosilica dispersion with a median particle diameter of 3.4-3.8 nm was used 
throughout this chapter. Staphylococcal enterotoxin B, a superantigen known to induce chronic 
T cell activation, was used a positive control.  
5.2 Results and discussion  
5.2.1 The effect of nanosilica on CD4 T cells 
5.2.1.1 General markers of activation  
The ability of nanosilica to induce T cell activation was first assessed on helper T cells by 
monitoring the expression of the CD25 and CD69 surface activation markers, which are 
expressed after T cell encounter with cognate antigen presented on an APC (Broere et al., 
2011; Létourneau et al., 2009; Malek and Castro, 2010; Radulovic et al., 2013). T helper cells 
were identified by the CD3 receptor and the CD4 co-receptor (Chakraborty and Weiss, 2014).  
Figure 5.01 shows CD25 and CD69 expression on CD4 T cells after PBMC cultures were 
treated with SEB, silicic acid and nanosilica. The fluorescent intensity (Figure 5.01A) and the 
percentage of cells positive (Figure 5.01B) for CD25 and CD69 was low in the control cultures. 
In cultures treated with the SEB positive control, the fluorescent intensity increased 
significantly and approximately half of the CD4 T cells were positive for the activation markers. 
These results indicate that the CD4 T cells in the PBMC cultures employed here were 
unstimulated and, upon addition of SEB, they were chronically activated (i.e., respond 
appropriately to SAgs). The percentage of cells positive for the activation markers in the 
negative and positive control cultures was consistent with those reported in the literature 
(Reddy et al., 2004; Sancho et al., 1999). The expression of the activation markers on CD4 T 
cells in cultures treated with silicic acid were similar to those in the untreated control. These 
results would suggest that soluble silica does not activate resting T helper cells. In cultures 
treated with nanosilica, which was produced from the same stock solutions (sodium silicate, 
HCl and H2O) as the silicic acid control, the CD4 T cells expressed significant levels of the 
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activation markers. The levels of CD25 and CD69 induced by nanosilica were comparable to 
those induced by SEB, both in fluorescent intensity (Figure 5.01B) and in percentage positive 
(Figure 5.01C). These results would suggest that nanosilica induces activation of CD4 T cells. 
As the silicate treatments were both prepared from the same stock solutions, it is highly unlikely 
that a contaminate in the nanosilica stock (e.g., an endotoxin) was responsible for the induction 
of the activation markers. The high percentage of cells positive for the activated markers would 
suggest that nanosilica, like SEB, is inducing activation regardless of the T cell antigenic 
specificity (i.e., TCR clonotype). Whether the nanosilica induced activation shown here is 
similar to the one eluded to by Chen et al. is unknown (Chen et al., 2014). 
Figure 5.02 shows the effect of nanosilica concentration on the expression of CD25 and CD69 
on T helper cells. At 150 μM Si, nanosilica increased CD69 positivity on CD4 T cells, but had 
no effect on CD25 levels. At higher concentrations (300 μM), nanosilica induced significant 
expression of both activation markers. Interestingly, the concentrations which induced 
significant T cell activation were the same as those that induced significant cell death (Chapter 
4). Whether monocyte and B cell death is involved in the activation of T cells was investigated 
in Chapter 6.   
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Figure 5.01. The effect of SEB, silicic acid and nanosilica on the expression of CD25 and 
CD69 on CD4 T cells in PBMC culture after 24 h. A. Flow cytometric gating strategy for 
selecting CD4 T cells within PBMC. T cells were first selected based on FSC versus SSC 
profiles through a T cell gate also which excluded debris, followed by a viable T cell gate  
(7-AAD(-)CD3(+)) and a CD4(+) gate. B. Representative dot plots showing the expression of 
CD25 and CD69 on CD4 T cells. C. The percentage of CD4 T cells positive for CD25 and 
CD69. Tabulated data represent the mean ± standard deviation for 7 donors (* denotes a 
significance compared to the control, two-tailed paired T test, p < 0.05).  
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Figure 5.02. The effect of nanosilica concentration on the percentage of CD4 T cells 
positive for CD25 and CD69 in PBMC culture after 24 h. Tabulated data represent the mean 
± standard deviation for 7 donors (* denotes a significance compared to the control, two-tailed 
paired T test, p < 0.05). T cells were first selected based on FSC versus SSC profiles through 
a T cell gate which also excluded debris, followed by a viable T cell gate  
(7-AAD(-)CD3(+)) and a CD4(+) gate 
 
The expression of CD25 and CD69 on T cells can be induced by antigen stimulation alone 
(Reddy et al., 2004; Sprent et al., 1997). Other markers of T helper cell activation, like 
proliferation, require secondary signals supplied by APCs for their induction (Chen and Flies, 
2013). Whether nanosilica induces T cell proliferation was investigated using CFDA-SE flow 
cytometric assays (Chapter 2). In these assays, resting T cells were stained with CFDA-SE, 
treated, and incubated for 3-5 days. Figure 5.03A shows representative flow cytometric dot 
plots of T cell proliferation after 3 days. In the control cultures, there was a single population 
at high fluorescent intensity, corresponding to undivided CD4 T cells. In the flow cytometric dot 
plot of the SEB treated cultures, there were two populations of lesser CFDA-SE intensity to the 
parent cells. These populations correspond to T cells that have undergone cell division, as the 
CFDA-SE from the parent cell is split between the two daughter cells (thus fluorescence 
decreases by 50%). A high percentage of the helper T cells in cultures treated with SEB 
underwent 1 or 2 rounds of division, indicating that complete T cell activation was induced by 
the superantigen. There was no distinct daughter cell population in flow cytometric dot plot of 
the culture treated with nanosilica, which would suggest that nanosilica does not induce T cell 
proliferation. Figure 5.03B shows the percentage of CD4 T cells that had undergone 1 or more 
rounds of division. Although a distinct population was not present in the flow cytometric dot 
plots, there was significant induction of CD4 T cell proliferation in cultures treated with 
nanosilica. However, the low percentage of T helper cells that had undergone proliferation 
would suggest that the T cells are not completely activated by nanosilica. The reason for the 
low levels of T cell proliferation was investigated in Chapter 6. 
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Figure 5.03. The effect of nanosilica on CD4 T cell proliferation in PBMC culture after 3 
and 5 d. A. Representative dot plots showing the CFSE proliferation profile of CD4 T cells. 
Percentages correspond to divided CD4(+) cells. B. The percentages of CD4 T cells that had 
undergone 1 or more rounds of division. Tabulated data represent the mean ± standard 
deviation for 7 donors (* denotes a significance compared to the control, two-tailed paired T 
test, p < 0.05). T cells were first selected based on FSC versus SSC profiles through a T cell 
gate which also excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a 
CD4(+) gate 
 
In Chapter 4, nanosilica was found to induce apoptosis of CD4 and CD8 T cells. T cells can 
undergo apoptosis through a process called activation induced cell death (AICD) (Arakaki et 
al., 2014). AICD is initiated when the CD95 (Fas) receptor is engaged by the CD178 ligand 
(FasL). Upon engagement, CD95 trimerizes and downstream signalling is initiated, which 
leads to the release of intracellular caspases and apoptosis. The engagement of CD95 
receptor on T cells does not always initiate AICD, as it also acts as a co-stimulatory receptor. 
In this co-stimulatory role, the magnitude of signalling will dictate its effect on T cell response, 
where low levels of signalling through CD95 enhances the T cell response while high levels of 
signalling inhibits/decreases T cell response (Paulsen and Janssen, 2011). Consequently, the 
expression of CD95 increases after T cell activation, as it involved in the modulation of the T 
cell response (McLeod et al., 1998; Paulsen and Janssen, 2011). Whether nanosilica effects 
the expression of Fas was investigated here. 
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Figure 5.04 shows the levels of Fas on CD4 T cells after treatment with nanosilica. The 
baseline levels of CD95 on CD4 T cells was high, >50% Fas(+), despite low expression of 
other activation markers (CD25, data not shown). This may suggest that the CD95 antibody is 
detecting both the monomeric and trimeric (activated) forms of the receptor. The SEB 
treatment significantly increased the expression of CD95 on the surface of CD4 T cells, which 
is consistent with studies in the literature (McLeod et al., 1998). Silicic acid did not alter the 
expression of CD95, further indicating that soluble silica has no effect on T cell function. 
Nanosilica significantly increased CD95 expression on CD4 T cells, which provides further 
evidence that nanosilica induces T cell activation. These results might suggest that CD4 T cells 
treated with nanosilica are more susceptible to AICD, potentially indicating a mechanism for 
the nanosilica induced T cell apoptosis shown in Chapter 4.  
In this section, it was shown that nanosilica induces T cell activation. The expression of CD25, 
CD69 and CD95 were induced on CD4 T cells. The lack of T cell proliferation after nanosilica 
treatment would suggest that complete activation is not induced. Next, the responses specific 
to T helper cell lineages were investigated. 
 
 
Figure 5.04. The effect of nanosilica on the expression of CD95 on CD4 T cells in PBMC 
culture after 24 h. A. Representative dot plots showing the expression of CD95 on CD4 T 
cells. B. The percentage of CD4 T cells positive for CD95. Tabulated data represent the mean 
values for 8 donors (* denotes significance compared to the control, two-tailed paired T test, p 
< 0.05). T cells were first selected based on FSC versus SSC profiles through a T cell gate 
which also excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a CD4(+) 
gate 
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5.2.1.2 The effect of nanosilica on helper (CD4(+)) T cells lineage 
As CD4 T cells can take on a number of different Th lineages upon their activation (Geginat et 
al., 2015), the polarization of the CD4 T cells to specific helper cell lineages in response to 
nanosilica was investigated here.  
Regulatory T cells 
Regulatory T cells (Treg) are responsible for suppressing immune responses. During 
inflammation, Tregs release cytokines to inhibit further activation, thus limiting damage to the 
surrounding tissues and preventing autoimmunity (Arpaia et al., 2015). There are two types of 
regulatory T cells, natural (nTreg), which can be identified by the foxhead box P3 (FoxP3) 
protein and CD25, and inducible (iTreg), which can be identified by CD25 but can be both 
FoxP3 positive and negative (Mellanby et al., 2009). FoxP3 is a regulator of development and 
maintenance for this T cell subset in humans (Sakaguchi et al., 2010). Whether nanosilica 
induces a Treg lineage was first investigated by determining the levels of FoxP3 in 
CD4(+)CD25(+) T cells. These analyses therefore excluded inducible FoxP3(-) Tregs. Figure 
5.05 shows the levels of intracellular FoxP3 in activated (CD25(+)) CD4 T cells. There were 
few T cells in the flow cytometric dot plot of untreated cultures due to the low baseline activation 
levels, where approximately 5% of the CD4 T cells were CD25(+). Of the activated cells, 
approximately 5-10% were positive for the FoxP3 protein, corroborating the peripheral CD25 
and FoxP3 levels reported in the literature (Finney et al., 2010; Olkowska-Truchanowicz et al., 
2013; Valmori et al., 2005). The SEB positive control increased the number of cells positive for 
FoxP3, but the proportion of activated cells FoxP3 positive did not significantly change 
compared to that of the control. The percentage of activated CD4 T cells positive for FoxP3 
increased significantly after treatment with nanosilica. Approximately 25% of the 
CD4(+)CD25(+) T cells were also positive for intracellular FoxP3 after treatment with high dose 
nanosilica. These results might suggest that nanosilica is inducing a Treg phenotype on a 
portion of the Th cells. The percentage of CD4 T cells that have a regulatory phenotype and 
are CD25(+)FoxP3(-) is unknown. 
Next, the expression of latency-associated peptide (LAP) and glycoprotein A repetitions 
predominant (GARP) on activated CD4 T cells was assessed. LAP and GARP are proteins 
associated with the latent-TGF-β complex, which is only expressed on regulatory T cells 
(Gauthy et al., 2013; Stockis et al., 2009). This complex is responsible for releasing the 
immunosuppressive cytokine TGF-β. Figure 5.06 shows the expression of LAP and GARP on 
activated (CD25(+)) CD4 T cells. As with the FoxP3 analysis, low baseline activation levels in 
the untreated cultures resulted in few cells being present in the flow cytometric dot plots. Also 
similar to the other Treg marker, SEB increased the number of activated CD4 T cells positive 
for LAP and GARP but it did not increase the overall percentage of activated cells positive for 
these markers. The percentage of activated CD4 T cells positive for LAP and GARP 
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significantly increased after treatment with 800 μM nanosilica. Indeed, nanosilica induced 
similar levels of FoxP3, LAP and GARP on activated CD4 T cells. These results would suggest 
that a fraction of activated CD4(+) T cells have a regulatory phenotype.   
 
 
Figure 5.05. The effect of nanosilica on intracellular FoxP3 levels in activated CD4 T 
cells in PBMC culture after 24 h. A. Representative flow cytometric dot plots showing the 
levels of FoxP3 in activated (CD25(+)) CD4 T cells. B. The percentage of activated CD4 T 
cells positive for FoxP3. Tabulated data represent the mean values for 6 donors (* denotes a 
significance compared to the control, two-tailed paired T test, p < 0.05). T cells were first 
selected based on FSC versus SSC profiles through a T cell gate which also excluded debris, 
followed by a viable T cell gate (7-AAD(-)CD3(+), a CD4(+) gate and a CD25(+) gate 
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Figure 5.06. The effect of nanosilica on LAP and GARP expression on activated CD4 T 
cells in PBMC culture after 24 h. A. Flow cytometric gating strategy for selecting activated 
CD4 T cells within PBMC. T cells were first selected based on FSC versus SSC profiles 
through a T cell gate which also excluded debris, followed by a viable T cell gate (7-AAD(-
)CD3(+)) and a CD4(+)CD25(+) gate. B. Representative dot plots showing the expression of 
LAP and GARP on activated CD4 T cells. C. The percentage of activated CD4 T cells double 
positive for LAP and GARP. Tabulated data represent the mean values for 7 donors (* denotes 
a significance compared to the control, two-tailed paired T test, p < 0.05).  
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Regulatory T cells can inhibit immune responses by releasing immunosuppressive cytokines. 
IL-10 is a cytokine released by Tregs to inhibit an inflammatory response (Couper et al., 2008). 
Whether nanosilica induces IL-10 production was investigated. Figure 5.07 shows the levels 
of IL-10 present in the supernatants collected 24 h after nanosilica treatment. There was only 
detectable IL-10 in the supernatants from the SEB treated cultures. The levels of IL-10 in 
untreated and nanosilica treated cultures remained below the limit of detection (< 30 pg/mL). 
These results would suggest that although certain regulatory markers (FoxP3 levels, 
LAP/GARP) are induced by nanosilica, a full regulatory response is not.  
 
  
Figure 5.07. The effect of nanosilica on IL-10 levels in PBMC culture supernatants after 
24 h.  Tabulated data represent the means ± standard deviation for 10 donors. * denotes a 
significance compared to the control, two-tailed paired T test, p < 0.05) 
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Th1 T cells 
CD4 T cells with a Th1 lineage mediate a cytotoxic T cell response and activate monocytes 
(Geginat et al., 2015). They are characterized by the production of IFN-γ, though other cell 
subsets have also been shown to produce this cytokine (Thäle and Kiderlen, 2005). The ability 
of nanosilica to induce a Th1 response was investigated by assessing supernatant IFN-γ 
levels. Figure 5.08 shows the levels of IFN-γ in cell supernatants after 24 h. There was no 
detectable IFN-γ in the supernatants from untreated and silicic acid treated cultures. The 
supernatants from cultures treated with nanosilica contained ca. 2 ng/mL IFN-γ. These results 
would suggest that nanosilica is inducing a Th1 response. However, direct evidence that CD4 
T cells are producing IFN-γ is still required as other cell types in culture are capable of 
producing this cytokine (Thäle and Kiderlen, 2005). 
   
 
Figure 5.08. The effect of silicic acid and nanosilica on IFN-γ levels in PBMC culture 
supernatants after 24 h.  Tabulated data represent the means ± standard deviation for 7 
donors. (* denotes a significance compared to the control, two-tailed paired T test, p < 0.05) 
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Th2 T cells 
CD4 T cells with a Th2 lineage are responsible for mediating B cell responses. The type of B 
cell response is dependent on the signals Th2 cells provide (Crotty, 2015; Sahoo et al., 2016). 
Whether nanosilica induces a Th2 response was investigated.  
CD40L (CD154) is expressed on Th2 cells and, when it engages the CD40 receptor on B cells, 
it induces B cell proliferation and survival (Crotty, 2015; Elgueta et al., 2009; Janeway Jr et al., 
2001; Jenkins et al., 2008). Figure 5.09 shows the effect of nanosilica on CD40L expression. 
The percentage of CD4 T cells positive for CD40L was low in the control and silicic acid treated 
cultures, and was similar to the levels reported in the literature (Desai-Mehta et al., 1996). SEB 
significantly increased the levels of CD40L positive cells, consistent with its non-specific 
activation of T cells. Indeed, SAgs are known to induce responses from all Th phenotypes 
simultaneously (Terman et al., 2013), which explains the induction of Treg, Th1 and Th2 
responses shown in this chapter. Nanosilica was also found to significantly increase CD40L 
expression on CD4 T cells. These results might suggest that nanosilica, like SEB, is inducing 
non-specific CD4 T cell activation as at least one activation marker from each Th lineage was 
induced. 
Whether nanosilica induces other Th2 responses was investigated by assessing the 
expression of inducible T cell costimulator (iCOS). iCOS is expressed on Th2 cells and is 
involved in the induction of antibody and cytokine production by B cells (Sahoo et al., 2016; 
Wikenheiser and Stumhofer, 2016; Yong et al., 2009). Figure 5.10 shows the effect of 
nanosilica on iCOS expression. As with CD40L, the levels of iCOS on CD4 T cells in the 
untreated and silicic acid treated cultures were low and similar to those reported in the literature 
(Chen et al., 2009a). The expression of iCOS significantly decreased after nanosilica 
treatment, contradicting the results that show nanosilica increases the expression of the gene 
corresponding to iCOS (Chapter 4). It remains unclear whether nanosilica induces a full Th2 
response.  
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Figure 5.09. The effect of nanosilica on CD40L (CD154) expression on CD4 T cells in 
PBMC culture after 24 h. A. Representative dot plots showing the expression of CD25 and 
CD154 on CD4 T cells. B. The percentage of CD4 T cells positive for CD154. Tabulated data 
represent the mean values for 7 donors (* denotes a significance compared to the control, two-
tailed paired T test, p < 0.05). T cells were first selected based on FSC versus SSC profiles 
through a T cell gate which also excluded debris, followed by a viable T cell gate  
(7-AAD(-)CD3(+)) and a CD4(+) gate. Note – only 4 of replicates were tested for silicic  
acid in B. 
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Figure 5.10. The effect of nanosilica on iCOS (CD278) expression on CD4 T cells in 
PBMC culture after 24 h. A. Representative dot plots showing the expression of CD25 and 
CD278 on CD4 T cells. B. The percentage of CD4 T cells positive for CD278. Tabulated data 
represent the mean values for 8 donors (* denotes a significance compared to the control, two-
tailed paired T test, p < 0.05). T cells were first selected based on FSC versus SSC profiles 
through a T cell gate which also excluded debris, followed by a viable T cell gate  
(7-AAD(-)CD3(+)) and a CD4(+) gate 
 
The presence of IL-4 in nanosilica treated cultures was assessed to determine whether a 
complete Th2 response was induced. IL-4 is produced by Th2 cells and further supports 
development of this Th phenotype (Geginat et al., 2015; Jiang and Dong, 2013; Silva-Filho et 
al., 2014). Figure 5.11 shows the levels of IL-4 in cell supernatants after 24 h. The levels of IL-
4 were below the limit of detection (15 pg/mL) in the supernatants of the untreated, silicic acid 
and nanosilica treated cultures. These results would suggest that nanosilica is not inducing a 
Th2 response in cell culture.  
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Figure 5.11. The effect of nanosilica on IL-4 levels in PBMC culture supernatants after 
24 h.  Tabulated data represent the means ± standard deviation for 8 donors.  
 
In this section, the effect of nanosilica on the polarization of CD4 T cells to specific lineages 
was investigated. The results would suggest that nanosilica likely induces a Th1 phenotype, 
as there was significant levels of IFN-γ present in cell supernatants after nanosilica treatment. 
Cytokines of Th2 and Treg phenotypes (IL-4 and IL-10, respectively) were not detected in cell 
supernatants after nanosilica treatment, though activation markers of these Th subsets were 
induced. These results would suggest that nanosilica is non-specifically inducing CD4 T cell 
activation.  
5.2.2 The effect of nanosilica on cytotoxic lymphocytes 
5.2.2.1 The effect of nanosilica on CD8 T cells 
The effect of nanosilica on cytotoxic T cell activation was investigated next. Cytotoxic T cells 
(CTLs) are an essential part of the adaptive immune system as they eliminate stressed, 
abnormal, and infected cells (Barry and Bleackley, 2002). As with the CD4 T cells, activated 
CTLs express the CD25 and CD69 activation markers. Cytotoxic T cells were identified by the 
CD3 receptor, which flanks the TCR, and the CD8 co-receptor, which binds the TCR:pMHC 
class I complex. 
Figure 5.12 shows CD25 and CD69 expression on cytotoxic T cells after PBMC cultures were 
treated with SEB, silicic acid and nanosilica. The control cultures show the baseline expression 
levels of CD25 and CD69, where the majority of cells were negative for the activation markers. 
The percentage of resting cells positive for CD25 and CD69 was consistent with levels reported 
in the literature (Reddy et al., 2004; Sancho et al., 1999). Adding SEB to culture resulted in 
significant expression of the activation markers, indicating that the CTLs responded 
appropriately in culture. As with the T helper cells, soluble silica (silicic acid) did not alter the 
expression of CD25 or CD69 on cytotoxic T cells, indicating that the nanosilica degradation 
product has no effect on T cell activation. Nanosilica induced significant expression of the 
activation markers on CD8 T cells. The levels of CD25 and CD69 induced by nanosilica were 
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less than those induced by SEB, both in fluorescent intensity (Figure 5.12A) and in percentage 
positive (Figure 5.12B), but they were still significantly greater than that of the control. The high 
percentage of cells positive for the activated markers and the activation of both CD4 (Section 
5.2.1) and CD8 T cells would suggest that nanosilica is inducing activation regardless of the T 
cell antigenic specificity and co-receptor.  
Figure 5.12C shows the effect of nanosilica concentration on the expression of CD25 and 
CD69 on CTLs. Nanosilica increased CD69 positivity on CD8 T cells but had no effect on CD25 
levels at 150 μM Si. At higher concentrations (300 μM), nanosilica induced significant 
expression of both activation markers. As indicated in Section 5.2.1, the concentrations which 
induced significant activation were the same that induced significant cell death.  
 
 
Figure 5.12. The effect of SEB, silicic acid and nanosilica on the expression of CD25 and 
CD69 on CD8 T cells in PBMC culture after 24 h. A. Representative dot plot showing the 
expression of CD25 and CD69 on CD8 T cells. B. The effect of silicic acid and nanosilica on 
the percentage of CD8 T cells positive for CD25 and CD69. C. The effect of nanosilica 
concentration on the percentage of CD8 T cells positive for CD25 and CD69. Tabulated data 
represent the mean ± standard deviation for 7 donors (* denotes a significance compared to 
the control, two-tailed paired T test, p < 0.05). T cells were first selected based on FSC versus 
SSC profiles through a T cell gate which also excluded debris, followed by a viable T cell gate 
(7-AAD(-)CD3(+)) and a CD8(+) gate 
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The effect of nanosilica on cytotoxic T cell proliferation was investigated next, using CFDA-SE 
flow cytometric assays (same as those used in the CD4 T cell assays). Figure 5.13A shows 
representative flow cytometric dot plots of CD8 T cell proliferation after 3 days. The dot plot of 
the control culture showed one population of high CFDA-SE intensity, corresponding to resting 
(parent) CD8 T cells. The dot plot of the culture treated with SEB showed an additional two 
populations of lesser fluorescent intensity, which correspond to CD8 T cells that had 
undergone 1 and 2 rounds of division. These populations were not evident in the dot plots of 
the cultures treated with nanosilica, indicating that nanosilica does not induce CD8 T cell 
proliferation. Figure 5.13B shows the percentage of CD8 T cells that had undergone 1 or more 
rounds of division. As with the CD4 T cells, there were significant levels of CD8 T cell 
proliferation in cultures treated with nanosilica after 5 days, despite a lack of a discernible 
population in the flow cytometric dot plots. The low levels of induced proliferation would 
suggest that nanosilica does not induce complete T cell activation. 
In Section 5.2.1, nanosilica was found to induce CD95 expression on CD4 T cells, potentially 
suggesting that the apoptosis shown in Chapter 4 was through Fas mediated AICD. CD8 T 
cells can also proceed through AICD via the Fas death receptor (Arakaki et al., 2014). CD95 
also acts a co-stimulatory receptor, modulating the T cell response depending on the 
magnitude of CD95 ligation and the activation state of the T cell during its ligation (Paulsen 
and Janssen, 2011). Whether nanosilica could be inducing CD95 expression on CTLs was 
investigated here. Figure 5.14 shows the levels of Fas on CD8 T cells after treatment with 
nanosilica. As with the CD4 T cells, there was a high CD95 baseline on CD8 T cells in untreated 
cultures, potentially suggesting that the CD95 antibody is detecting both the monomeric and 
trimeric forms of the receptor. Despite the high baseline levels, the SEB treatment significantly 
increased the expression of CD95. The silicate treatments, both nanosilica and the soluble 
silica control, did not significantly affect receptor expression, though nanosilica inconsistently 
increased CD95 on CD8 T cells. The slight increase in CD95 expression after nanosilica 
treatment further indicates that the nanoparticulate activates CD8 T cells, and can induce 
expression of ligands which can further modulate the T cell response. 
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Figure 5.13. The effect of nanosilica on CD8 T cell proliferation in PBMC culture after 3 
and 5 d. A. Representative dot plots showing the CFSE proliferation profile of CD8 T cells at 
3 d. Percentages correspond to divided CD8(+) cells. B. The percentages of CD8 T cells that 
had undergone 1 or more rounds of division. Tabulated data represent the mean ± standard 
deviation for 7 donors (* denotes a significance compared to the control, two-tailed paired T 
test, p < 0.05). T cells were first selected based on FSC versus SSC profiles through a T cell 
gate which also excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a 
CD8(+) gate 
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Figure 5.14. The effect of nanosilica on the expression of CD95 on CD8 T cells in PBMC 
culture after 24 h. A. Representative dot plots showing the expression of CD95 on CD8 T 
cells. B. The percentage of CD8 T cells positive for CD95. Tabulated data represent the mean 
values for 8 donors (* denotes a significance compared to the control, two-tailed paired T test, 
p < 0.05). T cells were first selected based on FSC versus SSC profiles through a T cell gate 
which also excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a CD8(+) 
gate 
 
5.2.2.2 The effect of nanosilica on γδ T cells and NK/NKT cells 
There are other lymphocyte subsets with cytotoxic capabilities present in the periphery. The 
effect of nanosilica on these cell subsets was also investigated.  
γδ T cells are a low frequency T cell subset with a T cell receptor (TCR) consisting of γ and δ 
chains rather than the more common α and β TCR chains. γδ T cells comprise 1-5% of the T 
cells in the periphery and are known for their anti-tumour properties (Silva-Santos et al., 2015). 
Structurally, the γδ TCR has a much smaller angle between the constant and variable domain 
compared to that of the αβ TCR (Allison et al., 2001). γδ T cells do not recognize antigen 
presented in MHC receptors but instead recognize soluble antigens, CD1 receptors (MHC-
like) and other proteins expressed on cell surfaces (Dar et al., 2015; Vantourout and Hayday, 
2013; Wiest, 2016; Wu et al., 2014). Whether γδ T cells are activated by nanosilica was 
investigated.  
Figure 5.15 shows the effect of nanosilica on the expression of CD25 and CD69 on γδ T cells. 
The decreased frequency of this T cell subset, compared to αβ T cells, is evident in the flow 
cytometric dot plots. The SEB positive control induced significant expression of the activation 
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markers, indicating that the cells responded appropriately in culture. Superantigens are 
thought to activate γδ T cells in a similar fashion to αβ T cells (Ramesh et al., 1995; Rust and 
Koning, 1993). Soluble silica showed similar CD25 and CD69 levels to that of the untreated 
control, both of which similar to those reported in the literature (Kunzmann et al., 2000). As 
with αβ T cells, nanosilica induced significant expression of CD25 and CD69 on γδ T cells. 
These results further support that nanosilica induced T cell activation is non-specific. The 
mechanism in which nanosilica is inducing γδ T cell activation was investigated in Chapter 6.  
 
Figure 5.15. The effect of nanosilica on CD25 and CD69 expression on γδ T cells in 
PBMC culture after 24 h. A. Representative dot plots showing the expression of CD25 and 
CD69 on γδ T cells. B. The percentage of γδ T cells positive for CD25 and CD69. Tabulated 
data represent the mean ± standard deviation for 8 donors (* denotes a significance compared 
to the control, two-tailed paired T test, p < 0.05). T cells were first selected based on FSC 
versus SSC profiles through a T cell gate which also excluded debris, followed by a viablility 
(7-AAD(-)) and a γδ TCR(+) gate. 
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Natural killer (NK) cells are another lymphocyte subset that have cytotoxic capabilities. Unlike 
T cells, NK cells are a part of the innate immune system. NK cells do not have a TCR to 
recognize antigen but instead are activated through a number of different receptors, including 
NKp30, NKp44, and CD160 (Long et al., 2013; Vivier et al., 2008) and cytokines, including IL-
2, IL-12, and IFN-γ (Zwirner and Domaica, 2010). There is a T cell subset that also expresses 
NK cell markers. These cells, referred to as natural killer T (NKT) cells, have an invariant TCR 
that recognises the MHC-like CD1b receptor (Vivier et al., 2012). Whether nanosilica induces 
NK/NKT cell activation was investigated here. NK and NKT cells were identified by the CD57 
receptor (Leong et al., 2003). 
Figure 5.16 shows the effect of nanosilica on the expression of CD25 and CD69 on NK/NKT 
cells. The SEB positive control induced the expression of CD25 and CD69 on these cells, 
corroborating studies in the literature which show that both NK and NKT cells are activated by 
superantigens (Chen et al., 2009b; D'Orazio et al., 1995). Nanosilica also induced significant 
expression of CD25 and CD69 on NK/NKT cells, while the soluble silicic acid control did not. 
The mechanism of nanosilica-induced NK/NKT cell activation is unknown. However, it is 
possible that nanosilica induces stress markers on other cell types, thus leading to NK/ NKT 
cell activation. Indeed, gene expression of the stress receptor MHC class I polypeptide-related 
sequence A (MICA) was increased in PBMC and EBV transformed B cell cultures after 
nanosilica treatment (Chapter 4). The recognition of MICA by the NKG2D receptor on NK/NKT 
cells can induce their activation (Chan et al., 2014). Therefore, it is plausible that NK/NKT cell 
activation occurs through nanosilica induced cell stress. 
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Figure 5.16. The effect of nanosilica on CD25 and CD69 expression on NK/NKT (CD57(+)) 
cells in PBMC culture after 24 h. A. Representative dot plots showing the expression of 
CD25 and CD69 on NK/NKT cells. B. The percentage of NK/NKT cells positive for CD25 and 
CD69 after nanosilica treatment. Tabulated data represent the mean ± standard deviation for 
8 donors (* denotes a significance compared to the control, two-tailed paired T test, p < 0.05). 
NK/NKT cells were first selected based on FSC versus SSC profiles through a T cell gate 
which also excluded debris, followed by a viability (7-AAD(-)) and a CD56(+) gate 
 
In summary, the effect of nanosilica on activation of cytotoxic lymphocytes was investigated. 
The expression of CD25 and CD69 was induced by nanosilica on all cytotoxic lymphocyte 
subsets, including CTLs, γδ T cells, and NK/NKT cells.   
5.3 Conclusions 
In this chapter, the effect of nanosilica on T cell activation was investigated. Previously (in 
Chapter 4), it was shown that labile nanosilica particles, 3-4 nm in diameter, induce significant 
cell death in PBMC cultures. Of the cells tested in PBMC, T cells were most resistant to death 
upon exposure to the particles, though a significant portion of both CD4 and CD8 T cells did 
undergo cell apoptosis. It was later found that a number of genes associated with T cell 
activation were more highly expressed after nanosilica treatment. These results, along with the 
complete lack of published work in the subject area, warranted a full investigation on the 
response of T cells to nanosilica.  
Nanosilica, 3-4 nm in diameter, was found to activate T cells. The expression of the T cell 
activation markers CD25 and CD69 increased significantly on both CD4 and CD8 T cells after 
nanosilica treatment, while soluble silicon did not increase their expression. Other T cell 
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subsets, including γδ T cells and NK/NKT cells, also expressed high levels of these activation 
markers after nanosilica treatment. The amorphous particles did not induce αβ T cell 
proliferation, which would suggest that it does not induce complete T cell activation.   
Investigations on the polarization of T helper cells were also conducted. Supernatants from 
PBMC cultures treated with nanosilica contained significant levels of the cytokine IFN-γ, which 
would suggest that a Th1 phenotype is induced. However, phenotypic markers of Tregs 
(FoxP3, LAP/GARP) were also induced by nanosilica, though its corresponding cytokine was 
not. Similarly, Th2 cytokines were not induced. These results, along with the activation of the 
various cytotoxic T cell subsets, would suggest that nanosilica is inducing significant non-
specific T cell activation.  
In the next chapter, the T cell response to nanosilica was further investigated. The mechanism 
of nanosilica-induced T cell activation, the effect of nanosilica on T cell recognition of cognate 
antigen and the effect of particle characteristics on induced activation were all studied.  
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Chapter 6 – Investigations into the mechanism of T cell activation by nanosilica 
6.1 Introduction 
As shown previously, nanosilica particles 3.6 nm in diameter were found to activate T cells. 
The expression of activation markers on both CD4 and CD8 T cells and the production of IFN-
γ was induced by the nanoparticulate. Exposure to nanosilica did not result in complete T cell 
activation, as T cell proliferation was not induced. In this chapter, the mechanism of nanosilica 
induced T cell was investigated using immunoblot and flow cytometry based assays, by using 
various cell lines, enriched cell cultures and cells from transgenic mice, and by using a range 
of nanoparticles.  
6.2 Results and discussion 
6.2.1 Role of antigen-presenting cells (APCs) 
Investigations were conducted to determine whether the activation of CD4 T cells by nanosilica 
is APC dependant. CD4 T cells require APCs for activation as they only recognise cognate 
antigen in the context of an MHC class II receptor, which are predominately expressed on 
APCs (Kambayashi and Laufer, 2014). By removing APCs from culture, it is possible to 
determine whether nanosilica requires MHC class II receptors for CD4 T cell activation. The 
MHC class I receptor, which presents antigen to CD8 T cells, is expressed on all mammalian 
cells (including T cells) and therefore cannot be removed from culture (Tourdot and Gould, 
2002).  
T cells from PBMC cultures were enriched using monocyte adherence or T cell isolation kits 
(through negative selection). Figure 6.01A shows the cell distribution of the enriched T cell 
cultures. The percentage of cells positive for CD3ε in the enriched cultures was >88%, 
increased from that of 50-70% in PBMC cultures (data not shown). The percentage of cells 
positive for CD11c (monocytes, the professional APCs) was <3% in the enriched T cell 
cultures, down from 10-35% in PBMC cultures. The enriched T cell cultures were treated and 
the expression of the CD25 and CD69 activation markers, which are expressed on activated 
T cells (D’Souza and Lefrançois, 2003; Mackay et al., 2015; Malek and Castro, 2010; 
Radulovic et al., 2013), were assessed.  
Figure 6.01B shows the effect of nanosilica on the expression of CD25 and CD69 on CD4 and 
CD8 T cells in enriched T cell cultures. SEB induced significant expression of CD25 and CD69 
on both T cell subsets. However, the percentage of CD4 T cells positive for the activation 
markers was much lower in enriched T cell cultures compared to that in full PBMC cultures. 
Figure 6.01C shows the difference in activation which was induced in enriched T cell cultures 
versus that which was induced in PBMC cultures, as determined by the following equation: 
% difference = (% CDXX(+)EN T cells - %CDXX (+)PBMC) / %CDXX(+)PBMC x 100% 
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CD25 and CD69 induced on CD4 T cells by SEB decreased by ca. 50% in the enriched cultures 
while the percentage of CD8 T cells positive for the activation markers remained relatively 
unchanged. Superantigens induce T cell activation by crosslinking MHC receptors to TCRs 
(Arad et al., 2011; Fraser, 2011; Li et al., 1998). The activation of CD4 T cells decreased in 
enriched T cell cultures as there were fewer MHC class II receptors for the SAg to crosslink. 
The activation of CD8 T cells in enriched cultures did not significantly decrease as its MHC 
receptor (class I) is expressed on all mammalian cells types including T cells (Tourdot and 
Gould, 2002).  
Nanosilica induced significant expression of CD25 and CD69 on CD4 and CD8 T cells in 
enriched T cell cultures (Figure 6.01B). The percentage of CD4 T cells positive for the 
activation markers in the enriched T cell cultures was similar to that found in PBMC cultures 
(Figure 6.01C). These results would suggest that the nanosilica does not require MHC class II 
receptors (APCs) to induce CD4 T cell activation. Interestingly, the percentage of CD8 T cells 
positive for CD25 and CD69 in enriched T cell cultures was significantly greater than that found 
in PBMC cultures. It is possible that the interaction (phagocytosis) of nanosilica with APCs in 
full PBMC cultures decreases its potential for interaction with CD8 T cells. 
To confirm that nanosilica induced CD4 T cell activation is APC independent, the effect of 
nanosilica on Jurkat T cells was investigated. Jurkat cells are a leukemic T cell line that are 
CD4(+), CD8(-) and MHC class II(-) (Holling et al., 2004; Sandberg et al., 2007). Jurkat cells 
therefore require an APC, i.e., a cell expressing an MHC class II receptor, for antigen 
presentation. As APCs were not added to Jurkat T cell cultures, the effect of nanosilica on T 
cell activation was investigated in a culture completely deplete of MHC class II receptors. 
Figure 6.02 shows the effect of nanosilica on the induction of CD25 and CD69 on Jurkat T 
cells. The SAg control did not induce expression of the activation markers, as wildtype Jurkat 
T cells do not have a TCR sequence in which SEB can bind (Fleischer et al., 1996; Hayworth 
et al., 2009). Nanosilica increased CD69 expression on Jurkat T cells but did not induce 
significant expression of CD25. The lack of CD25 induction is not a defect in this cell line, as it 
can be induced with PHA and PdBu (Shatrova et al., 2015). The reason nanosilica does not 
induce CD25 expression is not known. However, the induction of CD69 on Jurkat T cells would 
suggest that APCs, and therefore MHC class II receptors, are not required for the activation of 
CD4 T cells by nanosilica.  
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Figure 6.01. The effect of nanosilica on CD25 and CD69 expression on CD4 and CD8 T 
cells in enriched T cell cultures. A. The cell distribution in the cultures tested after T cell 
enrichment. B. The effect of nanosilica on the percentage of CD4 and CD8 T cells positive for 
CD25 and CD69. Tabulated data represent the means ± standard deviation for 6 donors (* 
denotes significance compared to the control, paired T test, p < 0.05). T cells were first selected 
based on FSC versus SSC profiles through a T cell gate which also excluded debris, followed 
by a viable T cell gate (7-AAD(-)CD3(+)) and a CD4(+) or a CD8(+) gate. C. The percentage 
difference in the induction of the CD25 and CD69 activation markers in enriched T cell cultures 
and in PBMC culture (* denotes significance compared to that in PBMC culture, unpaired T 
test, p < 0.05. PBMC activation data from Figure 5.01 was used for the calculations) 
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Figure 6.02. The effect of nanosilica on Jurkat T cell CD25 and CD69 expression. A. 
Representative dot plots showing the expression of CD25 and CD69 on Jurkat T cells. B. The 
percentage of Jurkat T cells positive for CD25 and CD69. Tabulated data represent the means 
± standard deviation for 3 independent replicates (* denotes significance compared to the 
control, unpaired T test, p < 0.05). Jurkat cells were first selected based on FSC versus SSC 
profiles to exclude debris followed by a viable T cell gate (7-AAD(-)CD3(+)). 
 
The requirement of the TCR/CD3 complex in nanosilica induced T cell activation was 
investigated next. Karpas 299 cells, a lymphomic T cell line lacking the TCR/CD3 complex, 
were employed in these investigations. Figure 6.03 shows the effect of SEB and nanosilica on 
the expression of CD25 and CD69 on Karpas 299 cells. Over 95% of the untreated Karpas 
299 cells were positive for CD25. These results corroborate studies which have shown that 
Karpas 299 cells have a regulatory T cell phenotype (Sandberg et al., 2007). Regulatory T 
cells require IL-2 for homeostasis and therefore constitutively express the IL-2 receptor, in 
which CD25 is a component (Létourneau et al., 2009; Malek and Castro, 2010). The baseline 
levels of CD69 were low, and treatment with SEB or nanosilica did not increase its expression. 
These results would suggest that the TCR/CD3 complex is required for T cell activation by 
nanosilica.   
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Figure 6.03. The effect of nanosilica on Karpas 299 cell CD25 and CD69 expression. A. 
Representative dot plots showing the expression of CD25 and CD69 on viable Karpas 299 
cells. B. The percentage of Karpas 299 cells positive for CD25 and CD69. Tabulated data 
represent the means ± standard deviation for 3 independent replicates (* denotes significance 
compared to the control, unpaired T test, p < 0.05). Karpas 299 cells were first selected based 
on FSC versus SSC profiles to exclude debris followed by a viability gate  
(7-AAD(-))  
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6.2.2 Induction of intracellular signalling pathways  
The mechanism of nanosilica induced T cell activation was further investigated by assessing 
intracellular signalling pathways. Upon TCR engagement, downstream signalling is initiated 
through the phosphorylation of ITAMs, Zap70 and LAT (Brownlie and Zamoyska, 2013). 
Whether nanosilica is inducing signalling downstream of the TCR complex was first 
investigated by assessing the phosphorylation of Zap70 in enriched T cells from PBMC using 
western blot analyses.  
Figure 6.04A shows an immunoblot, which was stained for vinculin and phosphorylated Zap70 
(pZap70), of enriched T cell lysates after cultures were treated with nanosilica. The bands at 
ca. 130 kDa correspond to the vinculin protein. Vinculin is a cell membrane protein involved in 
cell adhesion and is commonly used as an immunoblot loading control (An et al., 2012; Solan 
et al., 2003). The band at ca. 70 kDa corresponds to pZap70. The control and the PHA treated 
cells did not contain significant levels of pZap70. Known T cell activators (superantigens, anti-
CD3, PHA) are not commonly used as positive controls in phosphorylation studies as specific 
incubation steps, unlike those used here, are required to get an appropriate phosphorylation 
response (Watson and Lee, 2006). Instead hydrogen peroxide is commonly used, but was 
avoided here due to the long incubation times. Studies using Jurkat T cells with a hydrogen 
peroxide positive control showed significant levels of pZap70 (data not shown). The lysates of 
cells treated with nanosilica were positive for pZap70, indicating that nanosilica induces 
signalling downstream of the TCR. Figure 6.04B shows the normalized levels of pZap70 
(compared to the internal control) in cell lysates after nanosilica treatment of cultures for 0.2 to 
6 h. pZap70 was present in all cell lysates of cultures treated with nanosilica for 0.2-6 h, but its 
concentration was highest between 0.2 and 2 h. These results would suggest that nanosilica 
is inducing persistent signalling downstream of the TCR/CD3 complex. The concentration of 
pZap70 is approximately inversely proportional to the dissolution of nanosilica over time, 
potentially suggesting that nanosilica induces signalling as long as it is present in culture, 
corroborating studies shown later on in this section (Figure 6.10).  
Investigations assessing the phosphorylation of LAT after nanosilica treatment were also 
conducted using enriched T cells from PBMC. The LAT protein is essential in T cell activation 
and is involved in a number of signalling pathways, including one leading to CD69 expression 
(Balagopalan et al., 2010). It is phosphorylated by pZap70 after TCR engagement 
(Chakraborty and Weiss, 2014). Figure 6.05A shows an immunoblot of enriched T cell lysates 
after cultures were treated with nanosilica, staining for vinculin and phosphorylated LAT 
(pLAT). The levels of the pLAT protein (ca. 35 kDa in size) were low in the control culture 
lysates, where no distinct bands were evident. Bands corresponding to the pLAT protein were 
present in the lysates of cultures treated with nanosilica for 0.2 h. Figure 6.05B shows the 
normalized levels of pLAT (compared to the internal control) in cell lysates of cultures treated 
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with nanosilica. Nanosilica significantly increased the levels of the pLAT protein in lysates of 
enriched T cell cultures, corroborating the previous studies with pZap70 which show that 
nanosilica is inducing signalling downstream of the TCR complex.  
 
 
Figure 6.04. Effect of nanosilica on the phosphorylation of Zap70 in enriched T cell 
cultures. A. A representative immunoblot of lysates from cultures stimulated for 0.2-1 h. Blots 
were probed with antibodies to detect pZap70 (at Tyr319, protein ca. 70 kDa) and vinculin 
(protein ca. 128 kDa). B. Percentage of pZap70 band volume compared to the vinculin band 
(internal control). Tabulated data represent the means ± standard error for 6 donors (* denotes 
significance compared to the control, paired T test, p < 0.05) 
 
 
Figure 6.05. Effect of nanosilica on the phosphorylation of LAT in enriched T cell 
cultures. A. A representative immunoblot of lysates from cultures stimulated for 0.2 h. Blots 
were probed with antibodies to detect pLAT (at Tyr191, protein ca. 37 kDa) and vinculin 
(protein ca. 128 kDa). B. Percentage of pLAT band volume compared to the vinculin band 
(internal control). Tabulated data represent the means ± standard deviation for 6 donors (* 
denotes significance compared to the control, paired T test, p < 0.05) 
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6.2.3 Incomplete signalling in nanosilica induced T cell activation  
In the previous section, it was shown that nanosilica induces signalling downstream of the TCR 
complex. It was also shown, in Chapter 5, that nanosilica did not induce T cell proliferation. 
These results may provide a clue to the mechanism of T cell activation. T cell proliferation 
requires a secondary signal, i.e., costimulation, supplied by the cell presenting antigen if the 
stimulation through the TCR is inefficient  (Chen and Flies, 2013; Csencsits and Bishop, 2003). 
In this section, the effect of costimulatory signals on nanosilica induced T cell activation was 
investigated.  
Chemical inducers were employed to understand the signalling initiated by nanosilica. Phorbol 
12, 13-dibutyrate (PdBu) is a chemical compound known to induce signalling through MAPK, 
which, in a healthy interaction, is induced after engagement of the CD28 receptor (Macián et 
al., 2002). Calcium ionophores, such as ionomycin, increase intracellular levels of calcium and 
induce signalling through NFAT which, in a healthy interaction, is induced after TCR 
engagement (Macian, 2005; Macián et al., 2002). Extended incubation periods with these 
chemical inducers, like those used to measure proliferation, led to significant cell death (data 
not shown). Therefore, instead of assessing T cell proliferation directly, the production of the 
cytokine IL-2 was used as an early surrogate marker. IL-2 is required in late stage T cell 
proliferation, which makes its production an indirect measure of the potential for clonal 
expansion (D’Souza and Lefrançois, 2003). Figure 6.06 shows the IL-2 levels in supernatants 
of cultures treated with nanosilica, PdBu, and/or ionomycin. PdBu and ionomycin individually 
did not significantly induce production of IL-2, as signalling through both pathways (MAPK and 
NFAT, respectively) is required for complete activation. When both chemical inducers were 
added to cell cultures, high levels of IL-2 were present in the cell supernatants. Therefore, IL-
2 production indicates whether downstream signalling of both TCR and CD28 is induced. There 
were low levels of IL-2 in the supernatants after treatment with 400 μM nanosilica, which 
corroborates the results showing only a very small amount of T cell proliferation (Chapter 5). 
The addition of PdBu to the nanosilica treated cultures resulted in significant production of  
IL-2. A similar response was not evident with the addition of ionomycin. These results confirm 
that nanosilica is inducing signalling downstream of the TCR complex (which corroborates the 
immunoblot assays shown previously), but it does not induce signalling through pathways 
downstream of costimulatory receptors. As both these pathways can be induced by efficient 
TCR antigenic stimulation alone (Csencsits and Bishop, 2003), these results would also 
suggest that TCR stimulation by nanosilica is inefficient. 
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Figure 6.06. The effect of 400 μM nanosilica, 0.5 μg/mL ionomycin and 0.2 μg/mL PdBu 
on IL-2 levels in PBMC culture supernatants at 24 h.  Tabulated data represent the means 
± standard deviation for 4 replicates.  
 
The effect of a costimulatory antibody, specifically anti-CD28, on T cell proliferation was next 
investigated, using CFDA-SE based flow cytometric assays. Figure 6.07 shows the effect of 
nanosilica and anti-CD28 on CD4 and CD8 T cell proliferation after 3 days. Neither the 
nanosilica nor anti-CD28 treatments induced significant T cell proliferation. There was a 
modest, but significant, increase in CD4 and CD8 T cell proliferation when cultures were 
treated with both nanosilica and anti-CD28 compared to all controls. These results would 
suggest that TCR signalling induced by nanosilica is inefficient and costimulatory signalling is 
required for a full T cell response, corroborating the studies with the chemical inducers. These 
results might also suggest that treatment with nanosilica alone can induce T cell anergy. 
Anergy is an activated T cell state in which the cells are hyporesponsive (Schwartz, 2003). It 
can be induced with chronic TCR stimulus without the appropriate costimulatory signals 
(Macian, 2005; Wells, 2009; Zheng et al., 2008). Indications that nanosilica is inducing T cell 
anergy include the lack of proliferation and the lack of significant IL-2 production.    
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Figure 6.07.  The effect of nanosilica and anti-CD28 on CD4 and CD8 T cell proliferation 
at 3 d. A. Representative dot plots showing CD4 and CD8 T cell proliferation. Although the 
CD4(-) and CD8(-) cells were shown in CD4 and CD8  plots, respectively, they were not 
included in the analysis. Therefore, percentages correspond to divided CD4(+) or CD8(+) T 
cells. B. The percentage of CD4 and CD8 T cells that have proliferated. T cells were first 
selected based on FSC versus SSC profiles through a T cell gate which also excluded debris, 
followed by a viable T cell gate (7-AAD(-)CD3(+)) and a CD4(+) or a CD8(+) gate. Tabulated 
data represent the means ± standard deviation for 8 donors (* denotes significance compared 
to the negative controls (i.e., control, anti-CD28, nanosilica), paired T test, p < 0.05) 
 
In the above section, the inability of nanosilica to high amounts of T cell proliferation was 
investigated. Previous investigations have shown that nanosilica induces signalling 
downstream of the TCR complex. Here, it was shown that nanosilica does not induce signalling 
downstream of a co-stimulatory receptor, specifically CD28. When treated in combination with 
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the anti-CD28 antibody or PdBu (an inducer of the same pathway), nanosilica induced T cell 
proliferation and IL-2 production.  
6.2.4 Nanosilica-T cell interactions  
6.2.4.1 Primary screening  
In the previous sections, nanosilica was shown to induce signalling downstream of the TCR 
complex and induce CD4 T cell activation in cultures deplete of APCs (MHC class II receptors). 
It was not able to induce activation of a T cell line lacking the TCR/CD3 complex. Taken 
together, these results might suggest that nanosilica is interacting directly with the TCR/CD3 
complex. The effect of nanosilica on T cell staining with fluorescently conjugated antibodies 
was investigated to determine whether a direct interaction with the receptor is plausible. PBMC 
cultures were treated with nanosilica, incubated on ice for 5 min, and washed with PBS+BSA 
prior to staining for various T cell receptors. Figure 6.08 shows representative dot plots of 
TCRαβ, CD3ε, CD4 and CD8 staining of cells within a T cell selection gate based off FSC 
versus SSC profiles after nanosilica treatment. The control group shows the typical proportion 
of cells positive for the T cell antibodies. The cells negative for the fluorescently conjugated 
TCRαβ and CD3ε antibodies correspond to B cells and monocytes that have bled into the T 
cell selection gate, along with NK cells that are not positive for the T cell markers. The SEB 
positive control had no effect on antibody staining. This would suggest that the TCR binding 
domain of SEB differs from than that of the fluorescently conjugated antibody used in this 
assay. Nanosilica was found to have a large effect on T cell antibody staining, where only a 
fraction of the cells were positive for TCR and CD3. This inhibition of staining might suggest 
that nanosilica is binding these receptors in a similar region as the TCRαβ and CD3ε 
antibodies. Nanosilica also affected CD4 and CD8 antibody staining. There was a large 
reduction in the mean fluorescent intensity of their expression when exposed to nanosilica 
(Figure 6.08). It is possible that the CD4 and CD8 receptors attempt to bind the TCR complex 
after engagement by nanosilica (as they would for a healthy pMHC-TCR interaction), thus 
becoming less susceptible to antibody staining. Figure 6.09 shows the effect of nanosilica 
pretreatment on TCRαβ, CD3ε, CD4 and CD8 positivity within a T cell selection gate based off 
FSC versus SSC profiles. The consistent inhibition of TCRαβ and CD3ε antibody staining might 
suggest that nanosilica is interacting with the TCR-CD3 complex at the binding sites of the 
antibodies. Commercial fluorescent antibodies come with limited information regarding their 
binding site (and companies will not provide further details), so it is not possible identify exactly 
where they, and potentially nanosilica, are binding. Studies have extensively modelled the 
extracellular end of the TCR-CD3 complex, determining that the approximate size is 8 nm x 
5.8 nm for the TCRαβ unit, 4 nm x 5 nm for CD3εδ unit, and 4 nm x 5.5 nm for CD3εγ unit (Sun 
et al., 2004). It is unlikely that a single nanosilica particle (with a hydrodynamic diameter of 3.6 
nm) is blocking both the TCRαβ and CD3ε antibodies, especially as there are two CD3ε chains 
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flanking each side of the TCR unit. This might suggest that nanosilica is inducing receptor 
internalization and/or multiple particles are associating to the TCR receptor complex. 
 
Figure 6.08. Representative dot plots showing the expression of TCRαβ, CD3ε, CD4 and 
CD8 in cultures exposed to SEB and nanosilica for 5 min. T cells were selected based on 
FSC versus SSC profiles through a T cell gate which also excluded debris  
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Figure 6.09. Percentage of the cells positive for TCRαβ, CD3ε, CD4 and CD8 in cultures 
exposed to SEB and nanosilica for 5 min. Tabulated data represent the means ± standard 
deviation for 4 donors (* denotes significance compared to the control, paired T test, p < 0.05). 
T cells were selected based on FSC versus SSC profiles through a T cell gate which also 
excluded debris 
 
During healthy activation, the TCR complex is internalized after disengagement from the 
pMHC complex and is either recycled back to the surface or broken down (Finetti et al., 2015). 
By permeablizing the membrane and staining for CD3 and TCR, receptor internalization can 
be assessed.  Figure 6.10 shows the percentage of cells positive for internal TCR and CD3 
after treatment with nanosilica. Intracellular CD3 levels increased after nanosilica treatment, 
while levels of intracellular TCR did not. It is unclear whether the lack of intracellular TCR 
staining was due to the degradation of the TCR receptor. However, the results showing CD3 
internalization would suggest that nanosilica is inducing receptor internalization, likely 
contributing to the lack of surface TCR and CD3 staining. 
To explore whether the lack of staining shown in Figure 6.09 is solely due to receptor 
internalization, the effect of nanosilica on antibody staining in fixed cell cultures was 
investigated. Figure 6.11 shows the effect of nanosilica on TCRαβ, CD3ε, CD4 and CD8 
staining in cultures that were pre-treated with PBS+2% paraformaldehyde for 2 h. There was 
still a significant reduction in antibody staining after nanosilica treatment in the fixed cell 
cultures. This might suggest that nanosilica is directly binding the TCR/CD3 complex, thus 
inhibiting antibody staining. It is unknown where the nanosilica is binding but, as noted above, 
the size of the receptor, as modelled by Sun et al. (Sun et al., 2004), versus the size of the 
particle (3.6 nm) would suggest multiple particles are involved. Additionally, the ability of 
nanosilica to inhibit CD3ε staining might suggest that the particles are not interacting with the 
variable region of the TCR but instead a constant region on the TCR or CD3 receptor.  
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Figure 6.10. Percentage of the T cells positive for internal TCR and CD3 after treatment 
with nanosilica for 30 min. Tabulated data represent the means ± standard deviation (* 
denotes significance compared to the control, paired T test, p < 0.05). Studies (experimental 
and analysis) conducted by C. Fairbairn.  
 
Figure 6.11. Percentage of the cells positive for TCRαβ, CD3ε, CD4 and CD8 in fixed cell 
cultures exposed to nanosilica (800 μM) for 10 min. The cells were incubated in 2% 
paraformaldehyde prior to treatment with nanosilica/staining. Tabulated data represent the 
means ± standard deviation for 4 donors (* denotes significance compared to the control, 
paired T test, p < 0.05). T cells were selected based on FSC versus SSC profiles through a T 
cell gate which also excluded debris 
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Next, the inhibition of TCR and CD3 antibody staining by nanosilica was investigated over time. 
Figure 6.12 shows the effect of nanosilica on TCRαβ and CD3ε staining over 4 h, representing 
the data as percent inhibition calculated using the following equation (using TCR as an 
example).  
  % inhibition of antibody staining = (%TCR(+)control - %TCR(+)nanosilica) x 100% 
                                              %TCR(+)control 
There was significant inhibition of antibody staining up to 2 h after nanosilica treatment. At 4 
h, nanosilica no longer had an effect on antibody staining, where the percentage of cells 
positive for TCRαβ and CD3ε was no different than that of the control. This trend is inversely 
proportional to the dissolution rate of nanosilica (shown in the red dashed line). Approximately 
75% of the nanosilica is considered soluble (i.e., < 3 kDa (1-2 nm) in size) after 4 h in cell 
culture media, as explained in Chapter 3. These results further confirm that nanosilica, not 
soluble silicon, interacts with the TCR/CD3 complex. Further investigations showed that 
orthosilicic acid did not affect TCR or CD3 antibody staining (data not shown). These results 
are also similar to those from the western blot analyses, which showed that TCR downstream 
signalling (i.e., phosphorylation of Zap70) was greatest from 0.2 to 2 h after nanosilica 
treatment, and it decreased thereafter. Both western blot analyses and antibody staining 
inhibition would indicate that either the interaction between nanosilica and the TCR complex is 
persistent (i.e., an irreversible interaction) or that this interaction is transient and nanosilica 
(which is in great excess) is in constant exchange with the receptor. Whichever the case, the 
interaction between nanosilica and the TCR complex not natural. The half-life between an 
MHC-foreign antigen complex and a TCR is typically 2-10 s and is even shorter when the MHC 
complex is presenting self-antigen (Acuto et al., 2008). If the nanosilica:TCR/CD3 interaction 
is persistent, it could last up to 2 h, which is approximately 3,000 times longer than a healthy 
interaction. Alternatively, if the nanosilica is in constant exchange with the TCR/CD3 complex, 
it would transiently mimic an environment of infection which contains high antigen 
concentrations. 
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Figure 6.12. (Left y-axis) Percentage of the cells positive for TCRαβ, CD3ε, CD4 and CD8 
in cultures exposed to nanosilica (800 μM) for 0.1-4 h. Tabulated data represent the means 
± standard deviation for 4 donors. T cells were selected based on FSC versus SSC profiles 
through a T cell gate which also excluded debris (Right y-axis) Dissolution of nanosilica in 
cell-free growth media. The percentage of dissolved silica as determined through 
ultrafiltration (see Chapter 3).  
 
In the Chapter 5, nanosilica was found to activate γδ T cells. The TCR of this less common T 
cell subset is comprised of γ and δ chains, rather than the more common α and β TCR chains. 
There are structural differences between the TCRs, as the angle between the constant and 
variable domain is smaller for the γδ TCR than it is for the αβ TCR (Allison et al., 2001). 
Whether nanosilica inhibits the staining of a γδ TCR antibody was investigated. Figure 6.13 
shows the effect of nanosilica pretreatment on γδ TCR positivity within a T cell selection gate 
based on FSC versus SSC profiles. As with the αβ TCR antibody, nanosilica inhibited staining 
of the γδ TCR antibody. The tabulated values show the inter-individual variance in γδ T cell 
population size, which is consistent with that of the literature (Girardi, 2006). Despite inter-
donor variance, the percentage of cells positive for γδ TCR decreased after nanosilica 
treatment. The location of the nanosilica-TCR interaction remains unknown, but it is clear that 
nanosilica inhibits constant domain staining of the TCR complex. Whether the variable region 
of the receptor is also blocked is not known. 
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Figure 6.13. Effect of nanosilica on γδTCR and CD8 antibody staining. A. Representative 
dot plots showing the expression of γδTCR and CD8 on cells exposed to nanosilica (800 μM) 
for 10 min. B. Percentage of the cells positive for γδTCR and CD8. No significance compared 
to the control (paired T test, p < 0.05), likely due to the inter-donor variance in γδ T cell 
numbers. T cells were selected based on FSC versus SSC profiles through a T cell gate which 
also excluded debris 
 
In the above sections, the mechanism of T cell activation induced by nanosilica was 
investigated. The activation of CD4 T cells by nanosilica was shown to be APC (MHC class II 
receptor) independent. Nanosilica did not induce activation of a T cell line lacking the TCR 
complex and was later found to inhibit TCRαβ, TCRγδ, and CD3ε antibody staining.  
Additionally, the nanoparticulate was found to induce signalling downstream of the TCR 
complex. These results would suggest that nanosilica interacts directly with the TCR/CD3 
complex. The data would also suggest that nanosilica is not interacting with the variable region 
of the TCR/CD3 complex but instead the constant domain or a conserved section of the 
variable region as 1) the variable region of TCRs vary significantly (Laydon et al., 2015; Warren 
et al., 2011), 2) nanosilica non-specifically activates >50% of T cells in PBMC culture, and 3) 
nanosilica non-specifically inhibits both TCR and CD3 antibody staining.  
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6.2.4.2 Particle specificity for inducing T cell activation 
In the previous investigations (including those in Chapter 5), a nanosilica dispersion with a 
median diameter of 3.4-3.8 nm and specific dissolution rate was employed. The effect of 
particle characteristics, i.e., size, condensation and composition, on T cell activation was 
investigated next as it may provide further insight towards nanoparticle-T cell interactions.  
First, the effect of particle size on the induction of CD25 and CD69 was investigated. Figure 
6.14A shows the particle size distribution of the nanosilica dispersions employed in the 
investigations. Although the median particle size differed between the dispersions, there was 
significant overlap in the size distribution of the materials. Many of the dispersions contained 
particles of the same diameter, though the proportion of these particles differed.  
Figure 6.14B shows the effect of nanosilica particle size on the expression of CD25 and CD69 
on CD4 and CD8 T cells after 24 h. There were significant differences in the induction of the 
activation markers between the materials tested, as shown in Table 6.01 for clarity. The 
greatest expression of CD25 and CD69 was induced by dispersions with median particle 
diameters of 3.6 ± 0.5 nm and 5.1 ± 0.6 nm (by volume, DV0.5). At a median particle size of 
7.8 ± 0.7 nm, there was a significant decrease in the percentage of T cells positive for the 
activation markers compared that induced by the 3.6 ± 0.5 nm and 5.1 ± 0.6 nm dispersions. 
There was no significant induction of CD25 or CD69 on CD4 and CD8 T cells in cultures treated 
with the particles 16 ± 1.3 nm in size. The induction of the activation markers by particles 1.8 
± 0.7 nm in size was also significantly lower than that induced by 3.6 ± 0.5 nm and 5.1 ± 0.6 
nm dispersions. However, this response cannot be solely assigned to particle size, as the 
dissolution profile between these dispersions differ greatly. Nanosilica dispersions > 3.6 nm in 
size have similar dissolution rates (Figure 3.01). The dispersions 1.8 ± 0.7 nm in size dissolve 
much more rapidly than the larger particles (Figure 3.05). Therefore, it is not possible to assign 
the decreased induction of CD25 and CD69 by the 1.8 ± 0.7 nm dispersion to size, as particle 
lifetime is also likely involved. Nonetheless, these results would suggest that the ability of 
nanosilica to induce T cell activation decreases as median particle size increases above 5 nm.  
There are a number of possibilities to explain this size dependency. It is possible that T cells 
only interact with particles of a specific size range (likely between 1-5 nm). The induction of T 
cell activation by larger (>5 nm) particles could therefore be due to their change in size after 
dilution and incubation in cell culture media. The change in size can be achieved through 
dissolution or the breaking of large particle agglomerates. Alternatively, the size dependant T 
cell response could be due to particle affinity for the receptor. It is possible that the large 
nanosilica particles have a lower affinity for the receptor and therefore have decreased 
efficacy. Additionally, the particle concentration for larger dispersions is significantly lower than 
the smaller dispersions, potentially shifting the equilibrium away from TCR:nanosilica complex.  
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Figure 6.14. Effect of nanosilica particle size on expression of CD25 and CD69 on CD4 
and CD8 T cells. A. The particle size distribution of the stock nanoparticle dispersions tested 
in cell assays. B. The effect of the dispersions (at 800 μM Si) on CD25 and CD69 expression 
on CD4 and CD8 T cells. Tabulated data represent the means ± standard deviation for a 
minimum of 8 donors. T cells were first selected based on FSC versus SSC profiles through a 
T cell gate which also excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and 
a CD4(+) or a CD8(+) gate. Statistical analyses of cellular data is shown on the next page. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
Table 6.01. Statistical analysis of the induction of CD25 and CD69 on CD4 and CD8 T 
cell between nanosilica dispersions of different sizes (shown in Figure 6.14). Green 
denotes significant, red denotes non-significant Two-way Anova, p <0.05, n = 8-12 
  median particle diameter 
  1.8 ± 0.7 nm 3.6 ± 0.5 nm 5.1 ± 0.6 nm 7.8 ± 0.7 nm 16 ± 1.3 nm 
c
o
n
tr
o
l 
CD4-CD25      
CD4-CD69      
CD8-CD25      
CD8-CD69      
1
.8
 ±
 0
.7
 n
m
 CD4-CD25      
CD4-CD69      
CD8-CD25      
CD8-CD69      
3
.6
 ±
 0
.5
 n
m
 CD4-CD25      
CD4-CD69      
CD8-CD25      
CD8-CD69      
5
.1
 ±
 0
.6
 n
m
 CD4-CD25      
CD4-CD69      
CD8-CD25      
CD8-CD69      
7
.8
 ±
 0
.7
 n
m
 CD4-CD25      
CD4-CD69      
CD8-CD25      
CD8-CD69      
 
 
Condensation is another important property of amorphous nanosilica particles. Condensation 
refers to the connectivity within the particles and it correlates with dissolution rate in dilute 
conditions (see Chapter 3). Particles with a slower dissolution rate were shown to have a 
greater percentage of fully condensed (Q4) silicate centres and fewer partially condensed (Q2 
and Q3) silicate centres. Whether particle dissolution rate affects nanosilica induced T cell 
activation was investigated.  
Figures 6.15A and B show the size of the nanosilica dispersions and their dissolution rate in 
simple media at room temperature. For simplicity, the nanosilica dispersions were denoted as 
materials A and B. The particle size distribution of the materials was identical but their 
dissolution rates in dilute conditions differed, where material A dissolved more rapidly than 
127 
 
material B. All attempts made to prepare a more condensed particle resulted in increased 
particle sizes. This study was therefore limited to 2 materials.  
Figure 6.15C shows the effect of the materials on CD25 and CD69 expression on CD4 and 
CD8 T cells. Both materials induced significant expression of the activation markers on both T 
cell subsets. The percentage of cells positive for the activation markers on CD4 T cells was 
significantly lower in cultures treated with material A compared to those treated with material 
B (shown in Figure 6.15D for clarity). A similar response was evident with CD25, not CD69, on 
CD8 T cells. The decreased response of T cells towards material A could potentially be 
explained by the increased dissolution rate. Alternatively, the particles could have varying 
affinities for the TCR/CD3 complex. To determine which is more plausible, the effect of 
nanosilica dissolution rate on the inhibition of fluorescent antibody staining was investigated.  
Figure 6.16 shows the effect of material A and B on fluorescently conjugated antibody staining. 
Materials A and B both inhibited TCR and CD3 antibody staining to a similar extent. These 
results would suggest that both materials are rapidly engaging the TCR/CD3 receptor and have 
approximately the same affinity. Therefore, it is plausible that the decreased activation shown 
in Figure 6.15 is due to dissolution rate not affinity for the receptor. The increased dissolution 
rate would decrease the contact time with the receptor complex, thus decreasing induced 
activation.  
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Figure 6.15. Effect of nanosilica particle lifetime in dilute conditions on expression of 
CD25 and CD69 on CD4 and CD8 T cells. A. The particle size distribution of the stock 
nanoparticle dispersions tested in cell assays. B. The dissolution rate of the nanosilica particles 
after dilution to 1 mM Si in HEPES (pH 7.4) at room temperature. C. The effect of the 
dispersions (at 800 μM Si) on CD25 and CD69 expression on CD4 and CD8 T cells. Tabulated 
data represent the means ± standard deviation for 4 donors (* denotes significance compared 
to the control, paired T test, p < 0.05). D. Comparison of the induction of activation markers by 
materials A and B on CD4 and CD8 T cells.  (* denotes significance, paired T test, p < 0.05). 
T cells were first selected based on FSC versus SSC profiles through a T cell gate which also 
excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a CD4(+) or a CD8(+) 
gate 
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Figure 6.16. Percentage of the cells positive for TCRαβ, CD3ε, CD4 and CD8 within a T 
cell selection gate (based on FSC versus SSC profiles) after treatment with 400 μM 
nanosilica (materials A and B, as defined in Figure 6.20) for 10 min. Tabulated data 
represent the means ± standard deviation for 4 donors (* denotes significance compared to 
the control, paired T test, p < 0.05) 
 
The effect of iron nanoparticles on T cell activation was investigated to determine whether the 
response is limited to silica. Figure 6.17 shows the effect of nanoiron and nanosilica (sizes 
shown in A) on T cell activation. In addition to treatment in complete growth media, cells were 
also exposed to the nanoparticles in a basic salt solution (BSS) which was designed 
specifically to prevent nanoiron agglomeration (Pereira et al., 2015). Nanosilica induced 
significant CD25 and CD69 expression on CD4 and CD8 T cells in full growth media and BSS 
media. Interestingly, nanosilica induced greater expression of the activation markers in BSS 
media than in full growth media. This may suggest that protein may interact with nanosilica, 
thus preventing it from interacting with the T cell. Protein has been shown to interact and form 
a corona with nanosilica, even at the low protein concentrations used in complete growth media 
(Clemments et al., 2015; Lehman et al., 2016). In BSS, the iron nanoparticles induced 
significant CD69 expression on CD4 T cells, but had no effect on CD25 expression. It also did 
not affect CD25 and CD69 expression on CD8 T cells in BSS media or either T cell subset in 
full growth media. Similar to nanosilica, iron nanoparticles are known to interact with protein in 
sera (Safi et al., 2011), thus explaining the decreased response in the complete growth media. 
These results would suggest that the activation of T cells by nanoparticles is not completely 
restricted to silica, though the magnitude of the response to each material can vary 
significantly. In the literature there are studies that might suggest that other nanoparticles alter 
T cell function, as cobalt nanoparticles, ZnO nanoparticles and fullerenes have been shown to 
induce IFN-γ production in T cell containing cultures (Hanley et al., 2009; Liu et al., 2009; 
Petrarca et al., 2005). Further investigations are required to investigate the effect of 
nanoparticle composition on T cell activation.  
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Figure 6.17. The effect of nanosilica and iron nanoparticles on expression of CD25 and 
CD69 on CD4 and CD8 T cells after 24 h. A. The particle size distribution of the stock 
nanoparticle dispersions tested in cell assays. B. The effect of the dispersions (800 uM Si or 
Fe) on CD25 and CD69 expression on CD4 and CD8 T cells. In CGM, the particles were added 
to culture followed by incubation for 24 h. In BSS media, the particles were added to culture, 
incubated for 3 h, resuspended in CGM, and incubated for 21 h. Tabulated data represent the 
means ± standard deviation for 8 donors (* denotes significance compared to the control, 
paired T test, p < 0.05). T cells were first selected based on FSC versus SSC profiles through 
a T cell gate which also excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) 
and a CD4(+) or a CD8(+) gate 
 
In this section, it was shown that nanosilica size has a large effect on the induction of T cell 
activation. Further analyses, e.g., theoretical modelling, high resolution imaging (SuperSTEM, 
neutron scatter) or plasma resonance analyses, are required to better understand the 
nanosilica-TCR/CD3 interaction. Iron nanoparticles were shown to induce CD4 T cell 
activation, though the response was much less significant than that induced by nanosilica.  
 
6.3 Conclusions 
In this chapter, the mechanism of nanosilica induced T cell activation was investigated. 
Previously, it was shown that nanosilica induces T cell activation, inducing expression of 
surface activation markers and cytokine production. Nanosilica did not induce complete T cell 
activation, as most T cells had not divided in cultures treated with the nanoparticulate. 
Investigations into the mechanism of activation were warranted, as activation of T cells by 
uncoated nanoparticles has never been documented.     
First, it was determined that nanosilica does not require APCs for induction of CD4 T cell 
activation, suggesting that the effect is MHC class II independent. Next, it was shown that 
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nanosilica induces signalling downstream of the TCR/CD3 complex. In the previous chapter, 
it was shown that silica nanoparticles did not induce high levels of T cell proliferation, 
suggesting that it does not induce complete activation. Here, it was shown that full activation, 
i.e., production of IL-2 and proliferation, can be induced by nanosilica in the presence 
secondary signals, i.e., phobate esters or anti-CD28.  
Nanosilica was found to inhibit both TCR and CD3 antibody staining, which would suggest that 
nanosilica induces T cell activation by directly engaging the TCR/CD3 complex. A particle size 
range for maximum T cell response to nanosilica was determined, where particles 3.6-5.1 nm 
in size induced greatest expression of CD25 and CD69. T cell activation decreased 
significantly as size increased above 7 nm. Lastly, it was found that the induction of T cell 
activation was not specific to nanosilica, as low levels of CD69 were induced on CD4 T cells 
after nanoiron treatment.  
In the next chapter, the ability of nanosilica to induce activation in whole blood was 
investigated. These studies may infer to the safety of the amorphous silica used in biomedical 
applications (Bitar et al., 2012). 
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Chapter 7 – Effect of nanosilica on peripheral cells in whole blood and in vivo 
7.1 Introduction 
In Chapters 5 and 6, it was shown that amorphous silica nanoparticles induced T cell activation 
in isolated PBMC cultures. Nanosilica engaged the T cell receptor (TCR) complex, regardless 
of its antigenic peptide specificity, and induced downstream signalling leading to induction of 
activation markers (e.g., CD25, CD69 and, to a lesser extent, CD95) and cytokine production 
(i.e., IFN-γ and, to a lesser extent, IL-2). Nanosilica did not induce high levels of T cell 
proliferation and was later found not to induce signalling through MAPK, which can be induced 
through sufficient TCR signalling or engagement of the costimulatory receptor CD28 (Chen 
and Flies, 2013; Csencsits and Bishop, 2003).  
Previous investigations of T cell activation and cell viability were conducted isolated peripheral 
blood mononuclear cell (PBMC) and cell line cultures, suspended in complete growth media 
(CGM). Whole blood is a more complex matrix than CGM as it contains plasma, platelets, 
higher protein concentrations, red blood cells and polymorphonuclear cells, including 
neutrophils. Amorphous silica has been shown to interact with each of these components 
(Clemments et al., 2015; Gryshchuk and Galagan, 2016; Lehman et al., 2016; Zhang et al., 
2012; Zimmerman et al., 1986). These interactions could potentially alter the dynamic of 
nanosilica in culture. In this chapter, the effect of nanosilica on T cell activation and cell viability 
was assessed in whole blood, as it may infer towards the safety of these particles in vivo after, 
for example injection for used in biomedical applications (Bitar et al., 2012; Meddahi‐Pellé et 
al., 2014; Scaramuzzi et al., 2016; Skrastina et al., 2014). Additionally, whether these particles 
have therapeutic effects in vivo was investigated.  
 
7.2 Results and discussion 
7.2.1 Activation and toxicity in whole blood – preliminary investigations 
First, the ability of nanosilica to induce T cell activation in whole human blood was investigated. 
As with the previous chapters, T cell activation was assessed using the CD25 and CD69 
activation markers. These activation markers are expressed on T cells after recognition of 
cognate antigenic peptide (presented in a MHC receptor) (D’Souza and Lefrançois, 2003; 
Malek and Castro, 2010; Radulovic et al., 2013) and have been shown to be induced by 
nanosilica (Chapters 5 and 6). Here, T cells were identified by the CD3 receptor, which is a 
part of the T cell receptor complex and is involved in T cell activation and signalling (Wang et 
al., 2009b).  
Figure 7.01 shows the effect of nanosilica on CD3 T cell activation in whole blood after 24 h. 
In the untreated control, the expression of CD25 and CD69 was low, in both the intensity of its 
expression (fluorescence, Figure 7.01A) and in the percentage of cells positive for the 
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receptors (Figure 7.01B). The percentage of T cells positive for the activation markers were 
similar to those reported in the literature for peripheral T cells (Reddy et al., 2004; Sancho et 
al., 1999). The Staphylococcal enterotoxin B (SEB) positive control significantly increased the 
expression CD25 and CD69 on CD3 T cells. These results would indicate that T cells in whole 
blood culture respond appropriately to stimulation. SAgs are known to induce chronic T cell 
activation in the periphery, which can lead to a number of symptoms (vomiting, fever, rash) 
and even lethal shock (Fraser, 2011). A soluble silica (silicic acid) control was not used in these 
investigations due to the low solubility of Si at physiological pH. The addition of a neutral silicic 
acid stock would result in significant dilution of the blood and therefore would alter the whole 
blood environment. Nanosilica, at a concentration of 400 μM Si, did not significantly affect the 
expression of CD25 or CD69 on CD3 T cells. At the same concentrations in PBMC culture, 
there was significant induction of these activation markers (Chapter 5). These results would 
suggest that the effects of nanosilica are significantly attenuated in whole blood. At a 
concentration of 800 μM Si, nanosilica significantly induced the expression of CD69 on CD3 T 
cells in whole blood, though only ca. 2% of the T cells were positive for this marker. At 2 mM 
Si, a concentration which surpasses the solubility limit of amorphous silica at blood pH (ca. 1.7 
mM Si at pH 7.4 (Jugdaohsingh et al., 2008; Mosby, 2016)), the effect of nanosilica on T cell 
activation was still low. In these conditions, the particles would not be able to dissolve 
completely, meaning a fraction of the particles would be persistent throughout the incubation 
period. The phase of these particles is unknown, though in a complex matrix such as whole 
blood it is very likely that, for the particles not phagocytosed by monocytes and neutrophils, 
agglomerates would form with itself or with other components contained in blood. The 
response of nanosilica is significantly attenuated in whole blood. Whole blood is a much more 
complex matrix then cell culture media, with higher protein content (upwards of 4 g/L albumin 
(Don and Kaysen, 2004)) and other factors such as platelets and red blood cells that can and 
have been shown to interact with silica (Clemments et al., 2015; Gryshchuk and Galagan, 
2016; Lehman et al., 2016; Zhang et al., 2012; Zimmerman et al., 1986). Additionally, whole 
blood contains polymorphonuclear cells, such as neutrophils (commonly 40-80% of peripheral 
cells, cell counts shown in Figure 7.05), which are not present in isolated peripheral blood 
mononuclear cell (PBMC) cultures. The interaction of nanosilica with these components would 
limit its exposure to T cells and thereby decrease the cellular response. 
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Figure 7.01. The effect of nanosilica on the percentage of CD3 T cells positive for CD25 
and CD69 in whole blood culture after 24 h. A. Representative dot plots showing the 
expression of CD25 and CD69 on CD3 T cells. B. Tabulated data represent the averages for 
5 donors (* denotes a significance compared to the control, two-tailed paired T test, p < 0.05). 
T cells were first selected based on FSC versus SSClog profiles through a T cell gate which 
also excluded debris, followed by a singlets gate (FSClin vs FSCarea), a T cell gate (CD3(+)) 
and a viability gate (Invitrogen LIVE/DEAD, VioletLOW). 
 
Next, investigations were conducted using nanosilica dispersions with varying properties. In 
Chapter 6, the effect of nanosilica size on the induction of T cell activation was conducted in 
PBMC culture. In this simple matrix, it was found that the particles with a median diameter of 
3.6-5.1 nm induced greatest expression of CD25 and CD69 on CD4 and CD8 T cells, while 
particles both larger and smaller had decreased efficacy. However, it was not wholly 
established whether the decreased efficacy of the smaller particles was due to size or particle 
dissolution rate. In whole blood, the dispersion which induces greatest T cell activation could 
differ from that in PBMC cultures, as there are a greater number of components with which 
nanosilica can interact and higher concentrations of nanosilica are required to induce activation 
(thus normalizing for particle dissolution rate). Therefore, investigations were conducted to 
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assess the effect of 1-2 nm and 3.6 nm nanosilica dispersions on T cell activation in whole 
blood. In these investigations, additional markers were used to identify helper and cytotoxic T 
cells. Helper T cells, which can be identified by their CD4 co-receptor, mediate immune 
responses by releasing cytokines and expressing various surface receptors after recognition 
of cognate antigen (DuPage and Bluestone, 2016; Geginat et al., 2015; Meddahi‐Pellé et al., 
2014). Cytotoxic T cells (CTLs), which can be identified by the CD8 co-receptor, execute an 
immune response by directly engaging a target cell and releasing factors to induce its death 
(Aktas et al., 2009; Alter et al., 2004; Chakraborty and Weiss, 2014). Upon activation, both 
helper and cytotoxic T cells are known to express the CD25 and CD69 activation markers 
(Broere et al., 2011; Létourneau et al., 2009; Malek and Castro, 2010; Radulovic et al., 2013).  
Figures 7.02A and B show the representative sizes and dissolution rates of the materials 
employed in the whole blood investigations. Material A, which has a median diameter of 3.5 
nm, is a concentrated mimic of the dispersion tested in Figure 7.01. This material was originally 
developed for translation into in vivo studies, as more concentrated dispersions were required 
due to limited dose volumes. Material B is a nanosilica dispersion 1-2 nm in diameter. It is 
prepared at low pH and it dissolves rapidly when diluted below the solubility limit of amorphous 
silica. Figure 7.03 shows the effect of the materials, at a concentration of 4 mM Si, on the 
expression of CD25 and CD69 on CD4 and CD8 T cells in whole blood. The baseline 
expression levels were low in the control, indicating a contamination free environment, and 
exposure to SEB lead to the induction of the activation markers. The effect of the nanosilica 
particles on T cell activation was low, even at a concentration of 4 mM Si. These results further 
emphasize the attenuated responses present in whole blood cultures. At these concentrations 
more than half of the Si would remain insoluble for the entire incubation period (Jugdaohsingh 
et al., 2008; Mosby, 2016). However, it is likely that a large portion of the nanosilica would be 
phagocytosed and, the particles that were not, would likely agglomerate with itself and other 
components of blood. Given the low activation levels at 24 h, it is highly plausible that 
nanosilica does not stay in a form capable of inducing T cell activation. The nanosilica particles 
induced similar levels of CD25 and CD69 expression on both CD4 and CD8 T cells, regardless 
of particle properties. Given the complex matrix and the unknown form of nanosilica after its 
addition, it is difficult to interpret these results. For example, the exact form of the particle 
inducing activation is unknown, as it could be induced by the specific particle added into the 
blood or an agglomerate that is formed in blood. Nonetheless, these results would suggest that 
it is possible for nanosilica to induce T cell activation in whole blood.  
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Figure 7.02. Representative size (A.) and dissolution rate (B.) of nanosilica dispersions (40 
mM Si, various formulations denoted as materials A and B) employed in the whole blood 
assays (Figure 7.03) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.03 The effect of nanosilica on the percentage of CD4 and CD8 T cells positive 
for CD25 and CD69 in whole blood culture after 24 h (overleaf). A. Representative dot 
plots showing the expression of CD25 and CD69 on CD4 and CD8 T cells. B. Tabulated 
data represent the means ± standard deviation for 11 donors (* denotes a significance 
compared to the control, two-tailed paired T test, p < 0.05). T cells were first selected based 
on FSC versus SSClog profiles through a T cell gate which also excluded debris, followed 
by a singlets gate (FSClin vs FSCarea), a T cell gate (CD3(+)), and a CD4(+) or CD8(+) 
gate. 
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Next, the effect of nanosilica on γδ T cells and NK/NKT cells in whole blood was investigated. 
These lymphocyte subsets are activated differently than αβ T cell subsets. Instead of 
recognising antigenic peptide presented on an MHC receptor via a TCR, these cells are 
activated by the recognition of antigens on MHC-like CD1 receptors (γδ T cells and NKT cells), 
soluble antigens (γδ T cells) or stress receptors on expressed on the surface of cells (NK/NKT 
cells) (Dar et al., 2015; Long et al., 2013; Vantourout and Hayday, 2013; Vivier et al., 2008; 
Vivier et al., 2012; Wiest, 2016; Wu et al., 2014) . Nanosilica was previously shown to induce 
activation of these lymphocyte subsets in PBMC cultures (Chapter 5). Whether activation is 
also induced in whole blood was investigated here. γδ T cells were identified by its γδ TCR 
and NK/NKT cells were identified by the CD57 receptor (Leong et al., 2003).  
Figure 7.04 shows the effect of nanosilica (as characterized in Figure 7.02) on CD25 and CD69 
expression on γδ T cells and NK/NKT cells. The baseline activation levels of the lymphocyte 
subsets was low and the superantigen induced significant expression of CD69 on γδ T cells 
and both CD25 and CD69 on NK/NKT cells. After SEB treatment, upwards of 50% of these 
cytotoxic lymphocytes were positive for CD69, corroborating studies which show 
superantigens induce chronic activation of these cell subsets (Chen et al., 2009b; D'Orazio et 
al., 1995; Ramesh et al., 1995; Rust and Koning, 1993). The nanosilica dispersions did not 
induce significant expression of CD25 or CD69 on γδ T cells, though low levels of CD69 were 
induced by material B. As with the decreased responses of αβ T cells to nanosilica, the 
complex matrix of whole blood is likely responsible for the attenuated responses present here. 
CD69 was significantly induced on NK/NKT cells after treating with nanosilica (both materials). 
As discussed in Chapter 5, the mechanism of induced NK/NKT cell activation by nanosilica is 
unknown. It is possible that nanosilica induces the expression of stress markers on other cells 
in whole blood, thus leading to NK/NKT cell activation upon their recognition.  
Overall, these results would suggest that nanosilica is capable of inducing activation of 
lymphocytes in whole blood.  
 
 
Figure 7.04. The effect of nanosilica on the percentage of γδ T cells and NK/NKT cells 
(CD57(+)) positive for CD25 and CD69 in whole blood culture after 24 h (overleaf). 
Representative dot plots showing the expression of CD25 and CD69 on γδ TCR(+) (A.) and 
CD57(+) (B.). Tabulated data for γδ TCR(+) cells (C.) and CD57(+) cells (D.) represent the 
means ± standard deviations for 5 donors (* denotes a significance compared to the control, 
two-tailed paired T test, p < 0.05). γδ T cells and NK/NKT cells first selected based on FSC 
versus SSClog profiles through a lymphocyte cell gate which also excluded debris, followed 
by a singlets gate (FSClin vs FSCarea), and a γδ TCR(+) or CD57(+) gate 
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Next, the cytotoxicity of nanosilica towards cells in whole blood was investigated. In PBMC 
cultures, nanosilica was found to be toxic to monocytes, B cells and T cells at concentrations 
above 300 μM Si (Chapter 4). Whether whole blood also attenuates nanosilica toxicity was 
assessed. The viability was represented as viable cell counts. The flow cytometric analyses of 
the whole blood samples conducted in this chapter employed a high FSC threshold, as to 
eliminate the residual RBC remaining after the RBC lysis step and the increased amount of 
debris. Dead cells shift below this high threshold and skew the total percentage of viable cells, 
thereby making viable cell counts a more accurate way of representing cytotoxicity.  
Figure 7.05 shows the effect of nanosilica (as defined in Figure 7.02) on neutrophil, monocyte, 
B cell and T cell counts. The representative dot plots show two populations for each cell type 
corresponding to viable cells, i.e., those of low fluorescent intensity (intact membrane), and 
non-viable cells, i.e., those of high fluorescent intensity (compromised cell membrane). 
Decreased event numbers in the dot plots and an increased percentage of non-viable cells 
were evident after treatment with both nanosilica materials. Material B was found to be more 
toxic than material A, as it significantly reduced counts for all cell types tested. Material A 
significantly decreased B cell and monocyte counts but had no significant effect on neutrophil 
or T cell counts. On a percentage basis, monocytes were most susceptible to nanosilica 
induced cell death. However, on a per number basis, neutrophils showed the largest loss in 
cell numbers after nanosilica treatment, where ca. 105 neutrophils, which was greater than the 
whole monocyte population, were lost after treatment. The lymphocytes were most resistant 
to the nanosilica particles, corroborating reports that show phagocytes are the more 
susceptible to the cytotoxicity of nanosilica than cells with lesser phagocytic capabilities (Fedeli 
et al., 2013)  
 
 
 
Figure 7.05. The effect of 4 mM nanosilica on neutrophil, monocyte (CD14), T cell 
(CD3) and B cell (CD19) in whole blood culture after 24 h (overleaf). A. Representative 
dot plots showing viability on neutrophils, monocytes, T cells and B cells. B. Tabulated data 
show the counts for 3 donors (* denotes a significance compared to the control, two-tailed 
paired T test, p < 0.05). Neutrophils were first selected based on FSC versus SSClog 
profiles followed by a CD14(-)/CD14low gate. Monocytes were first selected based on FSC 
versus SSClog profiles followed by a CD14high gate. T cells and B cells were first selected 
based on FSC versus SSClog profiles followed by a CD3(+) or a CD19(+) gate.  
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In this section, it was shown that nanosilica is capable of activating helper T cells, cytotoxic T 
cells and NK/NKT cells in whole blood. In order to demonstrate this, the concentration of 
nanosilica had to be increased above the solubility limit of silicic acid. At these concentrations, 
nanosilica was significantly toxic towards all cell types, especially the phagocytes, 
corroborating studies in literature (Fedeli et al., 2013). In vivo, it is unlikely that these 
concentrations would be maintained as investigations have shown that nanosilica is rapidly 
cleared from the periphery and excreted (Jugdaohsingh, Appendix 2).  To determine whether 
nanosilica induced T cell activation in vivo is actually plausible, the effect of nanosilica in more 
applicable conditions was assessed. 
7.2.2 Activation and toxicity in whole blood – dynamic whole blood environment 
It was previously established that nanosilica particles can induce T cell activation in whole 
blood, though the conditions used were distant from an in vivo situation. After intravenous 
injection of a nanosilica dispersion, the particles would be continuously diluted and cleared 
from circulation quite rapidly. Indeed, it has been shown that most Si is removed from 
circulation hours after injection (Jugdaohsingh, Appendix 2). In vitro, it is not possible to mimic 
nanosilica clearance but continuous dilution is possible. By continuously diluting with untreated 
whole blood, information regarding the dynamics of nanosilica in blood after intravenous 
administration may be learned and may help narrow the materials to be used in future 
translational in vivo investigations (See Section 7.2.4).  
In these investigations, the effect of high nanosilica doses followed by continuous dilution on 
T cell activation and monocyte cell death in whole blood was investigated. Initial investigations 
employed a simplified dilution schedule, specifically a 4 mM Si incubation step for 1 h followed 
by 2 mM Si for 3 h and finally 1 mM Si for 20 h. As little is known of the dynamics of dilution 
immediately after intravenous administration, the effect of a concentrated pulse was also 
investigated. It can be speculated that at the site of injection of the in vivo studies conducted 
below (Section 7.2.4), nanosilica could reach a concentration upwards of 16 mM Si before it is 
evenly diluted throughout the periphery. Therefore, the effect of a 16 mM nanosilica pulse (for 
25 s) followed by the dilution schedule outlined above on T cell activation and leukocyte viability 
was assessed. Figure 7.06 shows the effect of a high nanosilica pulse on the expression of 
CD25 and CD69 on CD4 and CD8 T cells. In these investigations, a nanosilica dispersion of 
1-2 nm in size, with a rapid dissolution rate (when below Si solubility limit, rate exceeding that 
of material B in Figure 7.02)) was employed and is referred to as material C. In the cultures 
not treated with a 16 mM Si pulse, there was only significant induction of CD69 on CD4 T cells. 
The expression of CD25 on CD4 T cells did not significantly increase, neither did the activation 
markers on CD8 T cells. In the cultures pulsed with 16 mM nanosilica, CD69 was significantly 
induced on CD4 and CD8 T cells and CD25 was induced on CD4 T cells. These results would 
suggest that a highly concentrated pulse has a large effect on T cell activation. As the only 
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difference between the 2 treatment schedules was the 16 mM Si pulse, it is possible that the 
T cells present in the pulse are those that are expressing the activation markers. To determine 
the approximate percentage of cells activated during the pulse, the following equation was 
used (using CD69 as an example): 
% activated in pulse = ((%CD69(+)nanosilica  ─ %CD69(+)control)+pulse  ─ (%CD69(+)nanosilica ─ %CD69(+)control) -pulse)) x 27.3 
                                                                                                             
 
where 27.3 is the ratio final blood volume (390 μL) over pulse blood volume (14.3 μL). Table 
7.01 shows the percentage of the T cells activated (with respect to the various activation 
markers) in the 16 mM Si, 25 s pulse. The majority of the CD4 T cells were activated, 
approximately 50% being positive for CD25 and CD69. Upwards of 20% of the CD8 T cells 
present in the concentrated pulse became positive for CD69. These results would suggest that 
the intravenous injection rate would dictate the amount of T cell activation induced by 
nanosilica in vivo. For example, a rapid intravenous injection rate could create a high transient, 
localized concentration. The data shown here would suggest that the T cells present in this 
localized, concentrated environment would likely become activated. A highly concentrated 
localized environment would not be present if a slow injection rate was used, likely resulting in 
a lack of significant T cell activation. 
The effect of a 16 mM Si, 25 s pulse on monocyte counts was also assessed. For simplicity, 
the only monocyte counts were shown as they were previously demonstrated to be the most 
susceptible to nanosilica induced cell death. Here, the monocyte counts were represented as 
a percentage of the total cell distribution (neutrophils, monocytes, B cells, T cells), which better 
normalizes the cell numbers to account for varying cell losses during the staining protocol and 
sample transfers. Figure 7.07 shows the percentage of the monocytes within the cell 
distribution after nanosilica treatment. There was a decrease in monocyte cell counts after 
nanosilica treatment according to both dosing schedules. The concentrated pulse (16 mM Si, 
25 s pulse) did not seem to enhance the toxicity of nanosilica. These results might suggest 
that a rapid intravenous injection rate (i.e., the formation of a highly concentrated localized 
environment intravenously) does not enhance the toxicity of nanosilica to monocytes. Diluting 
the nanoparticulate to levels below its solubility (ca. 1.7 mM Si at pH 7.4 (Jugdaohsingh et al., 
2008; Mosby, 2016)) after 4 h did not attenuate all of its cytotoxicity towards monocytes. These 
results would indicate that even short term exposure (up to 4 h) to nanosilica above its solubility 
can result in monocyte death.  
145 
 
Figure 7.06. The effect of nanosilica on the percentage of CD4 and CD8 T cells positive 
for CD25 and CD69 in whole blood culture. Whole blood was treated with (+) or without (-) 
16 mM Si 25 s pulse, followed by a 4 mM Si incubation step for 1 h, 2 mM Si incubation for 3 
h and finally a 1 mM Si incubation for 20 h. Tabulated data represent the averages for 6 donors 
(* denotes a significance compared to their respective control, two-tailed paired T test, p < 
0.05). T cells were first selected based on FSC versus SSClog profiles through a T cell gate 
which also excluded debris, followed by a singlets gate (FSClin vs FSCarea), a T cell gate 
(CD3(+)), and a CD4(+) or CD8(+) gate. 
 
Table 7.01. The percentage of T cells activated (expressing CD25 and CD69) in the 16 
mM Si, 25 s nanosilica pulse.  
 CD4(+) T cells CD8(+) T cells 
 CD25 CD69 CD25 CD69 
Average +/- SEM 60.5 ± 20.1 45.4 ± 11.8 0.6 ± 5.5 21.4 ± 23.4 
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Figure 7.07. The effect of nanosilica on the percentage of monocytes within the cell 
distribution in whole blood culture. Whole blood was treated with (+) or without (-) 16 mM 
Si 25 s pulse, followed by a 4 mM Si incubation step for 1 h, 2 mM Si incubation for 3 h and 
finally a 1 mM Si incubation for 20 h. Tabulated data represent the averages for 3 donors (* 
denotes a significance compared to the control, two-tailed paired T test, p < 0.05)  
 
After intravenous injection, the dilution of the nanosilica likely occurs faster than the dilution 
schedule used above. For example, blood flow rate is approximately 2 mL/s on the right upper 
limb (Zhang et al., 2014) and, at the heart, blood is pumped at a rate of 4.7-6.6 L/min (Clayman, 
1995). Assuming that there would be sufficient mixing (e.g., at the heart or at vein/arterial 
intersections), the nanosilica dispersion would likely be diluted below its solubility quite rapidly. 
To better simulate this, the effect of a high nanosilica pulse (16 mM Si, 25 s) followed by 
immediate dilution to 1 mM Si (referred to a treatment schedule A) on T cell activation at 24 h 
was tested and is shown in Figure 7.08. As a point of comparison, the previous dilution 
schedule was tested in parallel (referred to as treatment schedule B (i.e., 16 mM Si for 25s, 4 
mM Si for 1 h, 2 mM Si for 3 h, 1 mM Si, for 20 h)). In cultures treated according to schedule 
A, there was significant induction of CD69 on CD4 and CD8 T cells, but CD25 was not 
significantly induced. In cultures treated according to schedule B, CD25 was also significantly 
increased on CD4 T cells. This would suggest that the dilution rate effects the ability of 
nanosilica to induce T cell activation. Indeed, the percentage of CD4 T cells positive for CD25 
and CD69 was significantly higher in cultures treated according to schedule B compared to 
those treated according to schedule A. The increased dilution rate would likely result in a 
shorter nanosilica:TCR complex occupancy time (as explained in Chapter 6), either by 
increasing the rate in which nanosilica is dissolving or, if the nanosilica-TCR/CD3 interaction 
is in equilibrium with free nanosilica and TCR/CD3 (i.e., it is a reversible reaction), shifting the 
equilibrium to the free species at a more rapid rate.  
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Figure 7.08. The effect of nanosilica and dilution schedule on the percentage of CD4 and 
CD8 T cells positive for CD25 and CD69 in whole blood culture. Whole blood was treated 
with material C at 16 mM Si for 25 s, followed either by a 1 mM Si incubation for 24 h (“treatment 
schedule A”) or a 4 mM Si incubation step for 1 h, 2 mM Si incubation for 3 h and a 1 mM Si 
incubation for 20 h (“treatment schedule B”). Tabulated data represent the averages for 6 
donors (α denotes a significance compared to the control, β denotes a significance compared 
other treatment schedule, two-tailed paired T test, p < 0.05). The percentage of CD4 and CD8 
T cells positive for CD69 after treatment with SEB exceeded 10%, but was left off scale to 
more clearly show activation induced by nanosilica. T cells were first selected based on FSC 
versus SSClog profiles through a T cell gate which also excluded debris, followed by a singlets 
gate (FSClin vs FSCarea), a T cell gate (CD3(+)), and a CD4(+) or CD8(+) gate.  
 
Figure 7.09 shows the effect of the dilution schedule on the monocyte cell counts, once again 
shown as the percentage of monocytes in the cell distribution (B cells, T cells, monocytes and 
neutrophils). There was a greater reduction in monocyte counts when cultures were treated 
according to schedule B compared to those treated according to schedule A. There was no 
significant difference in monocyte counts between the control and the cultures treated with 
nanosilica according to schedule A. These results would suggest that if nanosilica dispersions 
are rapidly diluted below their solubility limit, most of their cytotoxicity is attenuated. However, 
the response of T cells is also greatly attenuated after rapid dilution, which might indicate that 
there is a proportional relationship between T cell activation and monocyte cell death.   
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Figure 7.09. The effect of the nanosilica dilution schedule on the percentage of 
monocytes within the cell distribution in whole blood culture.  Whole blood was treated 
with material C at 16 mM Si for 25 s, followed either by a 1 mM Si incubation for 24 h (“treatment 
schedule A”) or a 4 mM Si incubation step for 1 h, 2 mM Si incubation for 3 h and a 1 mM Si 
incubation for 20 h (“treatment schedule B”). Tabulated data represent the averages for 6 
donors (* denotes a significance compared to the control, two-tailed paired T test, p < 0.05).  
 
7.2.3 Assessing dispersions for use in future in vivo trials 
The assays employed in Section 7.2.2 provide a closer mimic of the conditions after 
intravenous injection of nanosilicate and could provide information on which dispersions would 
be most efficacious in vivo (greatest T cell activation, minimal cell death). To identify possible 
candidates for in vivo trials, treatment schedule B (i.e., 16 mM Si for 25s, 4 mM Si for 1 h, 2 
mM Si for 3 h, 1 mM Si, for 20 h) was employed to test the effect of nanosilica formulation on 
T cell activation and monocyte cell death.  
It was shown previously that 1-2 nm nanosilica particles activate T cells and induce significant 
monocyte cell death in whole blood. Whether there is a particle that induces significant 
activation in the absence of monocyte death was investigated here. In these studies, nanosilica 
dispersions prepared at low pH were employed as they are labile (i.e., will dissolve into inert 
silicic acid rapidly after dilution) and would therefore be less likely to induce cell death.  
Figure 7.10A shows the relative condensation of the materials used in these investigations, 
represented as area under the absorbance curves (Chapter 3). The area under the absorbance 
curve is proportional to the release of silicic acid from the nanoparticles at low pH. Upon 
Si(OH)4 release, it is complexed by molybdic acid and it forms a complex that is absorbant at 
400 nm. The rate of Si(OH)4 release corresponds to the relative dissolution rate of the particles. 
For example, a distribution that has a large area under the curve would dissolve relatively 
faster than a dispersion that has a smaller area under the curve. There was a decrease in the 
area under the curve with an increase in particle age. This would suggest that the older 
dispersions would dissolve at a relatively slower rate than the fresher dispersions. Importantly, 
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the size of dispersions were all below 2 nm in median diameter (which is pushing the detection 
limits of the DLS device).  
Figure 7.10B shows the effect of particle age on the induction of CD25 and CD69 on CD4 and 
CD8 T cells in whole blood cultures after treatment according to dosing schedule B. The data 
(3 independent studies, all n=6) was left separated due to the interdonor variance between the 
studies. The particles prepared 0.2 and 2 h prior to addition to whole blood did not induce 
significant T cell activation. The decreased efficacy may be due to the increased dissolution 
rate of the particles (which was also shown in Chapter 6), as it would decrease the contact 
time between the nanosilica particle and the TCR complex. Alternatively, the formation of these 
particles, which is a mechanism that is not well understood, may be responsible for the 
decreased induction of T cell activation. Immediately after preparation of these (and most 
other) dispersions, the size measurements are quite inconsistent. Specifically, some 
measurement replicates show particles below 2 nm in size while others do not detect any small 
particles. This might suggest that there are particles (or “oligomers”) below 1 nm in size (and 
the detection limits of the DLS equipment) that eventually agglomerate to form the particles 1-
2 nm in size. It is possible that these ultrafine “oligomers” do not engage the TCR complex like 
the larger particles. Whatever the reason, what remains clear is that fresh, ultra-labile, 
dispersions do not induce T cell activation in whole blood. The particles that were aged 1-10 d 
induced significant expression of CD25 and CD69 on CD4 T cells and CD69 on CD8 T cells. 
Interestingly, the dispersions aged 10 days had decreased efficacy compared to the 
dispersions aged only 1 and 5 days. The reason for the reduced induction of the activation 
markers is unknown but it could relate to particle condensation. For example, there may be 
fewer particles present in the dispersion as a result of slight, undetectable, agglomeration. The 
particles aged 1 and 5 days induced the greatest expression of the activation markers. Whether 
these particles also induced significant monocyte cell death was also investigated. Figure 7.11 
shows the percentage of monocyte counts with the cell distribution after treatment with 1 and 
5 d old particles. As with the previous particles tested, both these dispersions induced 
significant monocyte cell death. It is quite plausible that the properties that nanosilica requires 
to induce significant T cell activation are the same as those that induce significant monocyte 
cell death. 
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Figure 7.10. The effect of nanosilica particle age on the percentage of CD4 and CD8 T 
cells positive for CD25 and CD69 in whole blood culture. A. The area under the curve, 
corresponding to the formation of the β-silicomolybdate complex, as measured by absorbance 
at 400 nm from 0-5 h, after dilution of aged 40 mM nanosilica dispersions (pH 2.3) to 1 mM Si 
in a molybdic acid solution. B. Whole blood was treated with 16 mM Si 25 s pulse, followed by 
a 4 mM Si incubation step for 1 h, 2 mM Si incubation for 3 h and finally a 1 mM Si incubation 
for 20 h. Tabulated data represent the averages for 6 donors (* denotes a significance 
compared to their respective control, two-tailed paired T test, p < 0.05). T cells were first 
selected based on FSC versus SSClog profiles through a T cell gate which also excluded 
debris, followed by a singlets gate (FSClin vs FSCarea), a T cell gate (CD3(+)), and a CD4(+) 
or CD8(+) gate. 
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Figure 7.11. The effect of the particle age on the percentage of monocytes within the 
cell distribution in whole blood culture. Whole blood was treated with 16 mM Si 25 s pulse, 
followed by a 4 mM Si incubation step for 1 h, 2 mM Si incubation for 3 h and finally a 1 mM Si 
incubation for 20 h. Tabulated data represent the averages for 6 donors (* denotes a 
significance compared to their respective control, two-tailed paired T test, p < 0.05). Monocytes 
were first selected based on FSC versus SSClog profiles followed by a CD14high gate.  
 
Lastly, the effect of a nanosilica dispersion prepared through an alternative synthetic route was 
investigated. It was previously shown that most dispersions require a 24 h incubation period 
to become efficacious. If the particles are used immediately after preparation, they have no 
effect on T cell activation (Figure 7.10). This prolonged preparation (incubation) step inserts a 
degree of complexity for an in vivo/clinical situation (below). An alternative synthesis strategy 
was developed to simulate the 24 h aged materials (prepared at low pH) which were previously 
shown to be most efficacious in whole blood. This alternative synthetic strategy involved a 30 
min incubation step at pH 5, generating a material, referred to as material D, with the same 
relative condensation (as determined through silicic acid release) and particle size (as 
determined by DLS) as the 1 d old material  (Material C) (Bastos and Faria, unpublished). 
Figure 7.12 shows the effect of the nanosilicate particles produced as previous and through 
the alternative synthesis strategy. Both materials induced significant, similar levels of CD25 
and CD69 on CD4 T cells and CD69 on CD8 T cells. Figure 7.13 shows the percentage of 
monocytes within the cell distribution after treatment with the materials. Both materials induced 
significant monocyte cell death. The alternative synthetic strategy successfully mimicked the 
material shown to induce greatest T cell activation in whole blood.  
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Figure 7.12. The effect of nanosilica (material C and D) on the percentage of CD4 and 
CD8 T cells positive for CD25 and CD69 in whole blood culture. Whole blood was treated 
with 16 mM Si 25 s pulse, followed by a 4 mM Si incubation step for 1 h, 2 mM Si incubation 
for 3 h and finally a 1 mM Si incubation for 20 h. Tabulated data represent the averages for 6 
donors (* denotes a significance compared to their respective control, two-tailed paired T test, 
p < 0.05). The percentage of CD4 and CD8 T cells positive for CD69 after treatment with SEB 
exceeded 10%, but was left off scale to more clearly show activation induced by nanosilica. T 
cells were first selected based on FSC versus SSClog profiles through a T cell gate which also 
excluded debris, followed by a singlets gate (FSClin vs FSCarea), a T cell gate (CD3(+)), and 
a CD4(+) or CD8(+) gate. 
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Figure 7.13. The effect of nanosilica (material C and D) on the percentage of monocytes 
in the cell distribution in whole blood culture. Whole blood was treated with 16 mM Si 25 
s pulse, followed by a 4 mM Si incubation step for 1 h, 2 mM Si incubation for 3 h and finally a 
1 mM Si incubation for 20 h. Tabulated data represent the averages for 6 donors (* denotes a 
significance compared to their respective control, two-tailed paired T test, p < 0.05). Monocytes 
were first selected based on FSC versus SSClog profiles followed by a CD14high gate. 
 
 
7.2.4 In vivo trials 
7.2.4.1 Preliminary study and post termination studies  
Prior to 2013, there were many unpublished investigations assessing whether nanosilica can 
effectively inhibit tumour growth rate. An example of these studies is shown (with permission) 
in Figure 7.14, where the effect of 3-84 nm nanosilica particles on the growth of an established 
subcutaneous tumour was assessed. It was found that particles less than 10 nm in size 
decreased tumour growth rate, while larger nanosilicates had little effect. The nanosilica 
particle 3.6 nm in size inhibited tumour growth as effectively as the temozolomide positive 
control. Interestingly, the size dependent decrease in tumour growth matches the size 
dependence for maximal T cell activation (Chapter 6). A number of post-termination studies 
were conducted to determine the possible mechanism of nanosilica induced tumour growth 
inhibition.  
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Figure 7.14. Tumour sizes after 14 d from mice injected subcutaneously with B16-F10 
melanoma and treated daily with saline, temozolomide and nanosilica (23 mM Si, 400 
μL) for 10 d. Tumours were allowed to grow to ca. 100 mm3 before mice were treated. ‡ 
represents prophylactic treatment prior to tumour inoculation and treatment during initial 
tumour growth. * denotes difference (p < 0.05) from vehicle (with permission from HS Pharma, 
dispersions prepared by B Vis prior to start of thesis, animal work conducted by Translational 
Drug Development (TD2). 
 
First, the concentration of silicon in the excised tumours was assessed. These studies may 
infer to whether nanosilica, previously shown to be quite toxic to cells (Chapter 4), could 
infiltrate and directly interfere with tumour cell growth. Figure 7.15 shows the concentration of 
Si in the tumours. The concentration of silicon present in the tumours was higher in the 
nanosilica treated groups than in the vehicle control group. These results are unsurprising as 
nanosilica was injected daily at high volumes (ca. 23 mM Si, 400 µL) and therefore increased 
Si levels in all tissues would be expected. The most effective nanosilica treatment (in terms of 
inhibition of tumour growth) had the lowest tumour silicon level. When tumour size was 
correlated against silicon level in the mice treated with 3.6 nm nanosilica, the larger tumours 
were found to have higher levels of silicon. This may suggest that the mechanism of tumour 
growth inhibition is not through a direct tumour infiltration/toxicity-based mechanism. In 
Chapter 4, the effect of nanosilica on viability of a cancerous cell line was investigated. It was 
found that the cancerous cells were resistant to nanosilica and high concentrations were 
required to significantly reduce cell viability. Considering the high concentration of nanosilica 
required to kill tumour cells directly, the low levels of silicon in the tumours and lack of 
correlation between tumour size and Si concentration, it is unlikely that nanosilica is inhibiting 
tumour growth through direct toxicity. The slight increase in Si levels in the tumours of the 
temozolomide treated group is likely due to contamination from the silica filler used in the 
tablets in which the temozolomide was extracted from. 
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Figure 7.15. A. Concentration of Si in tumours from the murine melanoma model shown in 
Figure 7.14. Concentration are mg Si per kg dry tumour mass. Values determined from >5 
different tumours from each treatment group. ‡ represents prophylactic treatment prior to 
tumour inoculation and during initial tumour growth. B. Correlation between tumour size and 
concentration of Si. 
 
Next, the post termination studies assessing cytokine, chemokine and antibody levels in sera 
were conducted. The sera from the vehicle and 3.6 nm nanosilica treated mice was sent to 
Myriad RBM for a thorough assessment of serum analyte levels.  
First, the levels of innate pro-inflammatory cytokines were assessed, mainly IL-1β, IL-6 and 
TNF-α. IL-1β is a cytokine released in response to pathogens or during pyroptosis to activate 
innate immune cells, mainly monocytes and neutrophils (Lopez-Castejon and Brough, 2011; 
Netea et al., 2010). TNF-α, produced predominantly by monocytes but also by T cells, NK 
cells, B cells, neutrophils and endothelial cells, is involved in the recruitment of white blood 
cells to the site of the infection (Bradley, 2008). IL-6, whose production is stimulated by IL-1β 
and TNF-α, is known to stimulate lymphocytes, contributes to both innate and adaptive 
immunity, and is involved in tissue homeostasis (Hunter and Jones, 2015). Together, the 
presence of these cytokines would indicate the induction of an innate inflammatory response. 
Figure 7.16 shows the sera analyte levels from the tumour bearing mice treated with nanosilica 
(3.6 nm), represented as a percentage of the saline control. Serum levels of IL-1β and TNF-α 
were below the detection limits while the levels of IL-6 remained unchanged in the nanosilica 
treated mice compared to the saline control. These results would suggest that nanosilica is not 
inducing an innate inflammatory response. These results conflict with those in the literature 
that showed increased IL-1β and TNF-α levels after intraperitoneal injection with 12 nm 
nanosilica particles (Park and Park, 2009). Whether particle characteristics (size and 
dissolution rate) or injection site (intravenous versus intraperitoneal) is responsible for the 
conflicting results is unknown. 
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Analytes associated with neutrophil recruitment and activation (macrophage inflammatory 
proteins (MIP) 1β, myeloperoxidase (MPO), granulocyte chemoattractant protein 2(GCP-2) 
and MMP-9) (Linge et al., 2008; Maurer and Von Stebut, 2004; Menten et al., 2002; Nauseef, 
2014; Parks et al., 2004) were elevated in the sera of nanosilica treated mice. In addition to its 
association to neutrophil recruitment and activation, the analyte MIP-1β is also known to be 
produced by cytotoxic lymphocytes upon their activation and it is present within their cytotoxic 
granules (Catalfamo et al.; Wooldridge et al., 2010). These results would suggest that 
nanosilica is inducing a response from neutrophils and cytotoxic cells after intravenous 
administration. 
An analyte associated with T cell recruitment and activation was also elevated after nanosilica 
treatment, specifically lymphotactin (Figure 7.17A). Lymphotactin is produced by CD4 T cells, 
CD8 T cells and NK cells, mediating Th1 and cytotoxic immune responses (Lei and Takahama, 
2012). The levels of lymphotactin correlated with a decreased tumour size after treatment with 
nanosilica, but not saline (Figures 7.17B-C). These results may suggest that T cells may be 
involved in the decreased tumour growth rates present after nanosilica treatment. In PBMC 
culture, nanosilica was also shown to increase lymphotactin levels (Figure 7.17D). This may 
infer that nanosilica is inducing T cell activation in vivo.  
 
Figure 7.16. Serum cytokine levels from mice injected subcutaneously with B16-F10 
melanoma and treated daily with saline and nanosilica (DV0.5 = 3.6 nm) for 10 d. Tumours 
were allowed to grow to ca. 100 mg before mice were treated. * denotes difference (p < 0.05) 
from vehicle 
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Figure 7.17. A. Serum lymphotactin levels from mice injected subcutaneously with B16-F10 
melanoma and treated daily with saline and nanosilica (DV0.5 = 3.6 nm) for 10 d. Tumours 
were allowed to grow to ca. 100 mg before mice were treated (* denotes difference (two-tailed 
unpaired T test, p < 0.05) from vehicle). B. Correlation between tumour size and lymphotactin 
levels after nanosilica treatment C. Correlation between tumour size and lymphotactin levels 
after saline treatment. One data point for the nanosilica treated animals was ruled as an outlier 
and excluded (Grubbs’ test, α = 0.05). D. The effect of silicic acid and nanosilica on 
lymphotactin levels in PBMC culture supernatants after 24 h. Tabulated data represent the 
means ± standard deviation for 7 donors. (* denotes a significance compared to the control, 
two-tailed paired T test, p < 0.05). ELISA analysis of supernatants for data shown in D were 
conducted by M. Miniter. 
 
Lastly, antibody levels in the sera was investigated. Figure 7.18 shows the effect of nanosilica 
treatment on IgA, IgG and IgM antibody levels. The levels of IgA, as determined in the RBM 
analyte analysis, increased significantly after nanosilica treatment. Similarly, nanosilica 
treatment increased IgG levels, as determined by ELISA (Figure 7.18B). The particles which 
induced greatest IgG production were not the same those that significantly inhibited tumour 
growth inhibition. Nanosilica did not increase the levels of all antibodies, as there were 
decreased IgM levels in the sera of silica treated mice (Figure 7.18C). Interestingly, the 
increase in IgG levels and decrease in IgM levels correlated to tumour size (Figure 7.18D), 
where the mice which had the largest antibody switch also had the smallest tumours. IgG is 
known to have anti-cancer properties (Sapir and Shoenfeld, 2005), though it remains unknown 
whether the IgG is directly responsible for the decrease in tumour growth rate. Whether 
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nanosilica induced T cell activation is responsible for the class switch or whether nanosilica 
directly acts on B cells to induce an immunoglobulin class switch is also unknown. However, 
both CD40L and IFN-γ, which nanosilica has previously been shown to induce in vitro (Chapter 
5), have been shown to effect immunoglobulin production (Kracker and Radbruch, 2004; 
Stavnezer, 1996). In the literature, there is evidence of other silicate particles effecting antibody 
production in vivo. Both crystalline and amorphous silica have been shown to increase 
antibody production in response to antigen (Brandenberger et al., 2013; Pernis and Vigliani, 
1960). Whether these responses relate to those shown here is unknown. 
Overall, the effect of nanosilica on serum analyte and antibody levels would suggest that IV 
administered nanosilica is inducing an immunological response.  
 
Figure 7.18. Serum IgA (A), IgG (B) and IgM (C) levels from mice injected subcutaneously 
with B16-F10 melanoma and treated daily with saline and nanosilica for 10 d. ‡ represents 
prophylactic treatment prior to tumour inoculation and treatment during initial tumour growth. 
Correlation between tumour size and IgM/IgG (D), Colour of the data points correlate to the 
different nanosilica dispersions where, black - 3.6 nm, blue - 5.6 nm, grey – 84 nm , and green 
– 84 nm‡). Line was significantly different than zero (linear regression p< 0.001) One data 
point for the nanosilica treated animals was ruled as an outlier and excluded (Grubbs’ test, α 
= 0.05). Tumours were allowed to grow to ca. 100 mg before mice were treated. * denotes 
difference (p < 0.05) from vehicle. IgA levels were conducted by RBM.  
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7.2.4.2 Follow up investigations 
Follow up investigations were conducted to replicate the tumour growth inhibition by nanosilica. 
Animal care regulations in the United Kingdom are more restrictive than those in the United 
States of America, where the previous in vivo investigation was conducted. Therefore, doses 
volumes needed to be reduced (to 200 uL from 400 uL), dose frequency was decreased (every 
3 days vs every day), and the study was terminated at an earlier timepoint (tumour sizes at 
time of termination <600 mm3 vs 2000 mm3). Figures 7.19A and B show the dosing schedule 
and the effect of nanosilica on subcutaneous tumour growth. As before, nanosilica significantly 
decreased subcutaneous tumour growth rate. However, the response to nanosilica was less 
pronounced in these studies than those conducted previously. The differences in efficacy are 
likely do to the differences in experimental design. In particular, it is suspected that nanosilica 
may have larger effect on more well established tumours. Cancer cells, like healthy cells, 
require oxygen and nutrients to survive. Larger tumours require greater vascular networks to 
obtain their nutrients than smaller tumours (Rieger and Welter, 2015). With a greater vascular 
network, nanosilica or nanosilica activated cells would have greater access to the tumour site. 
Previous studies (Figure 7.14) have shown that Si levels in the tumours increased with its size, 
potentially indicating a greater tumour vascular network and infiltration by nanosilica and/or 
nanosilica activated cells.  
A metastatic cancer model mimics a situation of the dissemination and growth of cancer cells 
in metastatic sites from either cancer cell release from a primary tumour site, (Steeg, 2016) or 
escape during/after surgery (Tavare et al., 2012). In fact, most cancer deaths are due 
metastatic (secondary) growths rather than the primary tumour site (Chambers et al., 2002). 
After entering the periphery, cancerous cells frequently establish on the lungs, a site where 
nanosilica has also been found to accumulate (Steeg, 2016; Xie et al., 2010). Here, the effect 
of nanosilica on the formation of tumour nodules on the lungs was assessed after intravenous 
injection of a melanoma cell line. Figures 7.19C and D show the dosing schedule and the 
number of surface nodules on the lungs upon study termination. Nanosilica was found to 
significantly decrease the number of nodules that formed, indicating that it has anti-metastatic 
properties. CD4 T cells, B cells, macrophages/monocytes, and neutrophils (though the 
involvement of neutrophils is still unclear/controversial) have been shown to contribute to the 
formation of metastases, immune cell populations which nanosilica has been shown to affect 
(Kitamura et al., 2015). Post-termination studies on the immune populations within the blood, 
lymph nodes and lungs were inconclusive (for these and the solid tumour studies), leaving the 
mechanism behind the anti-metastatic properties of nanosilica unresolved. 
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Figure 7.19. Treatment schedule (A.) and tumour sizes (B.) after 8-15 d of mice injected 
subcutaneously with B16-F10 melanoma and treated with saline and nanosilica. Blue dots 
represent treatment with saline/nanosilica. Treatment schedule (C.) and number of surface 
lung nodules (D.) 21 d after intravenous injection with B16-F10 melanoma and treated with 
saline and nanosilica. Blue dots represent treatment with saline/nanosilica. Studies were 
conducted by Drs J. Shields and L. Pedro. 
 
7.3 Conclusions 
In the previous chapters, it was shown that amorphous nanosilica particles less than 10 nm in 
size induced activation of T cells and significant cell death in PBMC cultures. Fresh PBMC 
were chosen for these assays because these cells are non-transformed and display 
behavioural, phenotypic and functional characteristics of peripheral blood cells in vivo. 
However, these assays lack many components of whole blood that would likely interact with 
nanosilica after intravenous injection. In this chapter, whole blood assays were conducted to 
better understand the in vivo safety of nanosilica.  
T cell activation induced by nanosilica was significantly attenuated in whole blood cultures 
compared to that in PBMC cultures. There was more than a 50% decrease in the induction of 
the CD25 and CD69 activation markers in whole blood versus that in isolated cultures, despite 
using concentrations that were 5 times higher and that surpassed the Si solubility limit. The 
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attenuated effect is likely due to the increased complexity of whole blood, as it contains 
additional cells and components known to interact with silica (Clemments et al., 2015; Don and 
Kaysen, 2004; Gryshchuk and Galagan, 2016; Lehman et al., 2016; Zhang et al., 2012; 
Zimmerman et al., 1986). The cytotoxicity of nanosilica was also greatly attenuated in whole 
blood cultures. There was a relationship between the amount of T cell activation and monocyte 
cell death. Specifically, only in conditions in which there was significant monocyte cell death 
was there a large induction of T cell activation. There was also significant T cell activation and 
monocyte cell death induced by nanosilica in conditions that more closely mimicked an in vivo 
situation after intravenous injection (i.e., short incubations at high nanosilica concentrations 
followed by continuous dilution). 
Post-termination studies of a murine subcutaneous melanoma model where nanosilica was 
injected at high doses and was found to have mild anti-cancer properties were conducted. It 
was found that Si infiltration into the tumour was low, suggesting that the anti-cancer responses 
are not through direct toxicity. Analysis of analytes in the sera would suggest that nanosilica is 
inducing an immune response, as concentrations of many chemokines and antibodies were 
greater after nanosilica treatment. The increase in chemokine and antibody levels were also 
shown to correlate to decreased tumour sizes. Follow up investigations confirmed the mild 
anti-cancer responses of nanosilica in the subcutaneous tumour model and showed that 
nanosilica inhibits metastatic tumour formation. The precise mechanism of the mild anti-tumour 
and anti-metastatic properties of nanosilica remain unknown.   
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Chapter 8 – Conclusions  
8.1 Summary of the project 
Due to their highly tailorable properties, amorphous silica particles are used in a vast range of 
applications. Increasingly, they are being used in biomedical applications including as binding 
agents in tissue repair, drug and gene therapy delivery agents, coatings for medical contrast 
agents and as vaccine adjuvants (Bitar et al., 2012). Despite their increasing use, the safety 
of amorphous silica is not completely understood. In this thesis, the safety of amorphous 
nanosilica particles under 10 nm in size was assessed. 
In Chapter 3, amorphous nanosilica particles were prepared and characterized. The particles, 
all less than 30 nm in diameter but predominately less than 10 nm, were highly resorbable, 
being completely dissolved within 48 h after dilution below the solubility limit of silica (< 2 mM 
Si). Particles with increased lifetimes under dilute conditions were also engineered. In general, 
particles generated and tested in this thesis were less condensed than most other particles 
reported in the literature, as determined by dissolution rate and by 29Si NMR spectroscopy.  
In Chapter 4, the toxicity of these engineered labile nanosilica particles was assessed using 
transformed, cancerous and primary peripheral blood mononuclear cells. Primary cells were 
most susceptible to nanosilica induced cell death and, particularly towards the phagocytes, 
corroborating studies in the literature (Fedeli et al., 2013). The engineered nanosilica particles 
were also found to induce pyroptosis/necrosis of primary monocytes, again corroborating 
published studies with larger nanosilica particles (Fedeli et al., 2014), and apoptosis of CD4 T 
cells. Further data collected suggested that the nanosilica particles have a unique effect on T 
cells (e.g., the nanosilica particles inhibited fluorescent TCR antibody staining, induced the 
expression of genes associated with T cell activation, and induced apoptosis possibly through 
activation induced cell death). Therefore, investigations were carried out looking specifically at 
T cell responses.  
In Chapter 5, the nanosilica particles were found to non-specifically induce T cell activation. 
The T cell activation markers CD25, which is a component of the IL-2 receptor, and CD69, 
which is involved in T cell migration, were both significantly expressed on T cells after treatment 
with nanosilica. Helper T cells, cytotoxic T cells, γδ T cells and NK/NKT cells all expressed 
significant levels of these receptors when exposed to nanosilica. The high percentage of cells 
expressing the activation markers would suggest that nanosilica induced T cell activation is 
independent of T cell antigenic specificity. Not all markers of T cell activation were induced by 
nanosilica, as only low levels of T cell proliferation was detected, which would suggest that 
complete activation was not induced.  
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Markers of activation from multiple T helper cell subsets were induced by nanosilica. Treatment 
with nanosilica was found to increase supernatant IFN-γ levels and surface LAP, GARP and 
FoxP3 expression, further indicating the non-specific nature of nanosilica induced activation.   
In Chapter 6, the mechanism of nanosilica induced T cell activation was investigated. It was 
determined that APCs are not required for the induction of CD4 T cell activation by nanosilica, 
indicating an MHC class II receptor independent activation mechanism. After confirming the 
requirement of the TCR/CD3 complex for nanosilica induced activation, it was shown that 
nanosilica directly engages the TCR/CD3 complex (likely on the constant domain of the TCR 
or a CD3 chain) and induces downstream signalling. TCR ligation by amorphous nanosilica 
was inefficient, as complete T cell activation (as determined by proliferation) was not induced. 
Proliferative responses were induced when treated in combination with co-stimulatory signals 
(signal 2). These results were confirmed using chemical inducers which would indicate that 
nanosilica does not induce signalling through MAPK, which is downstream of the CD28 
receptor. Figure 8.01 shows the proposed mechanism of amorphous nanosilica induced T cell 
activation. 
Silica dispersions with mean diameters between 3.6 and 5.1 nm induced the greatest 
expression of CD25 and CD69 on CD4 and CD8 T cells in PBMC cultures. Induction of the 
activation markers decreased when particle size was either increased or decreased from a 
median diameter of 3.6 nm. A nanoiron dispersion, 3-5 nm in size and coated in adipate and 
tartrate, induced low levels of CD69 expression on CD4 T cells, which would indicate that the 
induction of T cell activation is not specific to nanosilica, though the magnitude of its induction 
is, i.e., nanosilica is a more potent inducer of T cell activation.   
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Figure 8.01. Proposed mechanism of nanosilica induction of T cell activation. Nanosilica 
is suspected to bind the constant domain of the TCR/CD3 complex (as determined by 
fluorescent antibody binding inhibition), inducing phosphorylation of Zap-70 and LAT (as 
determined by western blot analysis), and inducing signaling through NFAT, not MAPK (as 
determined by co-incubation with chemical inducers and antibodies), leading to induction of T 
cell activation markers.  The cell signaling pathway was adapted from Acuto, Huehn, DuPage 
and Brownlie (Acuto et al., 2008; Brownlie and Zamoyska, 2013; DuPage and Bluestone, 2016; 
Huehn et al., 2009). Note – nanosilica particle size is not to scale.  
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In Chapter 7, investigations were conducted in freshly collected whole blood cultures as to 
better mimic the environment after intravenous injection of the nanosilica dispersions. There 
was significant attenuation of the induced T cell activation (expression of CD25 and CD69) in 
whole blood cultures compared to that in PBMC culture, likely due to the increased number of 
components present in whole blood and their known interactions with silica (Clemments et al., 
2015; Don and Kaysen, 2004; Gryshchuk and Galagan, 2016; Lehman et al., 2016; Zhang et 
al., 2012; Zimmerman et al., 1986). Concentrations of nanosilica surpassing the solubility of 
silicic acid were employed, and significant T cell activation and decreases in peripheral cell 
counts were evident. It was also shown that nanosilica induced both significant T cell activation 
and monocyte cell death when using a dosing schedule that more closely mimicked an in vivo 
situation after intravenous injection (i.e., short incubations at high nanosilica concentrations 
followed by continuous dilution).  
Studies conducted prior to 2013 showed that a nanosilica dispersion can inhibit tumour growth 
rate in mice (HS Pharma, unpublished data). Post-termination studies conducted here showed 
that the mechanism of tumour growth inhibition is not likely through direct toxicity, as 
determined by Si infiltration into the tumour. The levels of analytes and antibodies in the serum 
increased after nanosilica treatment, which would suggest an immune response was induced. 
One of the analytes induced, lymphotactin, a chemokine for and produced by T cells, increased 
after nanosilica injection and it correlated to a decreased tumour size, potentially inferring to 
the mechanism of tumour growth inhibition. The mild anti-cancer properties of nanosilica were 
confirmed in a subcutaneous tumour model and a metastatic tumour model, though the 
mechanism behind these responses remains unknown.   
8.2 Future perspectives 
The results in this thesis show that amorphous nanosilica particles under 10 nm in diameter 
induce non-specific activation of T cells. Evidence would suggest that the nanoparticulate 
directly engages the TCR/CD3 complex, the first non-MHC coated nanoparticle found to do 
so, and induces numerous surface activation markers and cytokine production. Complete T 
cell activation was not induced (as determined by the low percentage of cells which 
proliferated), suggesting that TCR ligation by nanosilica is inefficient and that costimulatory 
receptors are not engaged. Further investigations pertaining to the signalling induced by 
nanosilica are required. In the literature, insufficient TCR ligation in the absence of co-
stimulation can induce a hyporesponsive T cell state, specifically T cell anergy. Whether 
nanosilica induces T cell anergy is not known and would have an impact on its in vivo safety. 
The effect of nanosilica on natural killer cells also requires further investigation. Nanosilica was 
shown to induce CD25 and CD69 expression on NK/NKT cells. Whether NK cells, which lack 
a TCR, are activated by nanosilica remains unclear.  
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The studies conducted in this thesis were predominately carried out using materials comprised 
of silica, where the only other particle tested was an iron hydroxide nanoparticle (coated in 
adipate and tartrate). Given the wealth of particles that humans are constantly exposed to 
(Lomer et al., 2002), further investigations are required to identify whether other particles 
induce similar responses. In the literature, fullerenes, cobalt nanoparticles and ZnO 
nanoparticles were shown to induce IFN-γ production (Hanley et al., 2009; Liu et al., 2009; 
Petrarca et al., 2005). Whether they induce the production of this cytokine through engagement 
of the TCR (like nanosilica) is unknown. Additionally, further investigations are also required 
to assess the effect of the silicate materials used in the biomedical applications on T cell 
activation. 
The anti-tumour and anti-metastatic properties of nanosilica were confirmed and identified in 
this thesis, though the underlying mechanism remains unknown. Further investigations are 
required to determine whether these responses are due to nanosilica induced T cell activation. 
One way this could be accomplished is through isolating, labelling, and treating T cells with 
nanosilica (ex vivo) and administering the activated cells to cancer bearing mice. Whether 
treatment with nanosilica leads to greater tumour infiltration could then be identified. Further in 
vivo studies should include the effect of the high silica load on the animals and investigating 
the long term effects on the spleen, liver, and lungs.  
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Appendix 1 – Examples of gating strategies used in flow cytometry studies and 
integrations used in western blot studies 
 
 
Figure 9.01. Gating strategy for the assessing transformed EBV B cell proliferation 
without a viability stain. EBV B cells were selected based on FSC versus SSC profiles which 
also excluded debris. Examples of cells at time 0 (blue) and those treated with vehicle (red) or 
nanosilica (green) and incubated for 48 h are shown. The generational gates were set 
according to the intensity mean of the CFSE stained cells fixed at experimental time 0 
(generation 0) and gating in between the calculated mean intensities of each generation (the 
daughter generation has half the intensity of the parent generation) 
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Figure 9.02. Gating strategy for the assessing transformed EBV B cell proliferation with 
a viability stain. EBV B cells were selected based on FSC versus SSC profiles which also 
excluded debris followed by a viability gate (Violet LIVE/DEADlow). Examples of cells at time 0 
(blue) and those treated with vehicle (red) or nanosilica (green) and incubated for 48 h are 
shown The generational gates were set according to the intensity mean of the CFSE stained 
cells fixed at experimental time 0 (generation 0) and gating in between the calculated mean 
intensities of each generation (the daughter generation has half the intensity of the parent 
generation) 
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Figure 9.03. Gating strategy for assessing THP-1 viability. THP-1 cells were selected 
based on FSC versus SSC profiles which also excluded debris, and viability was assessed 
with a Violet LIVE/DEAD stain, where Violet LIVE/DEADlow cells were considered viable. 
Examples of untreated (grey filled), Si(OH)4 treated (blue) and nanosilica treated(black) cells 
are shown.  
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Figure 9.04. Gating strategy for assessing viability of monocytes (CD11c(+)), T cells 
(CD3(+)) and B cells (CD19(+)) in PBMC cultures. Monocytes were first selected based on 
FSC versus SSC profiles through a monocyte gate (R1) which also excluded debris, followed 
by a CD11c(+) gate. T cells and B cells were first selected based on FSC versus SSC profiles 
through a lymphocyte gate (R2) which also excluded debris, followed by CD3(+) and CD19(+) 
gate, respectively. Viability was assessed with a Violet LIVE/DEAD stain, where Violet 
LIVE/DEADlow cells were considered viable.  
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Figure 9.05. Gating strategy for assessing apoptosis and necrosis of monocytes 
(CD11c(+)) in PBMC cultures. Monocytes were first selected based on FSC versus SSC 
profiles through a monocyte gate which also excluded debris, followed by a CD11c(+) gate. 
Apoptosis and necrosis was assessed using a intracellular DNA stain (7-AAD) and a 
phosphatidylserine stain (Annexin V), where Annexin V(+)7-AAD(-) cells were considered 
apoptotic and  Annexin V(+) 7-AAD(+) cells were considered necrotic.  
 
Figure 9.06. Gating strategy for assessing apoptosis and necrosis of CD4(+) and CD8(+) 
cells in PBMC cultures. T cells were first selected based on FSC versus SSC profiles through 
a lymphocyte gate (R1), followed by negatively gating out debris (R2) and monocytes 
(CD11c(+), R3). Helper and cytotoxic T cells were then selected with respective CD4(+) and 
CD8(+) gates. Apoptosis and necrosis was assessed using a intracellular DNA stain (7-AAD) 
and a phosphatidylserine stain (Annexin V), where Annexin V(+)7-AAD(-) were considered 
apoptotic and Annexin V(+)7-AAD(+) were considered necrotic. A TCR/CD3 stain was not 
included due to the inhibition of its staining by nanosilica from 0-2 h (Figure 4.10 and in Chapter 
6). 
198 
 
 
Figure 9.07. Gating strategy for assessing fluorescent bead and bacteria by monocytes 
in enriched monocyte cultures. Monocytes were first selected based on FSC versus SSC 
profiles through a monocyte gate, followed by a monocyte gate (CD11c(+)) and a viability gate 
(Violet LIVE/DEADLOW). Uptake was assessed with a FITC(+) gate.  
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Figure 9.08. Gating strategy for assessing PD-L1 expression by monocytes in PBMC 
cultures. Monocytes were first selected based on FSC versus SSC profiles through a 
monocyte gate, followed by a monocyte gate (CD11c(+)) and a viability gate (Violet 
LIVE/DEADLOW). PD-L1 expression was assessed with a PD-L1(+) gate.  
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Figure 9.09. Gating strategy for assessing CD25 and CD69 expression on CD4(+) and 
CD8(+) T cells in PBMC cultures. T cells were first selected based on FSC versus SSC 
profiles through a T cell gate also which excluded debris, followed by a viable T cell gate (7-
AAD(-)CD3(+)) and a CD4(+) (R1) or a CD8(+) (R2) gate for helper and cytotoxic T cells, 
respectively. Expression of activation markers were assessed through CD25 vs CD69 dot plots 
and quadrant gating. 
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Figure 9.10. Gating strategy for assessing proliferation of CD4(+) and CD8(+) T cells in 
PBMC cultures. T cells were first selected based on FSC versus SSC profiles through a T cell 
gate also which excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a 
CD4(+) (R1) or a CD8(+) (R2) gate for helper and cytotoxic T cells, respectively. Proliferation 
was assessed through CD4/CD8 vs CFDA-SE dot plots, where divided cells were selected 
with a CFDA-SElow gate. The linear forward scatter (FSC)-side scatter gate used was generous 
to accommodate the cell size increase prior to division (as evident in the example SEB 
histogram plot) 
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Figure 9.11. Gating strategy for assessing CD95 (Fas) expression on CD4(+) T cells in 
PBMC cultures. T cells were first selected based on FSC versus SSC profiles through a T cell 
gate also which excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a 
CD4(+) gate. CD95 expression was assessed through SSC vs CD95 dot plots, where CD95(+) 
cells were selected  
 
 
Figure 9.12. Gating strategy for assessing FoxP3 levels in activated CD4(+) T cells in 
PBMC cultures. T cells were first selected based on FSC versus SSC profiles through a T cell 
gate also which excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)), a CD4(+) 
gate and a CD25(+) gate. FoxP3 expression was assessed through SSC vs FoxP3 dot plots, 
where FoxP3(+) cells were selected 
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Figure 9.13. Gating strategy for assessing LAP/GARP expression on activated CD4(+) T 
cells in PBMC cultures. T cells were first selected based on FSC versus SSC profiles through 
a T cell gate also which excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) 
and a CD4(+)CD25(+) gate. LAP/GARP double positive cells were assessed with LAP vs 
GARP dot plots and quadrant gating. 
 
 
Figure 9.14. Gating strategy for assessing CD40L (CD154) expression on CD4(+) T cells 
in PBMC cultures.  T cells were first selected based on FSC versus SSC profiles through a T 
cell gate also which excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a 
CD4(+) gate. CD154 positivity was assessed with CD154 vs CD25 dot plots and quadrant 
gating. 
 
Figure 9.15. Gating strategy for assessing iCOS (CD278) expression on CD4(+) T cells 
in PBMC cultures. T cells were first selected based on FSC versus SSC profiles through a T 
cell gate also which excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a 
CD4(+) gate. CD278 positivity was assessed with CD278 vs CD25 dot plots and quadrant 
gating. 
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Figure 9.16. Gating strategy for assessing CD95 (Fas) expression on CD8(+) T cells in 
PBMC cultures. T cells were first selected based on FSC versus SSC profiles through a T cell 
gate also which excluded debris, followed by a viable T cell gate (7-AAD(-)CD3(+)) and a 
CD8(+)gate. CD95 expression was assessed through SSC vs CD95 dot plots, where CD95(+) 
cells were selected 
 
Figure 9.17. Gating strategy for assessing CD25 and CD69 expression on γδ T cells in 
PBMC cultures. T cells were first selected based on FSC versus SSC profiles through a T cell 
gate also which excluded debris, followed by a viable γδ T cell gate (7-AAD(-)γδ TCR(+)). 
Expression of activation markers were assessed through CD25 vs CD69 dot plots and 
quadrant gating. 
 
Figure 9.18. Gating strategy for assessing CD25 and CD69 expression on NK/NKT 
(CD57(+)) cells in PBMC cultures. NK/NKT cells were first selected based on FSC versus 
SSC profiles through a lymphocyte gate also which excluded debris, followed by a viable 
NK/NKT cell gate (7-AAD(-)CD57(+)). Expression of activation markers were assessed 
through CD25 vs CD69 dot plots and quadrant gating. 
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Figure 9.19. Gating strategy for assessing CD25 and CD69 expression on Jurkat and 
Karpas 299 cells. Cells were gated through a FS-SS gate to exclude debris followed by 
either a viable T cell gate (7-AAD(-)CD3(+), Jurkat) or a viable cell gate (7-AAD(-), Karpas 
299). 
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Figure 9.20. Gating strategy for assessing cell distribution in enriched T cell cultures. 
Cells were first selected based on a generous FSC versus SSC profiles which also excluded 
debris first, followed by  viable T cell, monocyte and B cell gates ((7-AAD(-)CD3/11c/19(+)) 
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Figure 9.21. Integration strategy for the determination of pZap70 and vinculin levels in 
cell lysates. The volume (intensity of chemiluminescence) was determined between top and 
bottom lines, and the middle line denotes the maximum peak height. Similar integration 
strategy was used for pLAT. 
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Figure 9.22. Gating strategy for assessing αβTCR, CD3, CD4 and CD8 antibody binding 
inhibition in PBMC cultures. T cells were selected based on FSC versus SSC profiles 
through a T cell gate also which excluded debris. αβTCR, CD3, CD4 and CD8 expression was 
plotted against FCS and positive cells were selected. 
 
Figure 9.23. Gating strategy for assessing γδTCR and CD8 antibody binding inhibition 
in PBMC cultures. T cells were selected based on FSC versus SSC profiles through a T cell 
gate also which excluded debris. γδTCR expression was plotted against FCS and positive cells 
were selected. 
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Figure 9.24. Gating strategy for assessing CD25 and CD69 expression on CD3(+) T cells 
in whole blood cultures.  T cells were first selected based on FSC versus SSClog profiles 
through a T cell gate which also excluded debris, followed by a singlets gate (FSClin vs 
FSCarea), a T cell gate (CD3(+)) and a viability gate (Invitrogen LIVE/DEAD, VioletLOW , R1). 
The expression of the activation markers were assessed with CD25 vs SSClog and CD69 vs 
SSClog dot plots, where positive cells were identified. 
 
Figure 9.25. Gating strategy for assessing CD25 and CD69 expression on CD4(+) and 
CD8(+) T cells in whole blood cultures. T cells were first selected based on FSC versus 
SSClog profiles through a T cell gate which also excluded debris, followed by a singlets gate 
(FSClin vs FSCarea), a T cell gate (CD3(+)), and a CD4(+) (R1) or a CD8(+) (R2) gate for 
helper and cytotoxic T cells, receptively. The expression of the activation markers were 
assessed with CD25 vs SSClog and CD69 vs SSClog dot plots, where positive cells were 
identified. 
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Figure 9.26. Gating strategy for assessing CD25 and CD69 expression on γδ T cells in 
whole blood cultures. T cells were first selected based on FSC versus SSClog profiles 
through a T cell gate which also excluded debris, followed by a singlets gate (FSClin vs 
FSCarea), and a γδ T cell gate (γδ TCR(+)). The expression of the activation markers were 
assessed with CD25 vs SSClog and CD69 vs SSClog dot plots, where positive cells were 
identified. 
 
Figure 9.27. Gating strategy for assessing CD25 and CD69 expression on NK/NKT cells 
in whole blood cultures. NK/NKT cells were first selected based on FSC versus SSClog 
profiles through a NK/NKT cell gate which also excluded debris, followed by a singlets gate 
(FSClin vs FSCarea), and a NK/NKT cell gate (CD57(+)). The expression of the activation 
markers were assessed with CD25 vs SSClog and CD69 vs SSClog dot plots, where positive 
cells were identified. 
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Figure 9.28. Gating strategy for assessing viability of T cells and B cells in whole blood 
cultures. T cells and B cells were first selected based on FSC versus SSClog profiles through 
a lymphocyte cell gate which also excluded debris, followed by respective T cell (CD3(+), R1) 
and B cell (CD19(+), R2) gates. Viability was assessed with a Violet LIVE/DEAD stain, where 
Violet LIVE/DEADlow cells were considered viable. 
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Figure 9.29. Gating strategy for assessing viability of neutrophils and monocytes in 
whole blood cultures. Monocytes were first selected based on FSC versus SSClog profiles 
through a monocyte cell gate which also excluded debris, followed by a monocyte gate 
(CD14high). Neutrophils were first selected based on FSC versus SSClog profiles through a 
neutrophil cell gate which also excluded debris, followed by a negative monocyte gate 
(CD14low).  Viability was assessed with a Violet LIVE/DEAD stain, where Violet LIVE/DEADlow 
cells were considered viable. 
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Appendix 2 – Clearance of amorphous nanosilica from the periphery after intravenous 
injection 
10.1. Introduction  
Silicon absorbed from diet is rapidly cleared in urine, peripheral levels return to baseline within 
ca. 6 h after consumption of a silicate containing material (Jugdaohsingh et al., 2002; 
Sripanyakorn et al., 2009). The clearance of intravenous administered nanosilica particles is 
less well understood. The excretion and retention of intravenously administered silica 
nanoparticles (of varying sizes and functionalities) has been investigated (Cho et al., 2009; 
Ivanov et al., 2012; Kumar et al., 2010; Xie et al., 2010; Yu et al., 2013), but the short term 
clearance of these particles from the periphery has not. Here, the clearance of a nanosilica 
dispersion (3-5 nm) from the periphery after intravenous administration was assessed.  
10.2 Methods 
Nanosilica dispersions (40 mM, 3-5 nm in diameter) were prepared by Mr C. Bastos. In vivo 
studies were conducted under project licence 80/2574 by Drs J. Shields and L. Pedro. Briefly, 
C57BL6 mice were injected with a subcutaneous tumour on day 0 and left untreated for 6 days. 
Mice were then injected with 200 uL nanosilica or saline and were sacrificed at 4 or 24 h for 
collection of blood. At each timepoint, 3 mice (1 saline, 2 nanosilica treated) were sacrificed. 
An identical protocol was used with healthy mice without the subcutaneous injection of tumour 
cells and only 2 mice were sacrificed at each timepoint (1 saline, 1 nanosilica treated). ICP-
OES on the blood was conducted by Dr R. Jugdaohsingh. 
10.3 Results and discussion 
Figure 10.01 shows the blood silicon levels after intravenous injection of a 40 mM Si nanosilica 
dispersion. The concentration at the time of injection was estimated using the approximate 
blood volume (C57BL6 mice contain approximately 2 mL). More than 75% of the silicon 
injected was cleared from circulation within 4 h, were the tumour bearing animals had lower 
levels than healthy animals. Whether these differences are real or just an artefact from the low 
numbers (n=2 for tumour-bearing animals, n=1 for healthy animals) is unknown. At 24 h, blood 
silicon levels were below 5 μg/mL. These results would suggest that nanosilica particles (3-5 
nm) are rapidly cleared from the periphery after intravenous injection. A curve of best fit (one 
phase decay) would suggest that the concentration of nanosilica would decrease below Si 
solubility (ca. 1.7 mM Si (48 μg/mL) at pH 7.4 (Jugdaohsingh et al., 2008; Mosby, 2016)) within 
2 h. The nanosilica particles would likely dissolve relatively quickly in these conditions. It is 
important to note that the levels of Si injected into the mice are 100-1000 times higher than 
peripheral levels after ingestion of a highly bioavailable silicate containing material 
(Sripanyakorn et al., 2009).  
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Figure 10.01. Concentration of silicon in blood after mice were intravenously injected 
with 200 μL nanosilica (40 mM Si). The concentration at time of injection was estimated using 
the approximate blood volume. Open squares correspond to clearance in healthy mice and 
closed squares correspond to tumour bearing mice. A curve of best fit (one phase decay) was 
used to estimate rate of nanosilica dilution.  
 
10.4 Conclusions 
It was shown here that intravenous administered nanosilica particles are rapidly cleared from 
the periphery. It is likely that the concentration of Si drops below Si solubility within hours after 
injection, which would promote the dissolution of the particles.  
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Appendix 3 – The effect of nanosilica on bead and bacterial uptake by monocytes in 
enriched cultures from PBMC – flow imaging analysis. 
11.1. Introduction  
The effects of amorphous nanosilica particles on phagocyte function have been extensively 
studies. There have be studies showing both positive and negative effects monocyte function 
(Brandenberger et al., 2013; Chen et al., 2014; Fedeli et al., 2014; Fedeli et al., 2013; Hirai et 
al., 2012; Marzaioli et al., 2014; Mendoza et al., 2014). The effect of 3-5 nm nanosilica particles 
on uptake of bacteria and beads by monocytes was investigated in Chapter 4. Nanosilica was 
found to decrease the percentage of monocytes positive for the fluorescent beads/bacteria. 
Whether the decrease in fluorescence is due to degradation of the foreign material in the 
endosome/lysosome or a decrease in monocyte phagocytosis was investigated here using 
imaging flow cytometry.   
11.2 Methods 
Nanoparticle dispersions (3-5 nm) were prepared by diluting sodium silicate (cat. # 338443) in 
distilled deionized water to 23 mM Si and adjusting to pH 6.7 (pH strips) with hydrochloric acid. 
The dispersions were left to equilibriate for 12-24 h at room temperature. Low doses were used 
to avoid significant cell death.  
Peripheral blood mononuclear cells (PBMC) were isolated from single leukocyte cones 
purchased from the National Blood Service (Cambridge, UK) using density gradient 
centrifugation. Cells were froze down in freezing media (10% DMSO, 50% FBS, 40% RPMI 
1640). Frozen cells were thawed, washed in RPMI, and rested 2 h in RPMI containing 10% 
FBS, 0.3 g/L L-glutamine, 1% penicillin-streptomycin and 0.01 µg/mL DNase.  Enrichment of 
monocytes was conducted through monocyte adherence. Briefly, PBMC cultures were added 
to a 6 well plate and incubated for >1 h. Non-adherent cells were then discarded and adherent 
cells were scraped and transferred to a fresh 6 well plate. After repeating 3 times, cells were 
counted and rested for a minimum of 2 h prior to use. 
Enriched monocytes cultures were treated with nanosilica followed immediately by addition of 
fluorescent beads (final concentration 25 μg/mL) or bacteria (final concentration 3 μg/mL) 
(details of beads and bacterial can be found in Table 2.01). Cultures were incubated for 1 h, 
stained (using the Invitrogen live-dead stain) and flow imaging was conducted immediately by 
Dr. R. Hewitt. The same samples that were used in flow cytometry analyses were split for 
Image Stream IsX analysis. Antibody, bead and bacteria details can be found in Table 2.01 
(Chapter 2).  
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11.3 Results and discussion 
Figure 11.01 shows the effect of nanosilica on bead uptake by monocytes. The representative 
images show monocytes (CD11c(+)) negative and positive for the beads. As with the flow 
cytometry analyses, the percentage of cells positive for beads decreased when co-incubated 
with nanosilica. There was no indication of a decrease in fluorescence intensity of the beads 
after treatment with nanosilica. The decrease in bacterial phagocytosis after nanosilica 
treatment as determined by flow cytometry was also confirmed with imaging flow analyses, 
where there was no decrease in bacterial fluorescent intensity (Figure 11.02). These results 
would indicate that nanosilica negatively effects monocyte phagocytosis.  
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Figure 11.01. The effect of nanosilica on the phagocytosis of polystyrene fluorescent 
beads by monocytes. A. Representative flow images showing the CD11c cells negative and 
positive for fluorescent beads after 1 h incubation. B. The percentage of CD11c cells positive 
for fluorescent beads after nanosilica treatment for 1 h. Tabulated data represents the means 
± standard deviation for 3 donors (* denotes a significance compared to the control, two-tailed 
paired T test, p < 0.05). Monocytes were first selected through area (defined as the size of the 
masked cells in square microns) versus aspect ratio (the ratio of the minor axis divided the 
major axis) of the brightfield cell images to identify cell populations of interest as well as doublet 
and debris exclusion. The cells were then gated through a CD11c(+) gate. Uptake was 
assessed with a bead(+) gate. 
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Figure 11.02. The effect of nanosilica on the phagocytosis of fluorescent S. aureus by 
monocytes. A. Representative flow images showing the CD11c cells negative and positive for 
fluorescent bacteria after 1 h incubation. B. The percentage of CD11c cells positive for 
fluorescent bacteria after nanosilica treatment for 1 h. Tabulated data represents the means ± 
standard deviation for 3 donors (* denotes a significance compared to the control, two-tailed 
paired T test, p < 0.05). Monocytes were first selected through area (defined as the size of the 
masked cells in square microns) versus aspect ratio (the ratio of the minor axis divided the 
major axis) of the brightfield cell images to identify cell populations of interest as well as doublet 
and debris exclusion. The cells were then gated through a CD11c(+) gate. Uptake was 
assessed with a bacteria(+) gate. 
 
219 
 
11.4 Conclusions 
Nanosilica decreased bead and bacteria phagocytosis by monocytes as determined by 
imaging flow cytometry. These results would suggest that the decrease in phagocytosis as 
determined by flow cytometry is not due to degradation of the fluorescent foreign material 
(beads/bacteria) but a decrease in phagocytosis.  
 
 
